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 i
Abstract 
 
 
This thesis describes the West Nile virus (WNV) epidemic in horses by exploring 
all aspects: sub-clinical infection, development of clinical disease and case fatality. All of 
the collected data were then compiled to create predictive risk maps of WNV infection 
for the province of Saskatchewan.  
During the 2003 season, 133 clinical cases were documented with laboratory 
testing. Week of onset of clinical signs, gender, and coat color were significant predictors 
of whether the horse died or was euthanized due to severity of clinical signs.  
Studies of the serological response to vaccination and natural infection were 
examined to interpret the lab results from over 1100 samples taken from approximately 
875 horses in 2003. A serologic study involving 212 horses on 20 farms determined the 
prevalence of sub-clinical infection (55.7% (95%CI, 44.9% to 65.8%)) and identifed risk 
factors for infection. The study found risk of infection was highest in the Grasslands 
ecoregions compared to the Boreal Transition ecoregion. 
A case control study looked at risk factors for development of clinical disease. 
The study followed 23 case farms and control farms with a total of 300 horses sampled. 
This was the first field study to show that vaccination was efficacious in preventing the 
development of clinical signs.  
The inclusion of horse surveillance data in the Saskatchewan Health WNV 
Integrated Surveillance Initiative was useful; however, it was discontinued due to time 
constraints, logistics, and declining monetary resources.  
 ii
Since West Nile Virus is a mosquito-borne disease it is highly influenced by 
environmental changes, spatially and temporally. Discriminant analyses were used to 
partition Saskatchewan rural municipalities (RM) into categories of risk of infection with 
WNV based on acquired horse data and different environmental and meteorological data 
derived from both satellites or climate stations. The result was the creation of yearly 
predictive risk maps defining low to high risk of infection with WNV for each RM.  
The 2003 epidemic provided a novel opportunity to study an important zoonotic 
disease emerging in a new environment. The information gathered will further the 
knowledge base upon which decisions for prevention of infection and clinical disease are 
made.  
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1. Introduction  
 
 
 
 
 
 
 
 
1.1    Background 
 West Nile virus (WNV) emerged in North America  in 1999. The disease was 
first identified in humans, birds, and horses in New York State (Drexler 2002). The 
virus quickly spread across the North American continent. The first Canadian report 
was a bird in Southern Ontario in 2001 (Weese et al. 2003).  In 2002, WNV was 
identified in birds and horses in Saskatchewan (Abutarbush et al. 2004).  By 2003, the 
virus was found in all three of the prairie provinces and veterinary practitioners were 
receiving questions about the disease from  horse owners. The questions included: “Is 
my horse at risk?  What can I do to prevent the disease? Is the vaccine necessary, 
effective and safe?” However, there was very little evidence available to veterinarians 
on how to determine the extent of this new disease threat, how to prevent infection 
and to best manage clinical disease.  
The horse industry is very important in Western Canada. Canadian Equine 
Federation commisioned a study to develop a profile of the industry and the horse 
herd in Canada (Equine Canada 1998). The 1998 National Horse Industry Study 
estimated the number of horses in Saskatchewan at 123,441 by sampling respondents 
from registries of different equine organizations. The survey also reported that the 
average horse industry participant was well educated, middle aged and of moderate to 
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high income (Equine Canada 1998). Horse owners invest significant resources into 
their animal’s health and well being and the appearance of a new and potentially fatal 
infectious disease caused great concern to the horse-owning public. Despite the length 
of time that this virus has been present in Europe and Africa, there were few answers 
to address their questions. What was assumed based on the behavoir of the virus in 
Europe and Africa did not seem to apply in this outbreak. When WNV emerged in 
North America it became clear that the ecology of the virus differed in its’ affects on 
birds (Drexler 2002). 
The vast geographic differences that exist in North America also presented 
new challenges to the research of WNV. What was learned about the behavoir of 
WNV in one region would not necessarily apply across the continent. For example, 
the primary mosquito species in the transimssion cycle differs in the Prairies from the 
Eastern states and provinces (Curry 2004, Andreadis et al. 2001). Vastly different 
environmental conditions exist in North America from the temperate regions of 
southern Canada to the tropics of Florida. With these differences existing in North 
America, specific regional investigations would be required to address local concerns.  
Following the experience of other areas in North America and the incursion of 
the virus into Saskatchewan in 2002, the potential for a WNV outbreak was very real 
for the 2003 season. Attempts to predict areas of risk in the province were limited to 
historical mosquito data from the 1960’s when the last major outbreak of a mosquito-
borne disease in Saskatchewan horses occurred (McLintock et al. 1966, personal 
communication with Phil Curry). Researchers and public health officials recognized 
the need to monitor the extent of WNV infection in 2003, and horse owners and 
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veterinarians were eager to help investigate this disease and find answers to their 
questions about prevention and control. 
 
1.2 Investigative approach 
  
In the spring of 2003, a comprehensive study was designed to look at the risks 
associated with WNV infection in horses. The overall objectives of the 2003 study 
were to work with sentinel veterinary practices to document the occurrence of clinical 
cases, to use serologic tests to measure prevalence of asymptomatic infection, and to 
explore risk factors for infection and for clinical disease manifestation. The answers 
to study questions would describe geographic areas of risk, factors associated with 
increased risk, and potential methods for controling the disease.  
Once it was established where in the province the virus could exist and cause 
disease, the next step would be to see if there were methods of quantifying risk on a 
regional basis using minimal surveillance input. Surveillance initiatives while 
targetted at providing relevant data can be quite cost prohibitive. The primary push 
for surveillance is from the Public Health standpoint, making prediction of areas at 
high risk for humans the main goal. However, knowledge of regions and conditions 
of high risk of infection and disease of horses with this virus could provide critical 
information of risk for human infection. 
The investigation began in 2003, which was the second year of recognized 
WNV incursion into Saskatchewan as well as the most extensive epidemic year to 
date. The investigation encompassed the southern portion of the province of 
Saskatchewan and used information from private veterinary practices and commercial 
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laboratories to minimize costs. The study continued in 2004 and 2005 as a component 
of Saskatchewan Health’s integrated surveillance initiative.  
This study forms the foundation for this thesis. Speculation for the studies in 
this thesis to be carried out was that 2003 would be an epidemic year for West Nile 
virus equine clinical disease which would allow research on many aspects of the 
ecology and epidemiology of West Nile virus.   
Chapter 2 will review the pertinent literature to date for WNV infection in 
horses and, therefore, includes information that was not available at the time the 
studies were designed in 2003.  
Chapter 3 deals with the clinical cases that occurred in Saskatchewan in 2003. 
The goal was to document the distribution of the cases as well as assess risk factors 
associated with mortality from clinical disease.  
Chapter 4 summarizes a kinetics study that looked at changes in the 
concentration of IgG antibodies over time in horses exposed to WNV with different 
clinical and vaccination histories.  
Chapter 5 reports the results of a serologic study which documented the extent 
of asymptomatic infection in horses and examined risk factors associated with 
infection. This chapter will explain the cutoff value  that was used to determine the 
infection status for vaccinated horses.  
Chapter 6 describes the case-control study based on a subset of the 
documented clinical cases. It focuses on risk factors associated with the development 
of clinical disease.  
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Chapter 7 provides a summary of the surveillance of horses over a 4 year 
period, 2002-2005. It assesses the progression of WNV in the province’s horses 
population over that time period as well as the assessing the usefulness of this data in 
an integrated surveillance initiative by Public Health officials.  
Chaper 8 describes the ecology of WNV and the creation of a predicitve risk 
model and subsequent risk map of infection with WNV in the province of 
Saskatchewan.  
Chapter 9 will provide a summary of the major conclusions from this thesis 
with possible future implications.  
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2.  Literature Review 
 
 
 
 
 
 
 
 
 
                                                       
 
2.1   Introduction  
West Nile Virus (WNV) has a long history spanning many continents and 
countries. Until its introduction into North America, WNV was not widely researched 
and was considered a minor arbovirus with only sporadic outbreaks in either humans 
or horses (Zeller et al. 2004, Gerhardt 2006). The resulting rapid spread across North 
America has prompted interest in studying arboviruses; in the possibility that 
seemingly harmless pathogens can become a threat in a new environment or that 
because of climate change arboviruses may re-emerge as public health concerns 
(Jonsson et al. 2000, Zeller et al. 2004, Gerhardt 2006) .  
The first objective of this literature review was to present an overview of 
WNV as it was known until 1999 and then after the  virus was introduced into North 
America in 1999. The second objective was to review what is known about how 
birds, mosquitoes and the environment are involved in disease transmission, 
specifically those factors that might be important in Saskatchewan (SK). The third 
objective was to summarize what has been reported about WNV infection in horses 
including: clinical manifestations, testing options available within the Canadian 
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prairie provinces, and vaccination. Finally, this review examined the potential use of 
spatial epidemiology to predict the risk of infection from this vector-borne disease. 
 The databases that were searched included CAB Abstracts and Agricola, 
through the University of Saskatchewan Library website. The search parameters 
included the words “West Nile virus” with occasional specific reference to horses, 
mosquitoes, humans and birds. This search was initially performed  in early 2003, but 
was repeated in late 2006 to ensure that all of the most current published information 
was included. In late 2006, there was initially over 1800 references but through 
identification of duplicates and articles of limited usefulness, the list of usable 
references was decreased dramatically. In addition, the Yahoo internet search engine, 
was used to search for provincial and federal government sites, technical reports,  and 
other grey literature articles on WNV in North America. As well, pertinent articles 
published in 2007 were included in the thesis as they were identified by the 
researchers involved in this thesis.  
 
2.2   Old World experience with WNV 
West Nile virus is a vector-borne zoonotic disease that is transmited between 
birds and mosquitoes with occasional spill-over into susceptible hosts, usually human 
or equine (Hayes 1989). The virus was first identified in the blood of a woman in the 
West Nile Province of Uganda in 1937 (Smithburn et al. 1940). Ecological studies in 
Egypt established the natural amplification cycle between birds and mosquitoes 
(Work et al. 1955, Taylor et al. 1956).  
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Until 1999, the virus was only reported in Africa, Europe and Asia (Hayes 
1989). The virus is believed to have been transported from Africa to Europe through 
migrating birds (Hubalek et al. 1999, Durand et al. 2002). One such example was an 
outbreak in the summer of 1962 during which  50 horses with neurologic symptoms 
were diagnosed in the Camargue region in Southern France (Bouches-du-Rhộne 
Province) (Murgue et al. 2001). Several concurrent human cases were also reported. 
The area includes a large wet area corresponding to the delta of the Rhộne river 
which has a high mosquito density. The region is home to many wild bird species and 
is an important resting area for migratory birds (Murgue et al. 2001). There were no 
reports of avian species die-off associated with this outbreak.  
Following this outbreak, a serosurvey was completed during 1963 and 1964 
on 37 asymptomatic horses from the Camargue region. Six of the 37 horses were 
positive for antibodies to WNV (Durand et al. 2002). In 1965, WNV was confirmed 
as the cause of neurologic symptoms in three more horses. In 1975-1979 another 
serosurvey in the Camargue region showed a low frequency of antibody response to 
WNV (2%, 99 horses tested) (Murgue et al. 2001). It was not until the summer of 
2000, that the area had another confirmed symptomatic case of WNV in a horse. A 
serosurvey conducted during and following the 2000 outbreak (combined with WNV 
history since 1962), showed that the seroprevalence rate did not increase with age, 
indicating that this was an epidemic area with periodic outbreaks followed by long 
silent periods (Durand et al. 2002).  
Another serosurvey was conducted in southern France, near the French 
Riviera in 2003 (Durand et al. 2005). No unusual bird mortality was seen in the area 
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but an entomological study was conducted within the serosurvey region resulting in 
low mosquito numbers with all batches negative for the virus. Of most interest was 
that equine seroprevalence declined with increasing distance away from two 
important bird areas, with all stables where the Immunoglobulin (Ig)G seroprevalence 
was over 30% within 5 km and all IgM positive horses located within 3.5 km of these 
areas. In addition, stables with IgM positive horses had substantially higher IgG 
seroprevalence than stables with no IgM positive horses, 71% and 12% respectively. 
Many European countries have reported outbreaks with human cases. 
Examples include Romania in1996 (Tsai et al. 1998) and Russia in 1999 (Platonov et 
al. 2001). Others have reported outbreaks in the horse population such as Italy in 
1998 (Autorino et al. 2002), France in 2000 (Murgue et al. 2001), and Israel also in 
2000 (Steinman et al. 2002). Although WNV antibodies have been identified in wild 
birds in many countries of Europe, Africa, and Asia (Malkison et al. 2002, Lundstrom 
1999, Hayes 1989), clinical disease in wild birds was not reported prior to 1998 
(Zeller et al. 2002). In September-October 1998, there was an outbreak of WNV in a 
flock of wild migrating white storks and a flock of domestic geese in Eilat, Israel 
(Malkison et al. 2002). Table 1 gives an overall view of the outbreaks that have 
occurred in the Old World since WNV was first recognized in Uganda.  
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Table 1: Overview of human, horse and bird outbreaks of West Nile Virus in the Old 
World from 1960 to present. Adapted from Hubalek et al. 1999 and Zeller et al. 2004. 
Year Country  Species affected 
unknown Former Yugoslavia H 
1960’s Spain 
France  
Italy 
Portugal 
Bulgaria 
Romania 
Austria 
Russia 
H 
H, Ho, M, B (wild) 
H, B (migrating, chickens), Domestic mammals, Rodents, Goats 
C, S, Ho, H, M, B (wild)  
H, Domestic animals, B (wetland) 
M, H 
B (wetland), Reptiles, Domestic/wild animals, H 
H, Ticks, B (water), M 
1970’s Spain 
France 
Greece 
Bulgaria 
Hungary 
Slovakia 
Austria 
Belarus 
Ukraine 
Moldavia 
Czechland 
Rodents 
H, H 
H, Domestic animals, Rabbits, B 
M 
Rodents, C, H 
H, M, B (migrating, pigeons), Game animals, C, S, Dogs 
B (wetland), Reptiles, Domestic/wild animals, H 
H, B (wild) 
H, M, B 
Ticks, M, H 
Domestic animals, Hares 
1980’s Italy 
Romania 
Ukraine 
Bohemia 
Moravia 
Rodents 
H 
H 
Game animals 
B (wetland, cormorants), M, H 
1990’s Italy 
Romania 
Poland 
Morocco 
Israel 
Algeria 
Tunisia 
Russia 
Ho 
H, Domestic/wild animals, Dogs, B (wild) 
B (sparrows) 
H, Ho 
H, Ho, Birds (geese, storks) 
H 
H 
H 
2000 France 
Morocco 
Israel 
Russia 
H, Ho 
Ho 
H, Ho 
H 
Abbreviations: Humans (H), Mosquitoes (M), Horses (Ho), Birds (B), Cattle (C), Sheep (S). 
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2.3   New World experience with WNV 
West Nile Virus was introduced to the North American continent in 1999 
(Drexler 2002, Gerhardt 2006); however, the route by which the virus entered the 
United States is unknown (Lanciotti et al. 1999). The North American experience 
with WNV has been very different than that in Europe, namely in the rapid spread of 
disease across the continent and the presentation of clinical disease in many wild bird 
species. Following the introduction of WNV into the North American continent and 
before the first human and horse cases were recognized,  there were significant die 
offs of wild birds, specifically members of the corvid family (blue jays, crows, 
ravens, etc) . Corvids continue to be the sentinel for monitoring the progression of 
disease (Drexler 2002, Castillo-Olivares et al. 2004).  
The first reported cases of neurologic disease in humans occurred in early 
August of 1999 in the suburb of Queens, New York city (Drexler 2002) and in horses 
in late August on Long Island, New York (Ostlund et al 2001). Originally, due to lack 
of specific testing, a diagnosis of St. Louis Encephalitis (SLE) was given for the 
human cases. It was the combination of bird deaths, zoo specimen deaths, human and 
horse cases, along with the diligence of human doctors and one veterinarian at the 
Bronx Zoo that finally led to the correct diagnosis of WNV rather than SLE (Drexler 
2002). There were approximately 10,000 crows that died during the outbreak and 
state residents reported a total of 17,000 dead birds (includes crow numbers) in New 
York state alone.  
After the initial year, the virus made a swift and relentless  progression 
outward from New York State. Mosquitoes collected from sewers and dwellings in 
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New York City during the winter of 1999-2000 were found to be infected with the 
virus (CDC 2000) and, therefore, WNV was expected to reemerge the following 
summer. Using information on migratory bird involvement and the outbreaks seen in 
the Old World (Asia, Africa and Europe), one paper printed in July-August of 2000, 
suggested that the next likely spot for an outbreak would be the coastal plain of 
Georgia, northern Florida or Alabama (Rappole et al. 2000). However, the spread of 
WNV in the following year included only other Northeastern states (USDA 2001, 
Ostlund et al. 2001, Trock et al 2001). Despite this inconsistency, migratory birds 
have been a necessary element in understanding the large geographic spread of WNV 
in subsequent years (Peterson et al. 2003).  
Few random serologic studies were conducted or reported that looked at the 
infection rates of asymptomatic horses. In a 1999 geographically limited New York 
State serosurvey of 69 asymptomatic stable mates of clinical cases, 20 (29%) had 
titers to WNV (Trock et al. 2001). In 2000, a Staten Island serosurvey of 91 clinically 
normal horses (located within 3 miles of a clinical horse case of WNV) found 7 
(7.7%) seropositive horses (Trock et al. 2001). Further categorization of the 
serological results revealed that the seropositivity rate was higher on farms with 
clinical disease than without; in 1999, 23% to 8% respectively and, in 2000, 5% to 
<1% respectively (Kramer et al. 2001). 
A 2000 case-control study from the northeastern states used “case equid” to 
represent both those that were confirmed clinical cases and those that were 
asymptomatic seropositive horses (USDA 2001). The percentage of infected horses 
using only horses from farms with at least one ‘case’ horse was 9% (54/594). 
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Approximately 40% of the horses (both clinical cases and asymptomatic horses) in 
this study were housed within a barn (USDA 2001). This study made 
recommendations for the protection of horses from clinical disease which included 
vaccination, housing and mosquito control.  
The spread of WNV continued and by 2002 most eastern and mid-western 
states had reported the virus (CDC 2002). Up until this point, research on the virus 
and its spread involved detecting the virus in eastern moquito species and evaluating 
their transmission competency experimentally (Andreadis et al. 2001, Sardelis et al. 
2001). Different mosquito species carried the virus from the natural amplification 
cycle to horses in the Eastern areas (C. pipens, C. salinarius, C. nigripalpus, etc) 
compared to the Western or Great Plains areas (C. tarsalis) of the continent 
(Andrealis et al. 2001, Sardelis et al. 2001, Gerhardt 2006). As WNV moved across 
the North American continent, inter-year trends began to emerge which included an 
introductory year followed by an epidemic year and then subsequent years of 
substantially less clinical disease (Bell et al. 2006). In addition, environment 
conditions were shown to have a huge influence on local WNV activity (Bell et al. 
2005, Rainham 2005, Shaman et al. 2005). 
A preliminary descriptive study of the 2002 outbreak in Colorado and 
Nebraska was published in early 2003 (Salazar et al. 2003). The statistical analysis of 
this outbreak was presented in a paper published in 2004 which identified gender, 
age, recumbency and vaccination as factors associated with clinical outcome of the 
symptomatic horses. Similar findings were reported in two other studies, one from 
Indiana and the other from North Dakota (Ward et al. 2004, Schuler et al. 2004). In 
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addition, a study from Colorado looked at factors associated with testing positive for 
WNV infection in equids exhibiting clinical signs consistent with WNV (Tanner et al. 
2006). Factors significantly associated with testing positive compared to testing 
negative included vaccination status, severity of clinical signs, location of horses, 
duration of illness and season of illness. Age, breed and laboratory performing the 
testing were not significantly associated with test status in horses exhibiting clinical 
signs.  
By the summer of 2001, the virus had been diagnosed in southern Ontario. By 
2002, the virus had spread as far west as the southeastern area of Saskatchewan 
(Weese et al. 2003, Abutarbush et al. 2004). WNV was detected in horses, 
mosquitoes, domestic geese, corvids, sentinel chicken flocks and wild ducks across 
the southern one third of Manitoba in 2002 (Austin et al. 2004, personal 
communication, Shelagh Copeland). The number of reported horse cases in 2003 was 
dramatically less than 2002 (personal communication, Shelagh Copeland). The 
experience of WNV in Saskatchewan is the basis of this thesis and will be presented 
in the body of the thesis. The province of Alberta had its first case of WNV in 2003. 
A total of 170 symptomatic horses were confirmed IgM positive during a 5 month 
period beginning in July (Ollis et al. 2005). The outbreak was concentrated in 
southern Alberta with the majority of owners (98%) reportedly not using mosquito 
control programs or housing their horses outdoors at dusk and dawn.  
Serosurveys in the United States were likely not performed after 2003 as there 
was widespread use of a killed vaccine which would complicate interpretation of 
serologic test results (Long et al. 2006). Instead, the majority of serosurveys reported 
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were from Central America, with approximately 16% to 53% of sampled clinically 
normal horses showing evidence of WNV infection (Estrado-Franco et al. 2003, 
Blitvich et al. 2003, Quirin et al. 2004, Lefrancois et al. 2005). In Guadelupe, the 
overall prevalence of WNV in the first year of the virus (July 2002) was 2.8% and 
this increased to 50% in July 2003 (Quirin et al. 2004).  
In states and provinces in which the clinical disease emerged in humans and 
horses, clinical cases were usually preceded by avian die-offs at least a month or two 
before the first reported cases (Guptill et al. 2003, Zeller et al. 2004, Johnson et al. 
2006). In Canada, a WNV surveillance program was developed and was based on the 
submission of dead birds for viral testing. Many provinces also provided 
documentation of clinical human and horse cases (CCWHC 2005, Saskatchewan 
Health 2006). Many research studies from both Canada and the United States that 
analyzed bird, mosquito, horse and human cases began to emerge with much 
emphasis on early warning and surveillance systems (Johnson et al. 2006, Marfin et 
al. 2001,  Brownstein et al. 2004, Eidson et al. 2005, Orme-Zavaleta et al. 2006). 
These studies also provided the pros and cons of using of some or all of the different 
species in the surveillance of WNV.  
 In four short years, the virus had crossed an entire continent causing 
thousands of clinical horse cases with a wide range of mortality rates (Castillo-
Olivares et al. 2004). As of 2006, WNV should be considered endemic to most of 
North and Central America. A few review papers have been compiled that provide an 
overview of WNV in both the New and Old World (Zeller et al. 2004, Castillo-
Olivares et al. 2004, Gerhardt 2006). 
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2.4   Transmission cycle 
WNV is a member of the Japanese encephalitis virus serogroup in the genus 
Flavivirus, family Flaviviridae (Hayes 1989). Examples of viruses that make up this 
group are Japenese Encephalitis virus and St Louis Encephalitis virus. These viruses 
fit into the category of arthropod-borne viruses or arboviruses. This means that they 
are all transmitted among vertebrate hosts by arthropod vectors such as mosquitoes.  
WNV is maintained by a natural amplification cycle involving mainly birds 
(various species) and mosquitoes (mainly of the genus Culex (C.) but potentially 
other genera as well) (Hayes 1989). The particular species of mosquitoes involved in 
the cycle is geographically dependent. Virus containing mosquitoes can transmit the 
virus to susceptible mammals when conditions are favorable. Mammals, such as 
horses and humans, are considered dead-end or incidental hosts for the virus in that 
they do not produce enough virus to re-infect a mosquito and maintain the 
transmission cycle, but viremia in some cases is sufficient to result in clinical signs 
(Bunning et al. 2002). (See figure 1: Transmission cycle). 
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Figure 1: Transmission cycle (based on information known in 2003 with an emphasis 
on prairie mosquito species) 
 
Culex restuans and Culex tarsalis are the main mosquito species involved in 
the transmission cycle of WNV in Saskatchewan (Curry 2004). In Saskatchewan, 
WNV has also been found in Culiseta inornata, but its role in transmission remains 
unknown (Curry 2004). C. restuans feeds primarily on birds and is thought to be 
involved in the bird to bird amplification of the virus (Curry 2004). C. tarsalis prefers 
to bite birds, but switches to a mammalian source of blood meals around mid-July 
after the birds fledge (Curry 2004). This species prefers sedge meadow areas where 
there are shallow pools of stagnant water, such as hoof prints. This species is known 
to bite several times, especially in hot weather and is considered the main vector of 
transmission to mammals. Culiseta inornata prefers permanent wetlands, usually 
bites once and prefers a mammalian source (Curry 2004).  
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Until the summer of 2003 when mosquito trapping became part of the 
Saskatchewan provincial surveillance program, the only reliable mosquito data was 
from the 1960’s and 1970’s (see figure 2: Historical C. tarsalis data). The distribution 
of C. tarsalis was limited to “at or below the Yellowhead (Number 16) highway” 
(personal communication with P. Curry, Saskatchewan Health). Since the 2003 
summer season in which extensive mosquito trapping from all areas of the southern 
portion of Saskatchewan was carried out, the distribution map has changed 
dramatically to include areas as far north as Meadow Lake, SK. 
 
 
Figure 2: Historical C. tarsalis data (source: Phil Curry, Sask Health) 
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Birds are the other half of the natural amplification cycle. Crows, which are 
members of the corvid family of birds, are considered a hardy species that feed on 
everything from restaurant scraps to roadkill (Drexler 2002). However, when WNV 
first appeared in New York city in 1999, it was the massive die-off of crows and zoo 
specimens that finally assisted in identifying the correct diagnosis (Drexler 2002, 
Ludwig et al. 2002). During the winter of 1999-2000, study of dead birds continued 
with the first identification of WNV in the brain of a Red-tailed Hawk (Garmendia et 
al. 2000).  
Researchers have since recognized more than 130 species of birds in addition 
to other members of the corvid family, such as Magpies, Gray Jays and Blue Jays, 
that can become infected and probably transmit WNV (CDC 2003). Experimental 
infection studies have estimated reservoir competency for a variety of species. The 
Blue Jay had the highest reservoir competency index. American Crows and House 
Sparrows were very similar in the mean duration of infectiousness and reservoir 
competency, but Crows had a higher number of fatal infections (Komar et al. 2003).  
Experimental studies have also shown that bird to bird transmission can occur 
as well as transmission via mosquitoes (Komar et al. 2003). A report of an outbreak 
in domestic geese was recorded in Manitoba in 2002 (Austin et al. 2004). This report 
hypothesized that direct bird to bird transmission in addition to mosquito transmission 
was required for the seroprevalence patterns seen in this flock. 
In Saskatchewan, the first positive bird was found in August 2002. In 2003, 
the first bird was found at the beginning of June in Regina, SK (personal 
communication, P Curry). The Canadian Cooperative Wildife Health Center  
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(CCWHC) coordinated the submission of dead birds across Canada starting in 2001. 
A recent CCWHC report indicated after 2003 there was a steady decline each year in 
the submission rate in all three prairie provinces (CCWHC 2005).  
 A potential concern of the wild bird surveillance is that it relies solely on the 
public for detecting and reporting of dead birds (Ward et al. 2006). Therefore, the 
numbers and locations of submission can be influenced by human-related factors such 
as population density, awareness and collection services. In 2005 and 2006, research 
involving identification of the virus in House Sparrows was initiated in Saskatchewan 
(personal communication, F. Leighton). The use of House Sparrows was thought to 
better reflect the rural areas of the province and possibly provide more localized 
evidence of WNV (CCWHC 2005).  
 
2.5   Clinical manifestation in horses 
Horses are incidental hosts or “dead-end hosts”; individuals which can exhibit 
clinical signs but are thought to rarely develop high enough viral levels in the blood 
to infect mosquitoes or be a component in sustaining the cycle of WNV (Castillo-
Olivares et al. 2004). The incubation period is generally 6-10 days; however, it has 
been shown to be as long as 20 days (Smith 2002). In horses, the virus can produce 
varying degrees of clinical neurological symptoms ranging from mild ataxia, tremors 
or facial nerve paralysis to severe paralysis of one or more limb(s), recumbency and 
death (Oslund et al. 2000). A list of potential clinical signs is presented in Table 2; 
however, it is not an exhaustive list. Many infected horses show no clinical signs at 
all and without serologic testing remain unrecognized. In both field and experimental 
observations, it is estimated that up to 10% of horses infected with WNV will present 
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with neurologic disorders (Castillo-Olivaries et al. 2004, Bunning et al. 2002).  
Clinical attack rates calculated using popoulation at risk (not just infected horses) 
were estimated as 8.4% (Ward et al. 2006) and 12.9% (Salazar et al. 2004) for all 
premises with clinical cases, but <1% for the entire state of Texas (Ward et al. 2006). 
The case fatality rate of horses generally ranges from 25 – 40% in horses 
(Ostlund et al. 2000, USDA 2001, Murgue et al. 2001, Ostlund et al. 2001, Trock et 
al. 2001). The prognosis is poor for horses that have severe paresis or paralysis of one 
or more limbs that results in recumbency (Cantile et al. 2000, Ostlund et al. 2000, 
Long et al. 2002, Salazar et al. 2004). This is especially true if the horse is recumbent 
and unable to get up, particularly for more then 3-5 days (Long et al. 2002, Salazar et 
al. 2004).  
Duration of clinical signs for those that survive can range from days to weeks 
to months. In one study, 82% (276/338) of owners contacted reported “full recovery” 
1-3 months after diagnosis (Salazar et al. 2003, Salazar et al. 2004). In another study, 
16 of 19 (84%) owners contacted 6 months after discharge of their horse from the 
hospital reported their horses had recovered from WNV clinical signs (Porter et al. 
2003). Some mild lingering effects reported in horses consisted of decreased stamina, 
weight loss and or loss of condition, reversible weakness or ataxia and behavioral 
changes (Salazar et al. 2003, Porter et al. 2003). Treatment of the clinical disease 
usually involves anti-inflammatory drugs and supportive care aimed at minimizing 
injury or adverse effects of prolonged recumbency (Ostlund et al 2000). 
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Table 2:  Summary of clinical signs of WNV in horses. The percentages were 
compiled from multiple sources (Murgue et al. 2001, USDA 2001, Trock et al. 2001, 
Ostlund et al. 2001, Zeller et al. 2004, Ollis et al. 2005). 
 
Sign Percentage 
Ataxia (rear or all 4 limbs) 75-95% 
Weakness (mainly hind limbs) 48-69% 
Muscle Fasciculation (mostly facial) 40-60% 
Dull, Lethargic 61% 
Recumbency 38-45% 
Body stiffness or reluctance to move 43% 
Decreased appetite 36% 
Fever 23-35% 
Altered mentation 31% 
Hyperesthesia 30% 
Cranial nerve deficits (droopy lips, muzzle ears, etc) 18-27% 
Death 25-40% 
 
 
2.6   Diagnostics for horses 
There are several tests reported for use in diagnosing WNV infection in 
horses. The types of tests available are characterized by the type of sample collected 
(tissue versus serum), time-frame (detection versus diagnosis) and cost (research 
versus consumer). Virus isolation was available in some laboratories in 1999. 
However, because Level-3 laboratories are needed to isolate the virus, WNV 
diagnostics is usually based on the identification of antibodies to the virus (Ostlund et 
al. 2001). A plaque reduction virus-neutralization test  (PRNT) that looks for virus-
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neutralizing antibodies was used extensively in 1999 but it must be performed in a 
Level-3 facility (Ostlund et al. 2001). 
In anticipation of the increase in samples for detection of WNV infections 
post-1999, an IgM-capture enzyme-linked immunosorbent assay (ELISA) was 
developed (Ostlund et al. 2001). Prior to 2001, both a positive IgM and PRNT titer 
were considered confirmatory of WNV infection in a horse (Long et al. 2006). 
ELISAs are the most widely used method of diagnosis, likely due to factors such as 
the cost effectiveness, the ability to perform the test in any lab and fast turn-around 
time for a diagnosis using a single blood sample (Ostlund et al. 2000, Ostlund et al. 
2001, Long et al. 2006). However, while most diagnostic laboratories use this assay, 
it is not marketted as a commercial kit and as such the methodology and reagents do 
differ (personal comunication, Brian Chelack). A study conducted using the IgM 
ELISA from the National Veterinary Services Laboratory (USA), determined the 
sensitivity and specificity of the test to be 92% and 99% respectively (Long et al. 
2006). Prairie Diagnostic Services (Saskatoon, SK) obtained reagents from 
BioReliance (Rockville, Maryland) for an IgM ELISA test. This was not an 
established, validated assay kit and as such did not have any sensitivity or specificity 
estimates. This laboratory also had reagents available to perform an IgG ELISA.  
IgM antibody to WNV develops 8-10 days post infection and persists for less 
than 2-3 months (Ostlund et al. 2001). The presence of this antibody can be used to 
identify recently infected horses, specifically those which are ‘symptomatic’ or 
clinical cases of WNV displaying neurologic symptoms. It is less useful for 
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surveillance since the antibody response can be missed in some animals with sporadic 
sampling due to its short duration in the horse.  
The IgG antibody develops within 3 weeks post infection and has been known 
to persist for greater than 2 years (Durand et al. 2002). This antibody is good for 
surveillance, but the potential persistence of the antibody for over 2 years and 
potential  response to vaccination can complicate the interpretation. Little data are 
available on the kinetics of the IgG antibody over time in horses either naturally 
exposed to WNV or in horses that were vaccinated (Ng et al. 2003).  
 
2.7   Equine vaccination and other control measures 
In late 2001, a vaccine for prevention of clinical disease in horses was 
approved for use in horses in the United States  and was fully licensed in 2003. In late 
2002, this vaccine began entering the Canadian market (through emergency release) 
and was widely used after it was fully licensed in 2003 (personal communication, 
Larry Frischke, Wyeth Animal Health). The vaccine was a killed product produced by 
Wyeth Animal Health; West Nile-InnovatorTM (Wyeth 2005). Label 
recommendations stated that naïve horses should be vaccinated intramuscularly twice 
three to six weeks apart with adequate time for the vaccine to stimulate immune 
response prior to the mosquito season.  
In a study to assess the efficacy of the vaccine, development of viremia 
(surrogate for development of clinical disease) was assessed after a viral inoculation 
challenge conducted one year post vaccination (Ng et al. 2003). There was a 
significant difference between vaccinates and controls, demonstrating 94% efficacy. 
Preliminary field data from out of the USA was starting to emerge in 2003 which 
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appeared to show the vaccine was capable of increasing the survival rate of horses 
that did develop clinical signs (Salazar et al. 2003, Salazar et al. 2004, Schuler et al. 
2004).  
In late 2003,  a modified-live recombinant virus vaccine was introduced and 
manufactured by Merial (Minke et al. 2004). The company claimed the new 
recombinent vector vaccine technology stimulated both humoral and cell-mediated 
immune responses (Merial 2004). The company recommended that for horses 
previously vaccinated with the killed product, only a single booster was required to 
maintain protection (Grosenbauhg et al. 2004, Siger et al. 2004). The vaccine is 
licensed to protect against clinical disease and has been demonstrated to protect 
horses against disease induced by a virulent strain of WNV administered intrathecally 
(Siger et al. 2006).  
To date, only one study has tested the efficacy of the killed and the 
recombinant vaccines under natural field conditions (Gardner et al. 2007). Despite a 
small sample size, it seemed to show that both vaccines were effective in preventing 
clinical disease due to West Nile virus. A more indepth look at vaccination 
recommendations, specifically for pregnant mares, foals and weanlings can be found 
in the Proceedings of the 51st Annual Convention of the American Association of 
Equine Practitioners (AAEP) (Wilson 2005).  
Other vaccine technologies are being developed but their use will likely be 
limited due to the efficacy of the previously mentioned vaccines. Fort Dodge Animal 
Health created a DNA vaccine which it claims can induce protective immunity in the 
presence of maternally derived antibodies (Chiang et al. 2005). In addition, a live 
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attenuated WNV Chimera vaccine for horses was created by Intervet (Long et al. 
2005). Through clinical trials, this vaccine provided 95% protection against WNV 
disease.  
In 2000, many vector abatement recommendations were listed that people 
could use to protect themselves and their horses from the virus. These 
recommendations were aimed at decreasing exposure to the virus. These include 
housing in an enclosed barn, the use of fans or altered lighting in barns, mosquito 
repellent application and elimination of common mosquito habitat and breeding areas 
(Ostlund et al 2000). A common form of mosquito control for horses on prairie 
pastures is the use of smudges; smoky fires designed to provide temporary areas of 
decreased adult mosquito populations.  
 
     2.8 Role of environment in the ecology of WNV 
Warm winters with hot and dry conditions in the following summer are 
condusive to WNV outbreaks (Epstein 2001). Climate variations, including 
temperature and hydrologic conditions have effects on mosquito populations and the 
pathogens they can carry (Shaman et al. 2005, Mellor et al. 2000, Hay et al. 1996, 
Hay et al. 1998). Recently, vegetation cover, land cover and even elevation have been 
assessed as variables that affect or are indicative of vector habitat suitability (Ward et 
al. 2005, Curran et al. 2000). The ecology of vector-borne disease involves a complex 
interaction between the environmental determinants of vector abundance and 
distribution, the pathogen and the hosts (Kitron 1998). Incorporating this knowledge 
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into the epidemiological study of these diseases can greatly enhance the analysis 
(Rogers et al. 2003, Kitron 1998, Brooker et al. 2002). 
Several new spatial tools have become readily available for use in the study of 
disease. These include geographic information systems (GIS), global positioning 
systems (GPS), remote sensing data (particularly satellite imagery) and the 
specialized field of spatial epidemiology (Kitron 1998). GIS is a database that allows 
storage of the geographical information (often obtained by GPS) for each observation 
that when combined with spatial analysis tools can offer ways to map and explain 
relationships in both time and space (Rogers et al. 2003, Kitron 1998). Remote 
sensing is the measurement of properties of objects by sensors that are not in direct 
physical contact with the object (Jensen 2005). Satellite-derived data is one form of 
remote sensing that has gained wide use in the study of vector-borne diseases because 
it provides continuous spatial data across vast regions on defined temporal scales 
(Hay et al.1996, Kitron 1998, Rogers et al. 2003).  
By using remotely-sensed and other geographically linked data, 
epidemiologists can examine patterns, explain relationships and make predictions of 
disease potential, even in unsurveyed areas (Hay et al. 1998, Kitron 2000, Rogers et 
al. 2003). Examples of this have spanned a variety of different diseases such as 
malaria, schistosomiasis, Lyme disease, Hantavirus and Leishmaniasis (Dister et al. 
1997, Glass et al. 2000, Hendrickx et al. 2000, Kuhn et al. 2002, King et al. 2004). 
Applications to other diseases are limited only by the present technology and 
knowledge of the ecology of specific diseases (Beck et al. 2000). Assessment of the 
accuracy of these predictive models is essential but often forgotten; especially 
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whether existing models can be applied to different locations (Brooker et al. 2002). 
Accurate predictive models can have application in both control of the disease, 
designing of intervention strategies and refining research questions and surveillance 
systems (Kitron 2000, Rainham 2005).  
 
     2.9 Conclusions and research needs 
This literature review has summarized both the peer-reviewed literature  and 
other pertinent local sources of information relating to WNV. Many questions 
remained in 2003, four years after the virus first appeared in North America. What 
was the distribution of clinical disease in the temperate climate of Saskatchewan? 
What was the distribution and proportion of asymptomatically infected horses? Was 
vaccination efficacious in the field for the prevention of clinical disease or mortality 
from clinical disease? What risk factors were important for clinical disease and 
asymptomatic infection? How did WNV activity change over several years? Can 
environmental and climatic factors predict the risk of infection? These questions 
formed the basis of the studies designed and conducted for this thesis. This review 
represents the knowledge to date and therefore, surpasses what was known in 2003. 
While the primary goal of this research was to further expand the information 
available on WNV in horses, the result could perhaps highlight effective methods to 
approach other emerging diseases of public health interest in the future.  
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3.  Factors associated with West Nile virus fatalities in horses. 
 
 
 
 
3.1 Introduction  
 West Nile virus (WNV) is an arbovirus (arthropod-borne virus) that affects the 
nervous system of humans, horses, and birds, causing mild to severe illness and 
sometimes death (Hayes 1989). It was first reported in Africa in 1937 (Smithburn et al. 
1940) and has been identified sporadically in European countries from the early 1960s to 
the present (Hubalek et al. 1999, Murgue et al. 2001, Autorino et al. 2002). Since it was 
diagnosed in New York state in 1999, WNV has spread across the North American 
continent (Ostlund et al. 2001, USDA 2001, Porter et al. 2003, Salazar et al. 2003).  
In Canada, WNV infection was first seen in birds in southern Ontario in 2001 
(Weese et al. 2003). Since 2001, throughout Canada, the date and location of birds found 
dead that tested positive for WNV were systematically recorded by the Canadian 
Cooperative Wildlife Health Centre. In 2002, the first equine cases (those showing 
clinical signs consistent with WNV infection) were identified in Ontario, Manitoba (MB), 
and Saskatchewan (SK) (Weese et al. 2003, Abutarbush et al. 2004). In SK, there was 
only a passive system to monitor the occurrence of clinical disease in horses, which, 
unfortunately, resulted in the numbers reported varying, depending on the source of 
information.  
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The virus is amplified in a natural cycle between birds and mosquitoes and 
incidentally infects humans and horses. In western Canada, Culex (C.) restuans and 
Culex tarsalis are the major mosquito species responsible for transmission in the 
amplification cycle. Culex tarsalis is considered the most important vector for 
transmission of WNV to humans and horses (Curry 2004). Horses can become infected 
when bitten by a mosquito carrying the virus, but they do not contribute to the spread or 
amplifcation of the virus in the natural cycle (Bunning et al. 2002). Once bitten, a horse 
may eliminate the virus uneventfully or show clinical signs including fever, depression, 
muscle tremors, weakness, lack of coordination, inability to rise, and paralysis (Ostlund 
et al. 2000). The incubation period of infection to manifestation of clinical signs is 5-15 d 
(CFIA 2005). Most reports suggest that around 25%-45% of those horses that show 
clinical signs die or require euthanasia (Ostlund et al. 2000, Murgue et al. 2001, Ostlund 
et al. 2001, Autorino et al. 2002, Porter et al. 2003, Salazar et al. 2004).  
Factors significantly associated with fatality from WNV clinical disease include 
non vaccinated status for WNV; age; clinical signs such as inability to rise; early season 
onset of clinical disease; sex; and breed (Salazar et al. 2004, Schuler et al. 2004). Horses 
given either 1 or 2 doses of vaccine (even if it was not given according to the 
manufacturer’s recommendations) seemed less likely to die than unvaccinated horses 
(Salazar et al. 2004, Schuler et al. 2004). In one of these studies, death was more likely if 
clinical signs occurred first from March 1 to August 19, the animal was female, the 
animal was over 18 years of age or was unable to rise at any time during clinical illness 
(Salazar et al. 2004). 
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 Given the pattern of WNV spread across the continent, the number of horses in 
Saskatchewan showing clinical disease was expected to be higher in 2003 than in 2002. 
The first objective of this study was to document the date of onset, geographic location, 
and outcome of clinical cases of WNV infection in horses in Saskatchewan in 2003. The 
primary objective was to identify risk factors that could be associated with fatality in 
infected horses, including management, mosquito control, vaccination, individual horse 
characteristics, and environmental conditions.  
 
3.2 Material and methods 
3.2.1 Study population and protocol 
 Veterinarians in private practice, horse owners, and the staff of the regional 
diagnostic laboratory (Prairie Diagnostic Services (PDS), Saskatoon, SK) provided 
information on clinically affected horses in Saskatchewan during the summer and early 
fall of 2003. In June 2003, all large and mixed animal practices in the southern portion of 
Saskatchewan were contacted by facsimile and asked 1) to send any serum samples 
collected from horses where WNV infection was suspected to PDS in Saskatoon for 
Immunoglobulin (Ig)M enzyme-linked immunosorbant assay (ELISA) and 2) to allow the 
laboratory to notify the research team of any positive result from the samples submitted. 
Of the 79 veterinary clinics contacted, 51 responded to the facsimiles (signed) in June 
2003. Twelve more practices were contacted by PDS at the time a submitted sample was 
declared positive, giving a total cooperation rate of 80% (63/79).  
For the purposes of this study, the definition of a ‘clinical case’ was the presence 
of one or more of the classic signs of WNV clinical disease (ataxia, recumbency, paresis 
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or paralysis) or death; and a positive IgM ELISA. Once a ‘clinical case’ was identified, 
the veterinarian was contacted to obtain consent to contact the owner. If consent was 
given, owners were telephoned 2 to 4 weeks after the onset of clinical signs and asked for 
additional information. The telephone survey included questions about location, 
characteristics of the affected horse, management of that horse, vaccination status, other 
resident equids (horses, ponies, mules, donkeys), and mosquito control measures applied 
at both the farm and the individual animal level.  
In October, after the mosquito season, large or mixed animal veterinary clinics in 
each Regional Health Authority (RHA) were contacted to estimate the number of 
untested probable cases of WNV per region. A random numbers procedure was used to 
rank all of the the veterinary clinics in each RHA. Clinics from each RHA were then 
contacted by facsimile in random order until at least one third had responded. The 
participating veterinarians were asked to estimate the number of horses that were known 
or reported to have shown clinical signs consistent with WNV but were not tested for 
IgM antibodies during the 2003 season.  
 
3.2.2 Horse data 
The legal land location of the clinical case at the estimated time of exposure (up 
to 2 weeks before the first clinical signs) was requested for all cases where follow-up was 
obtained. Legal land location(LLL) included quarter, section, township, range, and 
meridian. In one instance, a global positioning system (GPS) unit was used to obtain the 
latitude and longtitude. For those cases in which the owner was unsure or unwilling to 
give the location, directions from the nearest town or township/range data were collected. 
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This information was cross-referenced with an electronic map of Saskatchewan. Using 
commercial geographical information systems (GIS) software (ArcView GIS version 3.2 
and ArcGIS version 8.0, Environmental Systems Research Institute Inc, Redlands, 
California, USA) spatial location was displayed as a point by using the centroid-of-the-
polygon for the land location. Confidentiality was maintained in all publications by 
summarizing location data at the RHA level.  
Statistics Canada’s 2001 Census of Agriculture estimated the number of horses 
and ponies (horse data) in Saskatchewan to be approximately 71300 and provided horse 
data by Census Consolidated Subdivisions (CCS). The CCS has similar boundaries to 
rural municipalities (RM), allowing estimation of the horse population by RHA 
(aggregations of RMs) and the mapping of cases per 1000 horse population by RHA. 
Data provided by the post season survey were aggregated and mapped by RHA to 
compare and assess the accuracy of surveillance using only confirmed cases of WNV for 
surveillance in 2003.  
The animals were classified by sex, color, age, and breed type, but not by specific 
breed. Breed type was divided into light horses, draft horses and crosses, ponies, and 
“other”. The category of “other” was composed of 3 miniature horses and one mule. Sex 
was reported in 3 categories: mare, gelding, and stallion. Color was divided into three 
categories: dark (chestnut, sorrel, brown, black, or bay), light (gray, white, palomino, 
buckskin, or dun), and multicolored (roan, paint, pinto, and appaloosa). Age was 
classified into three categories: young (≤5 years), adults (6-18 years) and geriatrics (>18 
years). Age was categorized because the odds of outcome was not thought to increase on 
a linear scale and so that the results were comparable with those of other studies (8).   
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Day of onset of clinical signs was aggregated into week of onset with Sunday as 
the start of the week. To allow for easier interpretation, week of onset was further 
categorized into weeks of the year, 31-33 (beginning of August), weeks 34-35 (epidemic 
peak, end of August), and weeks 36-38 (September). 
Housing was classified as housed in an enclosed barn, access to a simple three-
sided shelter with corral or pasture, or no access to a shelter in open pasture with or 
without trees. The method of mosquito control on farm was recorded as: smudges (smoky 
fire used to ward off mosquitoes), water removal, sealed barn, use of fans or special 
lighting in a barn, use of general insecticides, or no mosquito control attempted. The use 
of insecticide sprays on individual horses was recorded as yes (any amount or frequency) 
or no. 
 
3.2.3 Mosquito data      
      Mosquito data were obtained from the 2003 Saskatchewan Health mosquito trapping 
program. Center for Disease Control (CDC) traps were used for the collection of live 
mosquitoes for virus testing and New Jersey Light traps (NJLT) were used for the 
collection of dead mosquitoes for the determination of mosquito species.  C. tarsalis and 
C. restuans data were provided on a weekly basis from June to September as the average 
number of mosquitoes trapped per night. Variables of interest were (a) the highest weekly 
average for C. tarsalis from the whole season (Number of C. tarsalis), (b) the highest 
weekly average for C. restuans from the whole season (Number of C. restuans), (c) 
whether WNV was found in pooled mosquitoes of each species (Positive pool), and (d) 
the weekly average for C. tarsalis from the likely week of exposure for each case. For 
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each variable of interest, the results of the nearest mosquito CDC and NJLT trap were 
linked to each horse case.  
 
3.2.4 Environment data 
     Daily average temperature and precipitation data for all climate stations in 
Saskatchewan were obtained from Environment Canada. These values were used to 
create a ‘season average’ for temperature and ‘season total’ for precipitation. These 
variables were calculated for each climate station, using daily values for June, July, and 
August 2003.  The season average temperature was determined by dividing the sum of 
the daily temperature by the number of days; the season total for precipitation was the 
sum of the daily amounts of precipitation. The variables from the nearest climate station 
were linked to each horse case.  
     Cumulative growing degree days (GDD) are the sum of the positive daily differences 
between 16ºC (the threshold temperature for activity of C. tarsalis and virus 
transmission) and the mean temperature for that day (Woody Ornamentals 2003). ‘Season 
GDD’ was calculated for each climate station by using temperature data from May 1st to 
September 30th. Cases were assigned data from the nearest climate station with complete 
daily temperature and precipitation information. 
 
3.2.5 Statistical analysis 
The association between each risk factor and the final health outcome (fatality) 
was examined by using generalized linear mixed models with a binomial distribution and 
logit link function (Dohoo et al. 2003). The calculations were performed by using 
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penalized quasi-likelihood estimates and the second order of the Taylor series expansion 
(MLwiN version 2.0, Centre for Multilevel Modeling, Institute of Education, London, 
UK). The strength of the association between outcome and exposure was reported as odds 
ratio (OR) with 95% confidence intervals and P values. A two level hierarchical (RHA, 
Horse) logistic regression model was used to account for geographic clustering of 
observations and because the method of surveillance used clinics within RHAs (Dohoo et 
al. 2003).   
The linearity assumption was assessed for all continuous risk factors considered 
in the modeling process. Exposures were reanalyzed after being classified into quartiles 
and the linearity assumption was examined by looking for an increasing (or decreasing) 
series of coefficients. The “effect” of exposure in each higher category, as determined by 
the odds ratio, was compared with the level of the outcome in the baseline or referrent 
exposure category to identify patterns consistent with a linear, monotonic, or threshold 
effect. 
All exposure variables where the association with the odds of fatality was 
significant at P < 0.25 were considered in developing the final multivariable model. 
Nonexposure risk factors were defined as confounders, if removing or adding the factor 
changed the effect estimate for the exposure by more than 10%, in which case the factor 
was retained in the final model. Manual backwards elimination of variables was used to 
achieve a final model containing only the statistically significant exposure variables and 
any nonexposure risk factors that were either significant or acted as important 
confounders. Biologically reasonable interactions were assessed between significant risk 
factors (P <0.05) in the final model. 
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An approximation method based on latent variables was used to estimate the 
intraclass (intraregion) correlation coefficient (ρ=σ2r/(σ2r+π2/3)) to examine the clustering 
of clinical cases of WNV within RHA (Dohoo et al .2003).  
 
3.3 Results 
3.3.1 Onset date and location 
The date of onset of clinical signs for the first WNV IgM positive clinical case 
was July 30th, 2003. The last recorded date of onset of clinical signs in a horse was 
September 19th, 2003. Of the 130 horses for which a questionnaire was completed out of 
the total 133 clinical cases, 57 died or were euthanized because of complications 
associated with clinical disease (43.8% case fatality rate, 95%CI 35.2, 52.4) and the 
remainder recovered completely. Case fatality rates differed by RHA (Table 1). The 
epidemic curve appeared to peak one week earlier for horses that died from WNV clinical 
disease than for horses that survived, suggesting that there could be a difference in risk of 
fatality associated with time of onset (Figure 1).  This observation was explored in 
subsequent analyses. 
For all 133 confirmed clinical cases, location was reported at the RHA level, 
based on the location of the owner (N=130) or of the submitting clinic (N=3). For the 130 
clinical cases with further follow-up, exact legal land location was obtained for 117 cases 
(90%), exact GPS coordinates for 1 (1%), and partial legal land location (township and 
range) for 12 (9%).  
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Table 1: Post season survey results and case fatality rates by Regional Health Authority 
(RHA).  
 
RHA 
 
Surveyed Clinics  
 (Total number of 
clinics in RHA) 
 
Total 
probables
a  
 
Estimated 
probables
b  
 
Ratio 
(estimated 
probables: 
confirmed) 
 
Confirmed 
cases 
( )c 
 
Case 
fatality 
rates 
(%)d 
Sun Country 4 (11) 20 55 5.5:1 10 50 
Five Hills 3 (10) 58 193 16:1 12 75 
Cypress 3 (5) 36 60 3:1 17 (1) 47 
Regina Qu’Appelle 4 (10) 40 100 5.6:1 18 39 
Sunrise 2 (6) 21 63 4.8:1 13 23 
Saskatoon 5 (8) 7 11 0.5:1 22 41 
Heartland 3 (6) 8 16 1.6:1 10 30 
Kelsey Trail 1 (5) 2 10 2.5:1 4 (1) 75 
Prince Albert 
Parkland 
1 (4) 12 48 6:1 8 63 
Prairie North 
 
Totals 
2 (7) 
 
28 (72) 
21 
 
225 
74 
 
630 
4.6:1 
 
4.8:1 
16 (1) 
 
130 (3) 
31 
 
44 
a from surveyed clinics 
b based on proportion of surveyed clinics 
c  numbers in parentheses are cases with no further follow-up obtained 
d case fatality rates are calculated on confirmed cases only 
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 Figure 1: Number of clinical cases of West Nile virus infection in horses by week of onset 
of symptoms in 2003. The bars represent the total number of cases by week. The lines 
represent the number of cases by health outcome per week. Weeks begin on a Sunday 
and end on a Saturday, (Week 31 runs from July 27 to  August 2, Weeks 31-35 
correspond to the end of the month of July and the whole month of August 2003, and 
weeks 36-39 correspond to the month of September 2003). 
 
Clinical cases of WNV infection were reported in all 10 RHA’s in the southern 
portion of the province (Figure 2). When the raw data were adjusted for potential regional 
differences in reporting, based on the results of the post-season survey, the RHA with the 
highest number of clinical cases per 1000 horses was in the south central portion of the 
study area (Figure 3). Post-season results differed by RHA (Table 1), with the overall 
number of estimated untested probable clinical cases exceeding the tested clinical cases 
by approximately 4.8 to 1. 
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 Figure 2: Confirmed positive IgM clinical cases of West Nile virus infection per 1000 
horses at risk reported by Statistics Canada in each Regional Health Authority (RHA).  
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 Figure 3: Combined number of diagnosed positive IgM clinical cases and undiagnosed 
probable clinical cases per 1000 horses at risk reported by Statistics Canada in each 
Regional Health Authority.  
 
3.3.2 Description of affected horses 
Most clinical cases occurred in horses ≤10 years; the fatality rate for this age 
group was 46% (38/83). The oldest horse that survived was 25 years old while the oldest 
horse that died was 32 years old. Most horses that died (as opposed to being euthanized) 
did so during the month of August (11/12  or 92%). The fatality rate was 36% (21/59) for 
mares, 45% (27/60) for geldings,  and 82% (9/11) for stallions. Dark colored horses were 
most commonly affected (89/124), but they had a lower fatality rate (36%) than did those 
in other color classifications. Most of the clinical cases were light horse breeds and most 
were used for pleasure riding (Table 2).  
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Table 2: Summary of individual risk factors by survival outcome and case fatality rates 
(N=130).  
Health 
outcome 
Variable Cases
N 
Dead Alive 
Case 
fatality 
Rate 
Odds 
Ratioa 
 
95% CI 
31-33 27 17 10 63% 4.6 1.7, 12.5 
34-35 53 26 27 49% 2.5 1.1, 5.6 
Week of onset 
36-38 50 14 36 28% ref b  
<5 years 44 22 22 50% ref b  
6-18 years 69 28 41 41% 0.7 0.3, 1.5 
Age 
>18 years 17 7 10 41% 0.7 0.2, 2.2 
Gelding 60 27 33 40% 1.4 0.7, 3.0 
Mare 59 21 38 36% ref b  
Gender 
Stallion 11 9 2 82% 8.5 1.6, 43.5 
Pony 6 2 4 33% 0.6 0.1, 3.6 
Light 106 48 58 45% ref b  
Draft 11 4 7 36% 0.9 0.2, 3.3 
Cross 3 2 1 67% 2.6 0.2, 29.8 
Breed 
Other 4 1 3 25% 0.4 0.04, 4.0 
Dark 89 32 57 36% ref b  
Light 19 14 5 74% 4.4 1.5, 13.1 
Color 
Multi-color 16 8 8 50% 1.9 0.6, 5.4 
No shelter 86 42 44 49% 2.7 1.2, 6.1 Individual shelter 
Simple shelter 41 29 12 71% ref b  
no 108 51 57 47% 2.3 0.7, 7.4 Individual 
insecticide use yes 19 5 14 26% ref b  
No vaccine 121 53 68 44% 1.0 0.3, 3.9 Vaccine 
 Vaccinated c 9 4 5 44% ref b  
Pleasure 108 49 59 45% ref b  
Breeding 13 6 7 46% 1.6 0.5, 4.9 
Farm work 5 2 3 40% 1.3 0.3, 5.4 
Primary use 
Competition 4 0 4 0% d  
10 or less 92 53 39 58% ref b  
11-25 21 10 11 48% 1.1 0.4, 2.5 
Herd size 
25 or more 13 8 5 62% 1.1 0.5, 2.7 
None 97 42 55 43% 0.9 0.4, 2.1 Farm mosquito 
control Used at least 
one 
29 13 16 45% ref b  
a Univariable analysis adjusted for spatial location (RHA) by inclusion of a single random effect  
b ref = reference category 
c Vaccinated refers to fully vaccinated horses with the standard two vaccinations. Those horses with only one 
vaccination are considered non-vaccinates. 
d Not enough data entries to converge  
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Of the 130 clinical cases with follow-up, only 9 were reported to have been fully 
vaccinated according to the manufacturer’s recommendations (2 doses given 3-6 weeks 
apart, at least 2-3 weeks before the peak mosquito season), while 3 were vaccinated only 
once (Table 2). Initial vaccination dates for the 9 fully vaccinated horses were February 
(N=2) and April (N=7). The vaccination dates for the 3 horses given only one dose were 
May, August, and September. Of the 9 fully vaccinated horses, 5 recovered while 4 died 
or were euthanized (44% fatality rate). None of the three horses that were vaccinated 
once died or were euthanized. 
Five of the 130 (3.8%) horses had been taken more than 15 km (10 miles) from 
their home location in the three weeks before onset of clinical sigs. Of these, two stayed 
within the same RHA, two travelled to a different RHA in SK and one travelled to British 
Columbia (BC). In 2003, BC had no evidence of WNV infection. Five horses had a 
change of residence 2-3 days before onset of clinical signs. The location at which they 
were most likely exposed (given an incubation period of 5-15 days) was, therefore, 
recorded as the location of the previous residence. Most of the clinical cases were in the 
same RHA as the veterinary clinic that submitted the blood sample (94%). 
No horses were housed in a barn for any period of time and most horses (68%) 
did not have access to shelter. Nineteen of the horses had been sprayed periodically with 
insecticide during the mosquito season. None of the horses were blanketed for any period 
of time. The majority of clinical cases were kept on farms that did not use any on-farm 
mosquito control methods (97/126). For horses on farms that did use at least one method, 
the primary choice was smudges (18/29, 62%). Seven of the 8 horses on farms that used 
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water removal survived and 9 of the 18 horses on farms that used smudges survived 
(Table 2). 
Herd size ranged from a single horse to 300 horses. The majority of horses were 
in small herds of 10 or fewer horses (73%). On most of the farms, all horses were kept 
under the same conditions; however, at one farm, the horses were housed in a barn, with 
the exception of the case horse. There were five farms that had 2 clinical cases and 5 
farms that had at least one undiagnosed neurologic case in addition to the tested case.  
 
3.3.3 Description of environmental and mosquito data for the reported cases 
The mean ‘season average temperature’ was 18.7oC and the mean ‘season total 
precipitation’ was 123 mm (Table 3); both of these values differed by climate station and 
by region. The mean ‘season GDD’ was 357. There was no obvious or statistically 
significant difference between these values for those horses that died and those that 
survived. Average temperature and total precipitation for the week prior to the estimated 
exposure period were also calculated, but, again, there was no apparent or statistically 
significant difference between values for those horses that died and those that survived 
(Table 3). The median distance between horse cases and the nearest climate station was 
21 km (min, max = 2, 49). 
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Table 3: Summary of individual environmental data (continuous variables) by health 
outcome. These variables were calculated using only those climate stations or mosquito 
traps for which the data was matched up with the nearest case. 
Temperature (°C) Variable Health 
 Outcome 
Cases 
 N Min Max Mean 
Overall 
Mean (°C) 
Odds ratio b 
(95% CI) 
Dead 57 16.7 20.3 18.7 Season Average 
Temperature a 
(°C/day) 
Alive 73 16.4 20.3 18.6 
18.7 1.0 (0.7, 1.5) 
Dead 57 39.2 206 118 Season total 
Precipitation a 
(mm) 
Alive 73 39.2 215 128 
123 1.0 (1.0, 1.0) 
Dead 57 199 490 350 Season GDD a 
(degree days) Alive 73 178 507 355 
357 1.0 (1.0, 1.0) 
Dead 57 14.8 26.5 21.3 Exposure week 
Average Temperature 
(°C/day) 
Alive 73 14 26.5 20.6 
20.9 1.1 (1.0, 1.2) 
Dead 57 0 44.6 7.65 Exposure week 
 Total precipitation 
(mm) 
Alive 73 0 39.4 6.85 
7.30 1.0 (0.9, 1.0) 
Dead 57 0 4.80 0.38 Exposure Week 
 Culex (C.) tarsalis 
(number per night) 
Alive 73 0 4.40 0.51 
0.5 0.8 (0.5, 1.3) 
Dead 57 0 10.40 1.67 Number of C. tarsalis 
(number per night) Alive 73 0 15.00 1.98 
1.9 0.9 (0.8, 1.1) 
Dead 57 0 6.00 0.41 Number of C. restuans 
(number per night) Alive 73 0 2.60 0.25 
0.3 1.4 (0.8, 2.4) 
a In this table growing degree days (GDD) is the cummulative growing degree days for the whole season (May to 
September), season average temperature is calculated with daily values from June to August divided by the total 
number of days and season total precipitation is the cumulative daily data from June to August.  
b Univariable analysis adjusted for spatial location (Regional Health Authority) by inclusion of a single random 
effect 
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Variables summarizing mosquito data were similar for those horses that died or 
survived. The highest numbers of C. tarsalis and C. restuans over the whole season were 
1.9 and 0.3, respectively. The number of C. tarsalis mosquitoes during the estimated 
exposure week of each case ranged from 0 to 4.8 (mean, 0.5) (Table 3). Culex tarsalis 
numbers were higher for those horses that survived, while C. restuans numbers were 
higher for those horses that died; however, the comparisons were not statistically 
significant. 
WNV-positive C. tarsalis and C. restuans mosquito pools were found in the 
nearest CDC trap for 54% (70/130) and 39% (51/130) of clinical cases, respectively 
(Table 4). The median distance between horse cases and the nearest mosquito trap was 29 
km (min, max = 4, 92).  
 
Table 4: : Summary of individual environmental data (categorical variables) by survival 
outcome. 
Health outcome Variable Cases 
N Dead 
 
Alive 
Odds ratio a 
(95% CI) 
no 60 28 32 ref c Positive pool Culex 
tarsalis b yes 70 29 41 0.8 (0.4, 1.7) 
no 79 35 44 ref c Positive pool Culex 
restuans b yes 51 22 29 1.0 (0.5, 2.0) 
a  Univariable analysis adjusted for spatial location (Regional Health Authority) by inclusion of a single 
random effect  
b A positive pool of mosquitoes (collection of species of mosquito designated) at the nearest to the trap 
location of the case horse. 
c ref = reference category 
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3.3.4 Association between individual horse risk factors, environmental variables, 
and the odds of fatality in clinical cases of WNV 
Variables where there was a statistically significant association with fatality in the 
initial univariable mixed models that were adjusted for clustering by RHA included week 
of onset, coat color, gender, and availability of individual shelter. Horses affected in 
August had 3.1 (OR 95% C.I. 1.4, 6.8) times greater odds of dying than those affected in 
September. The month of August was further broken down into two categories, weeks 
31-33 and weeks 34-35. The odds of dying in both weeks 31-33 and weeks 34-35 
(August) was higher than the odds of dying in weeks 36-38 (September) (Table 2).  
 
Table 5: Risk factors associated with survival outcomes in horses with clinical infection 
with West Nile virus (WNV): final mixed multivariable model a. 
Variable Category Cases N Odds ratio 95% C.I. P  
Week 31-33 27 6.3 1.9, 20.4 0.003 
Week 34-35 53 2.4 0.9, 6.2 0.08 
Week of Onset 
Week 36-38 50 ref b   
Mare 59 ref b   
Gelding 60 1.2 0.5, 2.9 0.70 
Gender 
Stallion 11 14.7 2.5, 87.4 0.005 
Dark 89 ref b   
Light 19 6.4 1.9, 21.6 0.004 
Coat Color 
Multi-color 16 1.9 0.6, 6.5 0.31 
a Adjusted for Regional Health Authority (RHA) by the inclusion of a single random effect 
b ref = reference category 
 
The odds of dying was greater for light colored horses than for dark colored 
horses, while multicolored horses were at similar risk to dark colored horses (Table 2). 
The odds of dying for males (stallions and geldings combined) was 1.9 times (95% C.I. 
0.9, 3.8) greater than the odds of dying for females. Specifically, the odds of dying for 
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stallions was 8.5 times (95% C.I. 1.6%, 43.5%) greater than the odds of dying for females 
(Table 2). The odds of dying was greater for those with no shelter than for those with a 
simple shelter.  
The final mixed model included week of onset, gender, and coat color (Table 5).  
Shelter did not remain statistically significant in the presence of the other variables and 
was removed from the final model. The final model was a mixed model with a random 
intercept to account for geographic clustering with RHA. The variance accounted for at 
the region level (σ2r) was 0.35 (standard error, 0.36) or approximately 9.5% of the 
overall variance in the model.  
 
3.4 Discussion 
        West Nile virus infection and the development of associated clinical disease are 
influenced by many factors, including environment, mosquito populations, and individual 
susceptibility (Hubalek et al. 1999, Murgue et al. 2001, USDA 2001, Autorino et al. 
2002). The onset dates of WNV clinical disease reflect the time necessary for 
development of climatic conditions required for mosquito reproduction, natural 
amplification of the virus, and shift in mosquito feeding patterns to allow transmission of 
the virus to horses (Curry 2004). The location of the cases corresponded to areas where 
mosquito populations capable of transmitting WNV and susceptible horse populations 
coexist. 
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 3.4.1 Distribution of clinical cases 
Travel history was essential in determining where horses were potentially exposed 
to WNV. However, as few horses had travel histories, exposure could be assumed to have 
occurred near their place of residence, even without complete travel history. Clinical 
cases and the submitting clinic were within the same RHA. Thus, on the basis of this 
study, we could assume WNV activity in the locality of either the submitting clinic or of 
the individual horses, depending on the degree of available location accuracy.  
Most clinical cases were recorded in the 4 most southerly RHA’s while the fewest 
occurred in the most northerly RHA’s of the study area. This distribution corresponds 
mainly to differences in climate and mosquito populations; however, veterinarians and 
horse owners located in the Saskatoon RHA might have been more inclined to pursue 
veterinary services and diagnosis, as this is the location of PDS. No clinical cases were 
diagnosed from the northern portion of the province (outside the study area). This was 
probably because habitat and climate do not favor the principal vector, Culex tarsalis 
(Curry 2004).  
The post-season survey of veterinary clinics suggested that there were numerous 
cases of neurologic symptoms in horses for which owners did not seek diagnosis. Clinical 
diagnosis by clinical signs alone could be mistaken for other neurological conditions in 
horses such as rabies, wobbler syndrome, equine herpesvirus ecephalomyelitis (EHV1), 
Equine protozoal myeloencephalitis (EPM) and western equine encephalomyelitis (WEE) 
(Ostlund et al. 2000); however, all of these are considered relatively unlikely in this 
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region. Thus, typical neurologic symptoms in an area known to have active WNV are 
reasonably predictive of WNV clinical disease presentation.  
A mixed model was used to account for regional distribution of clinical cases 
because WNV has been shown to cluster by geographic area in other studies, including 
one recent study that identified statistically significant clusters of both horse and human 
cases of WNV infection in 2003 (USDA 2001, Brownstein et al. 2002, Corrigan 2005). In 
the current study, RHA was chosen as the unit to represent geographic location in the 
mixed model, because it was a reasonable geographic proxy for the veterinary clinics that 
were the main source of our information. Individual veterinary clinics were not used in 
the analysis, as most of these only sampled 1 or 2 cases. The boundaries of the RHAs 
often reflect patterns of travel from rural areas to larger centers for health services, and 
based on the maps appear to reflect a reasonable pattern of access to and use of veterinary 
services. In addition, case fatality rates differed by RHA, with the highest case fatality 
rate and highest post season survey ratio in the Five Hills RHA. Decisions on the form 
and timing of public education campaigns related to WNV and mosquito control 
programs are often made at the level of the RHA or by rural municipalities located within 
the RHA. 
 
3.4.2 Risk of fatality for clinical cases 
The only significant predictors of risk of fatality in the final model were week of 
onset of clinical signs, sex, and color, while controlling for region. A small amount of 
variation (9.5%) was accounted for by geographic region in the final mixed model 
(Dohoo et al. 2003). This could reflect variability of the RHA mosquito programs and 
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other inherent differences between the regions. Differences in clinic policy could have 
influenced the variation, but, overall, most clinics followed similar guidelines for 
diagnosis or treatment. Therefore, programs to control the outcome of clinical disease 
should be directed toward individual horses. Unfortunately, the variables found to be 
significant in this study are difficult to manage for disease control purposes.  
The case fatality rate was similar to rates from other studies conducted in North 
America (Ostlund et al. 2001,Porter et al. 2003, Salazar et al. 2004). The increased 
survival rate of horses with clinical signs as the season progressed was similar to findings 
in the western United States (US). Salazar et al. (2004) found that horses were 1.7 times 
more likely to die if they showed clinical signs early (before August 19th, 2003) in the 
season. The increased risk of death in August could be a result of earlier recognition of 
clinical cases as the season progressed. Owners may have checked their horses for 
clinical signs more often when they heard of clinical cases in nearby areas, sought 
veterinary assistance sooner (subtler clinical signs) and begun treament earlier. This 
assumes that horses have a steady progression of clinical signs and that owners of horses 
that died merely missed the onset of mild signs. However, in this study, many owners 
reported seeing nothing unusual with their horses the day before the onset of moderate to 
severe clinical disease (recumbency, paresis, or paralysis of limbs). An alternate theory is 
that the incubation period for different doses of virus corresponding to different time 
periods results in the difference in immune response and the varying presentations and 
outcomes of clinical disease. Further clarification of this finding is warranted. 
     Stallions were more likely to die as a result of WNV clinical disease than either mares 
or geldings. In some mammals, it has been noted that while testosterone boosts sexual 
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characteristics it also simultaneously impairs immune system functioning (Folstad et al. 
1992). Therefore, stallions may have a poorer immune response than either females or 
geldings. To compare our results to those of other studies from the United States, we 
recategorized the data as males (both stallions and geldings) and females (mares) for 
reanalysis. In both the other studies, the univariable analysis suggested that females were 
more likely to die, but this result was not statistically significant (Salazar et al. 2004, 
Schuler et al. 2004). There was no indication of pregnancy status of the mares in any of 
the studies mentioned which might affect this result. In our analysis, no statistically 
significant difference existed between mares and geldings, but rather between stallions 
and mares or geldings. Therefore the percentage of males that were intact stallions could 
influence this association. This was reported as 8% for one study (Salazar et al. 2004), 
compared to 15% for our study.  
Prevention education programs for humans list wearing light colored clothing as a 
method to decrease the possibility of  WNV infection (SK Health 2003). When seeking 
out potential explanations, no clear evidence for the reasoning behind the use of light 
colors as prevention of infection could be found. In this study, we looked at risk of 
outcome once infection and clinical disease had occurred. We found the light colored 
horses had greater odds of dying from WNV clinical disease than did dark colored 
horses. A possible explanation could be that the immune response is linked to color 
genetically. However, no references to justify this were found. Further information is 
needed to determine the role of coat color in the outcome of WNV clinical disease.  
Other factors assessed in this study, particularly age and vaccination, were not 
significantly associated with the risk of fatality in clinical cases. In other studies, older 
 70
affected horses have been more likely to die (Salazar et al. 2004, Schuler et al. 2004). In 
this study, the case fatality rate was highest in horses 5 years or younger; however, this 
was not statistically significant.  In this study only 7% of horses reported to have clinical 
signs in 2003 were vaccinated, so there was little power to assess vaccine effectiveness in 
prevention of fatality. Other studies have shown that the vaccine has a protective effect 
against fatality in clinically affected horses (Salazar et al. 2004, Schuler et al. 2004).   
The environmental variables (temperature, precipitation, GDD, and mosquitoes) 
examined also were not associated with the individual horse risk of fatality. Calculation 
of these variables involved averaging 3 to 5 months of data which may not represent the 
exposure period of each clinically affected horse or the developmental period of the 
mosquitoes prior to exposure. However, when temperature and precipitation were 
calculated by using only data from the week before the estimated exposure date of each 
clinically affected horse, the results were still not statistically significant. With so much 
variation in environmental variables by local macro- and micro-climates, the use of the 
nearest climate station may not have represented the conditions at the actual location of 
the clinical horse. More likely, however, is the conclusion that environmental conditions 
would not play a role in an individual horse’s health outcome once it had become 
infected with WNV, rather it would be associated with the risk of infection only.  
The role of various other prevention strategies were also explored. Mosquito 
reduction and avoidance strategies were not widely used by the owners’ of clinically 
affected horses. None of the mosquito reduction methods were significant predictors of 
fatality. Housing horses in a barn at night has been suggested to prevent infection and 
disease. In this study, no clinical WNV horses were housed in a barn at any time. When 
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variables sex, coat color, and onset of clinical signs were included in the analysis, the 
protective effect of simple shelter was not significant. Even with these findings, 
avoidance of mosquitoes is still the best method of prevention of clinical disease and 
death as a possible outcome.  In addition, owners should be aware of the timing and risk 
of WNV infection in their geographic area, so that they can use all methods available to 
them in the prevention of infection and in having a favorable outcome of clinical cases. 
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 4.  Serologic Responses of Horses Naturally Exposed to West Nile virus 
 
 
 
 
 
4.1 Introduction 
West Nile virus (WNV) was first isolated in horses in North America in the late 
summer of 1999 (Trock et al. 2001). The area of the epidemic was limited to New York 
State, specifically on Long Island. The 25 cases of WNV encephalitis were confirmed 
using the plaque reduction virus-neutralization test (PRNT). In 2000, 12 northeastern and 
mid-Atlantic states reported neurologic cases in horses due to WNV (Ostlund et al. 2001, 
Trock et al. 2001). Detection of these cases was by either PRNT or Immunoglobulin (Ig) 
M enzyme-linked immunosorbent assay (ELISA). As the virus continued to spread across 
the continent in the next two years, more horses developed neurologic disease and testing 
became routine with the IgM ELISA (Castillo-Olivares et al. 2004).  
Serologic responses of horses exhibiting clinical signs have been documented by 
using IgM. IgM antibodies develop early becoming detectable approximately 8-10 days 
post infection and around the time of onset of clinical signs (Ostlund et al. 2000). 
Duration of the IgM antibody response is from 1 to 3 months in horses with the majority 
of antibody disappearing by 1-2 months after infection (Durand et al. 2002). This makes 
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IgM suitable for detection of clinical disease caused by WNV even in areas where WNV 
was present the previous year.  
  Little published data were found to show the change over time in IgG antibody 
in response to natural infection in horses. WNV neutralizing antibodies (via PRNT) are 
sometimes detectable within one week post infection and can persist for 18 months to 
greater than 2 years (Ostlund et al. 2000, Ostlund et al. 2001, Bunning et al. 2002, 
Durand et al. 2002). In one study, 18/20 (90%) of horses that were clinically affected still 
had PRNT titers greater than or equal to 1:100 5 to 7 months later (Davidson et al. 2005). 
However, the same has not been confirmed for IgG antibodies by the IgG ELISA test. A 
serosurvey of horses in Southern France in 2000 used indirect IgG ELISA to assess 
serology at one point in time and thus infection status of asymptomatic horses in an 
epidemic area (Murgue et al. 2001, Durand et al. 2002). The study then made the 
assumption that anti-WNV IgG usually persists for several years post infection to allow 
assessment of the epidemic versus endemic status of the study area.  
Due to the overwhelming spread of the virus in North America and the increase in 
the numbers of neurologic WNV cases being reported each year, a killed vaccine was 
developed with a claim for protection from severe clinical disease (Ostlund et al. 2000). 
In a vaccination study to assess the efficacy of the vaccine and kinetics of the specific 
IgG response, sera from 8 vaccinated horses were tested using pan-flavivirus IgG Capture 
ELISA at a 1:100 dilution (Ng et al. 2003). The results showed significant IgG response 
detectable as early as 14 days post first vaccination with another rise after the second 
(booster) vaccination. The duration and the evolution of the IgG response was followed 
further but using PRNT instead of the IgG ELISA (Ng et al. 2003).  
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The introduction of the vaccine complicated surveillance efforts since both 
vaccinated and naturally infected horses could potentially create IgG antibodies. A 
vaccination study undertaken by this research team documented that no serologic IgG 
response to a two dose vaccination protocol was seen with a WNV-specific IgG Capture 
ELISA test (Epp et al. 2007). With this test, horses could be defined as naturally infected 
on the basis of IgG antibodies whether they had been vaccinated or not. The objective of 
this study was to document the changes in IgG concentrations (kinetics) resulting from 
natural infection over an 8 month period in both vaccinated and non-vaccinated horses.   
 
4.2 Materials and methods 
4.2.1 Study design 
Data on the changes in antibody concentrations following natural exposure were 
required in order to use the ELISA test to differentiate between past and present season 
infections. To better understand the kinetics of the immune response as measured by the 
ELISA, the time-related variation in the concentrations of antibody to WNV were studied 
in several groups of horses (Table 1). These groups were chosen on the basis of their 
vaccination status and a positive IgG and/or IgM status during the 2003 mosquito season. 
These groups included 1) non-vaccinated WNV clinical case horses, 2) asymptomatic 
vaccinated horses with an IgG ELISA positive test result during August to October 2003, 
and 3) asymptomatic non-vaccinated horses with an IgG ELISA positive test result 
during August to October 2003. A horse was considered a confirmed positive “WNV 
clinical case” if it had one or more of the classic signs of WNV, such as ataxia, 
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recumbency, paralysis or paresis of limb(s), or death and a positive IgM ELISA test by 
the provincial laboratory. 
Table 1: List of possible groups based on vaccination status, clinical history and the 
relationship with serum antibody levels that need to be distinguished in WNV 
surveillance. 
 
Vaccination 
status 
IgG 
status* 
IgM 
status* 
Groups to follow Reason for not 
following group 
No Pos Pos Follow;  
Both asymptomatic and symptomatic 
groups 
 
No Pos Neg Follow; 
Likely just the asymptomatic group 
 
No Neg Pos Group not important to follow  Because IgM denotes 
recent infection 
No Neg Neg Group not important to follow  Because results denote 
animal is not infected 
Yes Pos Pos Follow;  
Both asymptomatic and symptomatic** 
groups 
 
Yes Pos Neg Follow; 
Likely just the asymptomatic group 
 
Yes Neg Pos Group not important to follow  Because IgM denotes 
recent infection 
Yes Neg Neg Group not important to follow  Because results denote 
animal is not infected 
* Status was reported as a positive (pos) or negative (neg) test result that was reported during August to 
October 2003. 
**Symptomatic vaccinated animals were not followed because of too few numbers (n=5) 
 
For each group, a minimum of 10 horses that met the criteria were selected from 
studies on-going by the research team at the Western College of Veterinary Medicine 
(WCVM) at the University of Saskatchewan. The fourth group, ‘vaccinated clinical 
horses’ were not included as a group because there were only 9 clinical case vaccinated 
horses of which only 5 recovered. The horses in each of the three groups were bled 
during an eight month period at least three times: August or early September, October, 
December and March. These samples were tested with both the IgG and IgM ELISA and 
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results were reported as a sample-to-positive (S/P) ratio. Results were graphed (Microsoft 
Office Excel 2003, Microsoft Corporation, USA) and differences in S/P ratios among 
groups at different time points were analyzed using Generalized Estimating Equations 
analysis (proc GENMOD). Due to multiple comparisons, a Bonferroni correction was 
used with significance at P=0.006 for between groups and P=0.003 for within groups. 
The model contained a repeated term for horse, assumed a normal distribution and used 
an identity link function and an exchangeable covariance structure (PROC GENMOD, 
SAS for Windows ver. 8.2, SAS Institute Inc., Cary, NC). 
 
4.2.2 Testing and reporting of results 
 Testing of the samples was done using an in house IgM and IgG WNV antibody-
capture ELISA. All samples were classified as positive, suspicious or negative for both 
IgG and IgM based on the OD results of the appropriate ELISA. A sample-to-positive 
(S/P) ratio was then calculated for the IgG test results to allow comparison of results from 
multiple ELISA plates. The following formula was used (Adaska et al. 2002): 
S/P ratio =           sample OD  –  negative control OD____          
                       positive control OD –  negative control OD 
The optical density (OD) was determined as the difference in values between the 
duplicate wells on the plate for each test serum and control. Sera were tested on tissue 
culture derived WNV antigens in one of the wells. In the other well, sham infected tissue 
culture antigen preparations (control antigen) were used to ensure the specificity of the 
response was to WNV. The strong positive control from the top left corner was used in 
 81
the calculation of the above formula for the first four rows of the plate and the strong 
positive control at the bottom right corner of the plate for the bottom four rows.  
Both the IgM and IgG assays used in this study were antibody capture ELISAs 
using reagents supplied by BioReliance Corporation (Rockville, Maryland). No 
sensitivity or specificity estimates were available for the reagents used in this test.  
For the IgM ELISA, 100 microlitres of a 1:250 dilution of monoclonal antibody 
specific for Equine IgM in Phosphate buffered saline (PBS) was coated onto wells of a 
polyvinyl chloride (PVC) ELISA plate and incubated overnight at 4°C. The plates were 
washed 5 times between each step of the process. Control and test sera were then diluted 
in PBS-T, added to duplicate wells of the ELISA plate and incubated for 2 hours at 37°C. 
Then 100 microlitres of WNV antigen or control antigen preparations were diluted 1:5 in 
PBS-T, added to one of the duplicate wells and incubated for 2 hours at 37 °C. One 
hundred microlitres of a 1:100 dilution of WNV specific monoclonal antibody were 
added to the test wells. The monoclonal antibody was diluted in PBS-T + 5% skim milk. 
The plates were incubated for 2 hours at 37 °C. Then 100 microlitres of a 1:100 dilution 
of anti-mouse IgG –Horse Radish Peroxidase (HRPO) conjugate in PBS-T + 5% skim 
milk were added to each well and incubated for one hour at 37 °C. Finally 100 microlitres 
of ABTS (2,2’-azino-di(3-ethyl-benzthiazoline-6-sulfonate, KPL cat# 50-66-00) were 
added to each well and incubated for 30 minutes at 37 °C. The test was read using a 
spectrophotometer at 410 nm. A positive test was one that had a net O.D. of 0.2 or greater 
after subtraction of the control (duplicate) well O.D. and had at least 2 times the control 
well value. A suspicious test met one of these criteria and a negative test met none of the 
criteria. 
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For the IgG ELISA assay used in this study, 100 microlitres of a 1:50 dilution of a 
WNV specific monoclonal antibody is added onto wells of a polyvinyl chloride (PVC) 
ELISA plate and incubated overnight at 4 °C. The plates were washed 5 times between 
each step in the process. The WNV antigen and control antigen were diluted 1:50 in IgG 
lysis buffer (PBS+0.3% Igepal CA-630 Sigma #I3021) and incubated at room 
temperature for 15 minutes. Then 100 microlitres of the diluted antigen and control 
antigen were added to one of the duplicate wells on the ELISA plate and incubated at 37 
°C for 2 hours. The dilutions of the control and test sera were prepared in PBS-T + 4% 
normal goat serum (all test sera are diluted 1:200). A total of 100 microlitres of the 
diluted samples and controls were added to the duplicate wells and incubated at 37 °C for 
2 hours. Then 100 microlitres of anti-Equine IgG HRPO conjugate diluted in PBS-T + 
5% skim milk + 4% normal goat serum was added. One hundred microlitres of ABTS 
(KPL cat# 50-66-00) were added to each well and incubated for 30 minutes at 37 °C. The 
test was read using a spectrophotometer at 410 nm. Positive, suspicious and negative test 
results are as defined above. 
 
4.3 Results 
Group 1 consisted of 14 clinical case horses (all were non-vaccinates) (Table 2). 
Of these, 64% (9/14) had 3 samples drawn between August 2003 and March 2004 while 
36% (5/14) had only 2 samples drawn. Only the August time point differed from all other 
time points (P <0.0001). 
Group 2 consisted of 11 vaccinated horses with positive IgG or IgM test results at 
the August or October 2003 sampling with the potential for natural exposure (Table 2). 
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All of the horses were vaccinated with the two shot standard protocol; nine horses were 
vaccinated in April, while two horses were vaccinated in September after clinical disease 
had occurred in a herd-mate. Using the cutoff values (0.305 for horses vaccinated two 
times; 0.76 for horses vaccinated three times) determined by a vaccination study 
performed by this research team, all horses were deemed to be naturally exposed (Epp et 
al. 2007). Of the horses in this group, 73% (8/11) had four samples drawn between 
August 2003 and March 2004 while 27% (3/11) had only three samples drawn. All time 
points differed (P <0.0001) except August and March, and October and December. 
Group 3 consisted of 12 unvaccinated horses with positive IgG or IgM test results 
at the August or October 2003 sampling with the potential for natural exposure (Table 2). 
Of these, 1 horse had four samples drawn between August 2003 and March 2004 while 
50% (6/12) had three samples drawn and 42% (5/12) had two samples drawn. Only the 
August time point differed (P <0.0001) from both the October and December time points. 
Mean S/P ratios from non-vaccinated clinical case horses were higher than the 
mean S/P ratios from either the vaccinated or non-vaccinated asymptomatic naturally 
exposed groups (Figure 1). Average S/P ratios from clinical case horses were higher than 
from vaccinated asymptomatic naturally exposed horses at both the October (P=0.0007) 
and December (P=0.002) sampling dates and were also higher than S/P ratios from non-
vaccinated asymptomatic naturally exposed horses in October (P= 0.005). The average 
S/P ratios from clinical case horses remained higher than for vaccinated asymptomatic 
naturally exposed horses through March (P<0.0001). Clinical case horses did not have 
significantly different S/P ratios than non-vaccinated asymptomatic naturally exposed 
horses in December (P=0.04) and March (P=0.09). Average S/P ratios of vaccinated and 
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non-vaccinated asymptomatic naturally exposed horses did not differ over any of the 
sample time periods.  
Four positive IgM samples that were taken in late August or early September 
were negative when these horses were re-sampled anywhere between 41 to 60 days later. 
Two of the non-vaccinated asymptomatic horses and the two September vaccinated 
asymptomatic horses had positive IgM results in late August, but were negative when 
sampled approximately 100 days later. None of the horses vaccinated prior to exposure 
season had positive IgM samples despite showing increases in IgG S/P ratios over the 
sample period.  
 
 
Figure 1: IgG S/P ratios for each sample date by group (Total N=37). (—) denote 
medians for each group by sample date as listed in Table II. 
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Table 2: The change in IgG antibody concentration over time as measured by S/P ratios 
for groups of horses with different clinical histories and vaccination status (N=37).  
IQR  N n by 
month 
Month and 
Year 
Mean (s *) median 
25th 75th 
14 August 
 2003 
0.06  
(0.20 ) 
0.00 -0.10 0.19 
4 October  
2003 
0.96 
 (0.18) 
1.02 0.77 1.09 
6 December 
2003 
0.88 
 (0.16) 
0.94 0.74 0.97 
Group 1: 
Clinical case 
horses 
14 
13 March  
2004 
0.67 
 (0.24) 
0.73 0.45 0.90 
11 August  
2003 
0.14 
 (0.19) 
0.00 0.00 0.25 
9 October 
 2003 
0.62 
 (0.17) 
0.66 0.49 0.74 
11 December 
2003 
0.50 
 (0.24) 
0.58 0.35 0.69 
Group 2: 
Vaccinated 
naturally 
exposed  
asyptomatic 
horses 
11 
10 March  
2004 
0.23 
 (0.24) 
0.20 0.03 0.34 
7 August  
2003 
0.00 
 (0.00) 
0.00 0.00 0.00 
9 October 
 2003 
0.62 
 (0.27) 
0.63 0.36 0.90 
7 December 
2003 
0.58 
 (0.25) 
0.60 0.34 0.80 
Group 3: 
Non-vaccinated 
naturally 
exposed 
asymptomatic  
horses 
12 
9 March 
 2004 
0.46 
 (0.43) 
0.55 0.02 0.80 
*s = standard deviation 
 
 
4.4 Discussion 
Sero-conversion was not documented by samples taken 14 days apart. Rather on 
the basis of a positive IgM ELISA or an increase in the S/P ratio of IgG ELISA of two 
consecutive samples all horses in the study were considered naturally exposed to WNV in 
2003. The serologic responses of horses were followed over an 8 month period following 
the WNV season with 2-4 sampling times per horse. All groups of horses showed an 
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initial rise and subsequent fall of IgG antibodies. Clinical case horses showed 
significantly higher average S/P ratios at October, December and March time points 
compared to asymptomatic vaccinated horses while only at October for non-vaccinated 
horses. This indicates that clinical horses initially develop a greater IgG antibody 
response than non-clinical horses and may indicate that clinical disease is the result of an 
increased viral load which initially overwhelms the immune system of the horse or that 
clinical disease is the result of an overzealous immune system.   
Other studies have noted that WNV neutralizing antibodies have been detected up 
to 18 months post infection (Durand et al. 2002). In this study, IgG antibodies to natural 
infection detected by the ELISA test initially rose and then declined over the 8 month 
sampling period. If the decline in average IgG S/P ratios is extrapolated, WNV antibodies 
should have become negative (less than 0.30 S/P ratio) using the ELISA within another 
4-5 months (around July to August 2004) in the absence of additional exposure. This 
further supports the assumption that horses with positive IgG ELISA tests in the summer 
of 2003 were naturally exposed and infected with WNV during the summer of 2003. 
Humoral immunity is considered essential in the immune response to WNV 
because neutralizing antibodies are thought to limit dissemination of infection (Diamond 
et al. 2003). The majority of studies published to date look at the mouse as a model. In 
this study, the IgG response of naturally exposed clinical horses was on average higher 
than naturally exposed asymptomatic horses whether vaccinated or not. This apparent 
relationship between increased IgG response and development of clinical signs in the 
horse warrants further investigation.  
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IgM is used as a means of identifying recent clinical cases of WNV. In humans, 
IgM antibodies are present in more than 50 % of patients 2 months after onset of clinical 
signs and are thought to be present in blood for a maximum of 7 months (Tardei et al. 
2000, Prince et al. 2003). In this study, all of the 4 horses with two samples taken less 
than 2 months apart had sero-reverted and all of the 13 horses with two samples taken 
less than 4 months apart had sero-reverted. Thus, in horses IgM is useful for 
documentation of clinical disease due to WNV. However, unless frequent serial blood 
sampling is employed for surveillance, IgM would not be useful in monitoring infection 
status in a population as IgM antibodies usually do not persist in the serum longer than 1-
2 months after exposure. 
Serology using IgG ELISA in the presence of vaccinated horses may become 
more difficult to interpret as new vaccines become available and varied dosing regimens 
are employed. Further characterization of IgG responses of horses using the ELISA will 
be needed to assess the effect of more than two years of vaccination, vaccination of 
clinically infected individuals, different vaccination protocols (ie. multiple boosters per 
year) and the use of different vaccines.  
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5.  Serologic Prevalence and Risk Factors for Infection with West Nile virus in 
Saskatchewan Horses, 2003 
 
 
 
 
5.1  Introduction 
West Nile virus (WNV) was introduced to the North American continent in 1999 
(Ostlund et al. 2001) and was first diagnosed in horses in Canada, including the province 
of Saskatchewan, in 2002 (Weese et al. 2003, Abutarbush et al. 2004). Horses that are 
infected with the virus may show clinical signs or go on to eliminate the virus 
uneventfully (Ostlund et al. 2001). Several studies have tried to assess the prevalence of 
asymptomatic WNV infections by either a random sampling of horses in an epidemic 
area or by sampling horses with known contact with clinical WNV cases (Trock et al. 
2001, Autorino et al. 2002, Durand et al. 2002, Estrada-Franco et al. 2003). Reported 
prevalence varied from 1.2% in Yucatan, Mexico (Lorono-Pino et al. 2003) to 38% in 
Italy (Trock et al. 2001) in random sample surveys. A survey in France in 2000 showed 
geographical differences in prevalence from less than 5% to 58% (Durand et al. 2002).  
Serologic prevalence in horses tested in association with clinical case locations has 
ranged from 15% in Eastern United States (USA) in 2000 (6) to 43% on one ranch in 
Coahuila State, Mexico in 2002 (Blitvich et al. 2003). 
 92
 No published studies to date solely look at risk factors for asymptomatic 
infection with WNV. A study from the Eastern USA looked at differences in individual 
horse characteristics between infected horses (with or without signs) and non-infected 
horses as defined by serology or virus isolation (USDA 2001). Horses used for pleasure 
riding were more likely to be infected while housing horses in a barn at night was 
protective against infection. 
In July 2003, a seroprevalence study was initiated to measure the spread of the 
virus across Saskatchewan. However, the use of serology to identify infection status was 
complicated by the release of a new vaccine, an inactivated WNV vaccine that had been 
licensed for use in Canada during the spring of 2003 (West Nile®Innovator, Wyeth 
Animal Health, New Jersey, USA). The vaccine was widely used by horse owners across 
the province. Vaccinated horses were expected to produce immunoglobulin (Ig)G but not 
IgM antibodies in response to the vaccine (Ng et al. 2003) and to produce both IgG and 
IgM antibodies to natural infection. However, information on the IgM status of the horses 
in this study alone would not have been adequate to measure seroprevalence reflecting 
natural infection, because IgM antibodies persist for less than 2 months (Ostlund et al. 
2001).   
Reliance solely on IgM could lead to an underestimate of exposure to natural 
infection unless horses were sampled very frequently throughout the study period. In 
addition to IgM status, information on the concentration of IgG antibodies was necessary 
to identify all animals in this study with evidence of natural infection because of the 
timing of sample collection. To get the best potential estimate of seroprevalence, 
researchers had to first identify a cutoff value for the enzyme-linked imunosorbant assay 
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(ELISA) which would differentiate IgG antibody production in response to vaccination 
from that in response to natural infection.   
This paper reports the results of an observational field study during the second 
year of WNV incursion into Saskatchewan and following the widespread use of a new 
inactivated vaccine. The first objective of this observational study was to assess WNV 
seroprevalence in Saskatchewan horses to determine geographically the proportion of 
horses exposed to the virus. The second objective of this study was to assess the effect of 
geographic region, climate, and other potential risk factors (herd or individual level) on 
prevalence of WNV infection.  
 
5.2 Materials and methods 
5.2.1 Serological response to vaccination – study animals and sampling protocol 
Before the results from the seroprevalence study could be evaluated, it was 
necessary to generate a cutoff value to differentiate antibody production in response to 
the vaccine from antibody production in response to natural exposure or infection. 
Through a cooperative agreement, pre- and post-vaccination serum samples that had been 
obtained from a group of mares enrolled in a WNV vaccine study were made available 
for WNV serologic testing in our laboratory. The vaccinated and control mares were 
located on a ranch in Southern Manitoba and the samples had been collected over the 
winter and spring of 2002-2003 (outside the mosquito season). Testing of these samples 
using an IgG and IgM antibody capture ELISA provided data on the serologic response to 
WNV vaccination which were required for subsequent surveillance studies. Ethics 
approval was acquired by the researchers that performed the sampling. 
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On November 20, 2002, blood samples were collected from 40 mares (Table1). 
Twenty of the mares (“December vaccinates”) were then vaccinated twice with three 
weeks between subsequent doses (West Nile-InnovatorTM, Wyeth Animal Health, 
Madison, NJ, USA). Blood samples were collected seven days after the first vaccination 
(“December vaccinates”). The remaining 20 mares (Controls) were given saline 
injections and blood samples were collected at the same time points as for the vaccinated 
group. All mares were sampled again three weeks later, on December 10,  when a second 
dose of vaccine or saline was administered. A final blood sample was collected 10 days 
after the second vaccination. 
 
Table 1: Schedule of dates and procedures followed for horses in the study to evaluate 
serologic responses to vaccination.  
Groups  
Dates 
 
Procedure December vaccinates  
(20 mares) 
Controls  
(20 mares) 
Pre-bleed a 20  
(16 unexposed, 4 exposed) 
20 
(17 b unexposed, 3 exposed)  
Nov 20, 2002 
Vaccination First vaccination  Saline 
Nov 27, 2002 Bleed 20 20  
Bleed 20 20  Dec 10, 2002 
 Vaccination Second vaccination Saline 
Dec 20, 2002 Bleed 20  20  
   March vaccinates (12 mares) 
March 6. 2003 Vaccination First vaccination  
March 27, 2003 Vaccination Second vaccination 
April-May 2003 Bleed 12 
(10 unexposed, 2 exposed) 
a Horses with positive IgG test results in the pre-bleed are considered previously naturally exposed to WNV 
during the 2002 season. IgG results were initially reported as positive, negative and suspicious by the lab 
using a formula supplied by the supplier, Bioreliance (Rockville, Maryland). 
b One horse was classified as suspicious on the first two samples and negative afterward but was labeled as 
negative/unexposed for the analysis. 
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In March 2003, 12 of the mares that had been used as controls in November 2002, 
were also vaccinated according to label recommendations (March vaccinates). Blood 
samples were not taken on these occasions but were collected 6 weeks after the first 
vaccination. Also in March 2003, 10 of the previously (December) vaccinated mares 
received a third vaccination and were bled in late April or early May.  Following blood 
collection, the serum was separated by centrifugation and refrigerated until tested with 
both IgG and IgM capture ELISAs.  
 
5.2.2 Serum IgG and IgM ELISA   
All samples were classified as positive, suspicious or negative for both IgG and 
IgM based on the optical density (OD) results of the appropriate ELISA. A sample-to-
positive (S/P) ratio was then calculated for the IgG test results as follows: S/P ratio = 
(sample OD-negative control OD)/(positive control OD –  negative control OD). 
The OD was determined as the difference in values between the duplicate wells 
on the plate for each test sera and controls. Sera were tested on tissue culture derived 
WNV antigens in one of the wells. In the other well, sham infected tissue culture antigen 
preparations (control antigen) were used to ensure the specificity of the response was to 
WNV. The strong positive control from the top left corner was used in the calculation of 
the above formula for the first 4 rows of the plate and the strong positive control at the 
bottom right corner of the plate for the bottom 4 rows.  
Both the IgM and IgG assays used in this study were antibody capture ELISAs 
using reagents supplied by BioReliance Corporation (Rockville, Maryland). No 
sensitivity or specificity estimates were available for the reagents used in this test.  
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For the IgM ELISA, 100 microlitres of a 1:250 dilution of monoclonal antibody 
specific for Equine IgM in Phosphate buffered saline (PBS) was coated onto wells of a 
polyvinyl chloride (PVC) ELISA plate and incubated overnight at 4°C. The plates were 
washed 5 times between each step of the process. Control and test sera were then diluted 
1:400 in PBS-T, added to duplicate wells of the ELISA plate and incubated for 2 hours at 
37°C. Then 100 microlitres of WNV antigen or control antigen preparations were diluted 
1:5 in PBS-T, added to one of the duplicate wells and incubated for 2 hours at 37 °C. One 
hundred microlitres of a 1:100 dilution of WNV specific monoclonal antibody were 
added to the test wells. The monoclonal antibody was diluted in PBS-T + 5% skim milk. 
The plates were incubated for 2 hours at 37 °C. Then 100 microlitres of a 1:100 dilution 
of anti-mouse IgG –Horse Radish Peroxidase (HRPO) conjugate in PBS-T + 5% skim 
milk were added to each well and incubated for one hour at 37 °C. Finally 100 microlitres 
of ABTS (2,2’-azino-di(3-ethyl-benzthiazoline-6-sulfonate, KPL cat# 50-66-00) were 
added to each well and incubated for 30 minutes at 37 °C. The test was read using a 
spectrophotometer at 410 nm. A positive test was one that had a net O.D. of 0.2 or greater 
after subtraction of the control (duplicate) well OD and had at least 2 times the control 
well value. A suspicious test met one of these criteria and a negative test met none of the 
criteria. 
For the IgG ELISA assay used in this study, 100 microlitres of a 1:50 dilution of a 
WNV specific monoclonal antibody is added onto wells of a polyvinyl chloride (PVC) 
ELISA plate and incubated overnight at 4 °C. The plates were washed 5 times between 
each step in the process. The WNV antigen and control antigen were diluted 1:50 in IgG 
lysis buffer (PBS+0.3% Igepal CA-630 Sigma #I3021) and incubated at room 
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temperature for 15 minutes. Then 100 microlitres of the diluted antigen and control 
antigen were added to one of the duplicate wells on the ELISA plate and incubated at 37 
°C for 2 hours. The dilutions of the control and test sera were prepared in PBS-T + 4% 
normal goat serum (all test sera are diluted 1:200). A total of 100 microlitres of the 
diluted samples and controls were added to the duplicate wells and incubated at 37 °C for 
2 hours. Then 100 microlitres of anti-Equine IgG HRPO conjugate diluted in PBS-T + 
5% skim milk + 4% normal goat serum was added. One hundred microlitres of ABTS 
(KPL cat# 50-66-00) were added to each well and incubated for 30 minutes at 37 °C. The 
test was read using a spectrophotometer at 410 nm. Positive, suspicious and negative test 
results are as defined above. 
 
5.2.3 Serological response to vaccination – data analysis and establishment of cutoff 
value 
The distribution of S/P ratios were examined graphically for all time points. The 
distribution of the serological data prior to vaccination in the late fall of 2002 was 
examined to identify horses with IgG antibody concentrations before vaccination that 
suggested they had been previously exposed to WNV. The difference in S/P ratios at all 
sampling points between previously exposed and non-exposed horses were examined 
using generalized estimating equations assuming a normal distribution, and using an 
identity link function and an exchangeable covariance structure (PROC GENMOD, SAS 
for Windows ver.8.2, SAS Institute Inc., Cary, NC). A histogram of the residuals was 
examined to assess the normality assumption. 
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Subsequently, all data from previously exposed horses were analyzed separately 
from the non-exposed horse data. IgG ELISA S/P ratio results were graphed and the 
differences between December vaccinates and concurrent controls, and December and 
March vaccinates were analyzed using Mann-Whitney-U test (SPSS version 13.0, SPSS 
Inc., Chicago, IL, USA). 
The analysis of the change in antibody S/P ratios due to vaccination and 
subsequent cutoff value determination was performed using data from previously non-
exposed horses that had been vaccinated two or three times. A cutoff value to 
differentiate horses that were likely infected from those that were non-infected was 
calculated as two times the standard deviation added to the highest recorded S/P ratio for 
all previously unexposed horses (Richardson et al. 1983) first for the horses that had been 
vaccinated twice and then for the horses that were vaccinated three times. A relatively 
conservative cutoff value was chosen to optimize specificity.  
 
5.2.4 Seroprevalence study sample selection 
Twenty herds of horses were selected as a geographically stratified random 
sample from across the southern portion of the province of Saskatchewan. Before sample 
selection, five geographic zones were defined by amalgamating the 10 regional health 
authority (RHA) boundaries. The 5 geographic zones were defined to ensure that the 
entire southern portion of the province was adequately represented by the sampling 
method.  
From each of the 5 zones, 4 mixed or large animal veterinary practices were 
randomly selected from the listings of the provincial veterinary medical association using 
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a random number generator. Each selected clinic was asked to provide the names of 2 or 
3 owners with 10 or more horses on their property. One of the farms from each practice 
list was randomly selected and contacted. If the owner declined the invitation to 
participate in the study or did not meet the criteria for enrollment, the next name on the 
list was contacted until one owner per clinic was enrolled in the study.  
A minimum of ten horses from each herd was selected by the owner for sample 
collection. Approximately 5-10 ml of blood was collected from each horse in August and 
again in October, corresponding to the beginning of the risk period for clinical disease 
and the end of the period of risk of infection. If a horse was unavailable for sampling in 
October, a different horse was sampled. Samples were stored as serum in the refrigerator 
until testing was completed. Ethics approval for this study was obtained through the 
University of Saskatchewan Committee on Animal Care and Supply.  
 
5.2.5 Classification of infected versus non-infected horses for seroprevalence study 
In this study, serologic presence of antibodies to WNV was used as a proxy for 
natural exposure to or infection with WNV. A horse was considered naturally exposed or 
infected if the IgM result was positive or if the IgG S/P ratio of one or both samples 
(August and October) was above the appropriate cutoff value. 
 
5.2.6 Geographic, mosquito and environmental data  
At the time of sample collection, the legal land location (quarter, section, 
township, range, meridian) where the horses were kept, individual characteristics of all 
sampled horses, and information on the management of the herds and individual horses, 
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with emphasis on mosquito control measures, were recorded. Herd locations were 
mapped using ArcView GIS (version 3.2) and ArcGIS (version 8.0, Environmental 
Systems Research Institute Inc, Redlands, California). The location was displayed as a 
point using the centroid-of-the-polygon for the legal land location. 
Mosquito data were obtained from the 2003 Saskatchewan Health mosquito 
trapping program which operated 42 traps across the southern portion of the province. 
CDC (Center for Disease Control and Prevention) traps were used for collection of live 
mosquitoes for virus testing and New Jersey Light traps (NJLT) were used for collection 
of dead mosquitoes for the determination of mosquito species. Culex (C.) tarsalis and C. 
restuans data were provided on a weekly basis from June to September as an average 
number of mosquitoes trapped per night. Variables of interest were: (a) the maximum 
weekly average for C. tarsalis from the whole season (Number C. tarsalis) (b) the 
maximum weekly average for C. restuans from the whole season (Number C. restuans) 
and (c) whether WNV was found in a pooled collection of mosquitoes of each species 
(positive pool). For each variable of interest, the results of the nearest CDC and NJLT 
trap were linked to each herd.  
Geographic differences across the study area were described in the analysis by 
considering the ecoregion, which is a subdivision of ecological zones characterized by 
regional ecological factors such as vegetation, soil, climate, water and fauna (Marshall et 
al. 1999). Within the study area, the Prairie (Cypress Upland, Mixed Grassland, Moist 
mixed Grassland and Aspen Parkland ecoregions) and the Boreal Plain (Boreal Transition 
ecoregion) ecological zones are represented (Figure 1). The Mixed Grassland ecoregion 
is the driest area of the province with an absence of trees and scarce wetlands or 
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premanent bodies of water. About half of this area is cultivated while the rest is pasture 
for grazing. The Moist Mixed Grassland has semi-arid moisture conditions with small 
aspen groves and numerous undrained depressions or sloughs. Most of the land in this 
region is used for agricultural purposes. The Aspen Parkland is composed of a mosaic of 
aspen groves and farmed fescue grasslands, most of which are cultivated. The Boreal 
Transition is the sourthenmost limit to the boreal forest and the northernmost limit of 
arable agricultural land in the prairies. 
Average daily temperature and total daily precipitation data for all climate 
stations in Saskatchewan were obtained from Environment Canada. Season average 
temperature and season total precipitation were calculated for each climate station in the 
southern half of the province using daily values for June, July and August 2003. 
The suitability of environmental conditions for mosquito development was also 
summarized using cumulative growing degree days (GDD). GDD is the sum of the 
number of degrees above the base temperature of 16ºC (the threshold temperature of 
development and activity for C. tarsalis) for each day during a given season (McLintock 
1948). GDD was calculated using the average daily temperature data minus 16ºC, with all 
positive values accumulated across the period May to September 2003. Season GDD was 
then calculated for each climate station in the southern half of the province by adding up 
monthly totals from May to September 2003. Herds were assigned data from the nearest 
climate station with complete daily temperature and precipitation information. 
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Figure 1: The locations of herds in the study by ecoregion. The vaccinated herds are 
represented by (●) (n=16 herds ) and the non-vaccinated herds are represented by (□) (n= 
4 herds). Included on the map is the proportion of infected horses over the total number 
of horses sampled in each ecoregion expressed as a fraction and a percentage with the 
95% CI.  
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5.2.7 Herd and individual horse characteristics and management 
Breed information was captured as class or category of equid (light, draft and 
draft cross, pony and other equids). Gender was recorded as mare, gelding or stallion. 
The various colors were divided into three categories, dark (chestnut, sorrel, brown, black 
or bay); light (gray, white, palamino, buckskin or dun); and multi-colored (roan, paint, 
pinto and appaloosa). Travel off the farm was defined as any excursion where the 
distance was greater than 10 miles. Housing was classified as having access to an 
enclosed barn, a simple three sided shelter with corral or pasture, or having no access to a 
shelter in open pasture with or without trees. On-farm mosquito control was classified as 
whether or not any method of mosquito control was used. When mosquito control was 
reported, the method was recorded as use of fans in a barn and/or sealed at night, 
smudges (smoky fire used to ward off mosquitoes), general insecticides, or no mosquito 
control attempted. 
 
5.2.8 Epidemiological analysis of seroprevalence data 
The associations between the outcome variable – infection status – and each 
putative risk factor were examined using mixed models with a binomial distribution and 
logit link function. The calculations were performed using penalized quasi-likelihood 
estimates (2nd order PQL) (MLwiN version 2.0, Centre for Multilevel Modelling, Institute 
of Education, London, UK). The strength of the association between outcome and 
exposure was reported as an odds ratio (OR) with 95% confidence intervals. Within-herd 
clustering was accounted for as a random intercept in all models (Dohoo et al. 2003).  
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A null model (ie. a model which contains only the intercept) was used to calculate 
the subject-specific and then population-averaged prevalence of WNV exposure and 95% 
confidence intervals using a formula which incorporates the herd variance and the 
intercept of the null two-level model (Dohoo et al. 2003). All risk factors were evaluated 
for association with infection-status in a series of unconditional models. Independent 
variables for which P < 0.25 were considered in developing a final multivariable model.  
Manual backwards elimination of variables was used to achieve a final model 
containing only the statistically significant exposure variables and any nonexposure risk 
factors that were either significant or acted as important confounders. Nonexposure risk 
factors were defined as confounders if removing or adding the factor changed the effect 
estimate for the exposure by more than 10% and the factor was retained in the final 
model. Biologically reasonable interactions were assessed between significant risk factors 
(P <0.05) in the final model. 
 
5.3 Results 
5.3.1 Serological response to vaccination  
None of the horses (exposed or unexposed) had a positive IgM test result just 
prior to or following the vaccination phase of the study. There was, however, a distinct 
pattern of IgG concentrations in the samples collected prior to the start of the study 
(Figures 2A and 2B). Of the 40 horses tested on November 20, 2002, 7 (18%) had a 
positive IgG response which suggested previous natural exposure to WNV during the 
summer season (Table 1: 4 vaccinates and 3 controls). The median serum IgG S/P ratio 
for the animals considered to be previously exposed was 0.86 (min. 0.54, max. 2.08).  
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 (A)                                                                        (B) 
                                                 
      
 
Figure 2: IgG ELISA S/P ratios by vaccination status for previously exposed (A) and 
unexposed horses (B). The dates of vaccination (*) were November 20 and December 10, 
2002. The solid line (—) denotes median for each group. In the saline group, one horse 
was classified as ‘suspicious’ on the first two samples (S/P ratios of 0.32 and 0.26) but 
considered non-exposed for the analysis. Dotted line (- - -) shows the calculated cut-off 
point. 
 
In a model that included date of sampling, vaccination status and previous 
exposure status, the mean IgG S/P ratios were significantly different between previously 
exposed and non-exposed horses (difference=0.96 S/P ratio, 95% CI 0.74, 1.17, 
P<0.0001). However, there were no significant differences in mean IgG S/P ratios 
between sampling time points (P=0.08) or vaccination groups (P=0.16).  
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Of the 16 unexposed December vaccinates, none had a positive IgG response 
prior to vaccination and none developed an IgG S/P ratio >0.3 after vaccination 
(maximum S/P ratio, 0.09) on Dec 20, 2002 (Figure 2B). Of the 10 unexposed March 
vaccinates, none had an IgG S/P ratio >0.3 prior to vaccination and none developed an 
IgG S/P ratio >0.3 after vaccination (maximum S/P ratio, 0.19) on April-May sampling 
dates. Of the 10 mares vaccinated a third time in March 2003, 2 were previously exposed 
and 2 of the 8 unexposed horses had IgG S/P ratio >0.3 at sampling (maximum S/P ratio, 
0.44).  
In the first step of the analysis, we found no difference in the S/P ratios between 
December vaccinates and concurrent controls (P= 0.26; Table 2) measured on the last 
sample date (Dec 20), 10 days after the second dose of either vaccine or placebo. In the 
second step of the analysis, there was no difference in the S/P ratios measured 10 days 
after the second December vaccination and from samples collected approximately 1 ½ 
months after the second March vaccination (P=0.19; Table 2)  despite the different 
sampling times.   
There was also no evidence of serologic response to vaccination in previously 
exposed horses; however, the small number of horses in this category precluded testing 
this hypothesis (Figure 2A).   
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Table 2: The difference in antibody response (IgG S/P ratio) between groups of non-
exposed horses vaccinated on different dates with both two and three dose protocols and 
horses that were not vaccinated. 
Analysis 
 grouping 
Group N Sample date used in 
analysis 
Median 
S/P ratio 
P-
value 
Group B: Controls             17 Dec 20, 2002 0.03 P=0.26 1 
Group A: December vaccinates 
 
16 Dec 20, 2002 0.02 
Group A: December vaccinates 
 
16 Dec 20, 2002 0.02 2 
Group C: March vaccinates 
 
12 April-May 2003 0.04 
P=0.19 
 
 
A cutoff value used to distinguish infected versus non-infected horses was 
determined using data on 26 previously unexposed horses that had been vaccinated twice 
(16 from Nov-Dec 2002 vaccination and 10 from March 2003 vaccination). The 
minimum and maximum S/P ratio for the 26 horses was -0.07 and 0.19 respectively and 
the median S/P ratio was 0.02 (interquartile range (IQR) -0.01, 0.05). The standard 
deviation of the 26 WNV2 samples was 0.058. Thus the cutoff value (for horses 
vaccinated twice) for the IgG ELISA test at 1:200 dilution was estimated to be 0.305.  
All previously exposed horses were above the cutoff value at the first sampling 
time point which corresponds to 2 - 3 months after the 2002 exposure period (Figure 2A).  
In addition, the horse that had a suspicious result on the first two samples was also above 
the cutoff value on the first sample, making it possible that this horse was previously 
exposed earlier in the 2002 season. Removal of this horse from derivation of the cutoff 
value for horses vaccinated two times did not change the value itself.  
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A cutoff value for horses vaccinated three times was calculated with the same 
formula using the 8 previously unexposed horses sampled in April-May. The minimum 
and maximum S/P ratios were 0.02 and 0.44 respectively and the median S/P ratio was 
0.09 (IQR 0.06, 0.36). The standard deviation of the 8 samples was 0.16. The calculated 
cutoff value for horses vaccinated three times was estimated as an S/P ratio of 0.76.   
 
5.3.2 Seroprevalence study population 
The recruited herds were distributed across the southern half of the province 
(Figure 1) with 76% of the horses in the Grasslands and Parkland ecoregions. The 
number of horses sampled per herd ranged from 10 to 15 and the herd sizes ranged from 
10 to 250 horses. A total of 212 different horses were sampled in either August or 
October; 186 horses in the study were sampled in both time periods.  
The majority of herd owners (16/20) did not use any type of mosquito control on 
the farm. Only two of the four herds where mosquito control was employed used more 
than one type of mosquito control measure. The primary methods of mosquito control in 
these 4 herds included housing some horses in a barn with fans (1/4), applying insecticide 
on the farm (1/4), and use of smudges (2/4).  
The horses ranged in age from 1 month to 27 years (median, 6; IQR, 3, 9). The 
only foal in the study was born to a vaccinated mare but had no detectable IgG 
antibodies. Forty-seven percent of horses were mares (99/212), 40% were geldings 
(84/212) and 13% were stallions (29/212). Most of those sampled were dark colored 
(139/212, 66%), light breed (176/212, 83%), pleasure horses ((104/212, 49%).  
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Eighty-eight percent of the horses had no history of travel during the 2003 
summer and fall season. Insecticide was applied to only a few horses (36/212, 17%) and 
only a few horses were blanketed (8/212, 4%) during the summer. Most horses (155/212, 
73%) were kept in a pasture, 21% (45/212) had access to a three-sided shelter, and 6% 
(12/212) were housed in a barn at night. Most horses (79%, 167/212) were fully 
vaccinated according to the manufacturer’s recommendations. Four horses were 
vaccinated three times (one vaccine given in fall of 2002) and one horse was vaccinated 
once in April 2003. 
 
5.3.3 Serologic prevalence  
Six horses were IgM positive on the first sample but none of the 212 horses were 
IgM positive on the second sample. Of the 6 IgM positive horses, 4 were <0.3 IgG S/P 
ratio on the first sampling and all were > 0.3 on the second sample. None of these horses 
showed signs consistent with WNV. The IgG S/P ratio was > 0.3 for either one or both 
samples from 58.4% of horses (124/212); 29%(60/204) on first sampling, 56% (108/193) 
on the second sampling, 24% (44/185) on both sampling, 5% (9/185) on first but not 
second sampling and 31% (57/185) on second but not first sampling.   
The proportion of sampled horses in each herd classified as infected based on 
serum antibody concentrations ranged from 0% to 100%. The estimated population-
averaged prevalence, adjusted for herd-level clustering, was 55.7% (95%CI, 44.9% to 
65.8%).  
The risk of a horse being classified as infected was highest in the Mixed 
Grasslands ecoregion, followed by the Moist Mixed Grasslands ecoregion, the Aspen 
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Parkland ecoregion and lowest in the Boreal Transition ecoregion (Figure 1). Ten of the 
44 horses ( 23%) that were not vaccinated, the horse vaccinated once and 110 of the 163 
horses (67%) that were vaccinated twice had at least one S/P ratios >0.305 and were 
classified as being infected when information from both sampling periods was 
considered. Three of the four horses that were vaccinated three times were classified as 
not infected since the S/P ratios for both were less than the elevated cutoff value of 0.760. 
 
5.3.4 Risk factor analysis 
In the initial herd-adjusted unconditional analysis, vaccination, ecoregion, season 
average temperature, season total precipitation and season cumulative GDD were 
associated with risk of infection (Table 3). The odds of infection were 1.7 times higher 
for horses in the Mixed Grasslands than those from the Moist Mixed Grasslands and 2.1 
times greater for the Moist Mixed Grasslands than for the Aspen Parkland, which in turn 
had a 9.6 higher chance of infection than the reference ecozone Boreal Transition.  
The final model included only two explanatory variables: herd mosquito control 
and ecoregion; all other variables were not significant after accounting for ecoregion as a 
fixed effect and herd as a random effect (Table 4).  
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Table 3: Unconditional analysis of risk factors for WNV infectiona in a mixed model 
accounting for clustering by herd (N=212 horses, n=20 herds). 
Variable Categories Odds 
Ratio 
95% CI P 
No reference category  Vaccination 
Yes 4.3 1.2, 16.0 0.03 
    
Yes reference category  Herd Mosquito Control 
No 7.3 0.8, 69.5 0.08 
    
None reference category  
Simple 1.1 0.3, 4.2 0.8 
Individual Shelter 
Barn 0.2 0.03, 1.3 0.09 
     
Boreal Transition reference category  
Mixed Grassland 34.3 4.2, 277 <0.001 
Moist Mixed Grassland 20.1 1.7, 243 0.02 
Ecoregion 
Aspen Parkland 9.6 1.2, 79.2 0.04 
     
Temperature (°C)  3.0 1.3, 6.9 0.01 
Precipitation (mm)  0.98 0.96, 0.996 0.01 
GDD (degree days)  1.01 1.002, 1.02 0.006 
a Infection status determined by IgG antibody in the serum with an S/P ratio > 0.3 suggesting 
natural exposure to the virus at some time within the current season.  
 
Table 4: Multivariable model (adjusting for clustering by herd) showing the association 
between location and risk of infectiona considering the presence or absence of herd 
mosquito control (N=212 horses, n=20 herds). 
 
Variable Categories Odds Ratio 95% CI P 
Yes Ref   Herd mosquito control 
No 8.2 1.2, 57.8 0.03 
Mixed Grassland 34.6 4.9, 245.9 0.004 
Moist Mixed 
Grassland 
14.0 1.5, 135.5 0.02 
Aspen Parkland 16.1 2.1, 124.4 0.008 
Ecoregion 
Boreal Transition Ref   
Herd Variance (SE) 1.648 (0.788) 
a Infection status determined by IgG antibody in the serum with an S/P ratio > 0.3 suggesting 
natural exposure to the virus at some time within the current season.  
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The odds of being infected were 8.2 times higher for horses from herds where no 
method of mosquito control was used compared to those where any type of mosquito 
control method was used. Using the Boreal Transition as the reference region, the odds of 
being infected were greatest for horses residing in the Mixed Grassland and odds were 
similar for horses in both the Moist Mixed Grassland and the Aspen Parkland. The 
unexplained variance in infection status of horses within herds was 1.65 (S.E., 0.79). The 
intra-herd correlation coefficient, or proportion of total variance in the final model 
explained by between herd variation, was 0.33 (33%).  
Only the primary type of herd mosquito control per farm was assessed in a mixed 
model with ecoregion. The odds of being infected were 57 times higher for herds where 
no mosquito control was used than for herds where horses were housed in barns with 
fans, and 8.5 higher than for herds where owners used smudges for mosquito control. The 
odds of being infected did not differ between herds that used insecticides compared to 
herds where no mosquito control was used (P=0.45).  
 
5.4 Discussion 
The prevalence of horses with antibody concentrations suggesting infection from 
this study was greater than any reported to date (Trock et al. 2001, Autorino et al. 2002, 
Durand et al. 2002, Blitvich et al. 2003, Estrada-Franco et al. 2003, Lorono-Pino et al 
2003). However, the study area of southern Saskatchewan covered approximately 
390,000 km2 and there were substantial differences in seroprevalence identified across 
the study area. To explore the variation in risk of infection for horses with WNV, 
geographic differences that could be associated with changes in climate and vegetation 
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types were investigated by comparing seroprevalence among ecoregions. The proportion 
of infected horses differed greatly by area, from 20% in the northern Boreal Transition to 
76% in the southern Mixed Grassland.  
In the Boreal Transition ecoregion, both climate and mosquito habitat were less 
likely to facilitate WNV transmission than in the other ecoregions examined (curry 
2004). Until the mosquito trapping was conducted in the 2003 season, historical trapping 
data suggested that C. tarsalis was not commonly found in the northern portion of the 
Aspen Parkland and the Boreal Transition. Therefore, the risk of exposure to WNV prior 
to 2003 was considered extremely low in this area. North of the study area (white area in 
Figure 1), there were no clinical cases reported and the risk of infection was negligible; 
therefore neither mosquito trapping nor blood sampling of horses was conducted in this 
area.    
Ecoregion was a significant predictor of infection status. The odds of having been 
infected were more than 30 times greater in the Mixed Grassland than in the Boreal 
Transition. This finding is consistent with the fact that the Mixed Grassland ecoregion 
also had the most generations of the C. tarsalis mosquito in 2003 and the best climate and 
habitat for C. tarsalis mosquito growth (Curry 2004). There appeared to be a gradient of 
infection which progressed from high risk in the south-western most portion of the 
province to lower risk in the central region of the province, the northern most extent of 
documented WNV infection in any species (bird or human) in 2003 (Corrigan et al. 
2006). 
Vaccination was a significant predictor of infection status in an unconditional 
model adjusted only for clustering by herd. The odds of antibody concentrations 
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sufficiently high to suggest natural infection were 4 times greater for vaccinated horses 
than for non-vaccinated horses. The reason for this vaccine-related difference in antibody 
status was that the herds that were not vaccinated were most likely to be located in the 
northern area of the Aspen Parkland and the Boreal Transition ecoregions. In the spring 
of 2003, these areas were considered at low risk for infection due to climate and historical 
mosquito data. With this knowledge, horse owners in this region were less likely to 
vaccinate. When ecoregion was controlled for in the model, vaccine status was no longer 
significantly associated with IgG antibody concentrations and there was no evidence that 
vaccination prevented infection. This study did not examine whether the vaccine 
protected against clinical disease or whether the absence of detectable antibodies was 
related to efficacy of the vaccine or inference of immunity to WNV. 
Mosquito trapping measures were not significantly associated with risk of 
infection but this could be a result of biases such as trap locations and trap malfunctions. 
Temperature, precipitation and GDD were significant predictors of infection status in the 
unconditional models, but were strongly correlated with ecoregion in the final model. As 
season average temperature increased, so did the odds of horses becoming infected. As 
season total precipitation increased, the odds of infection decreased. Temperature and 
precipitation differed for each ecoregion and tended to follow a south to north gradient. 
Lower rainfall and higher temperatures were generally in the southern areas of the 
province that coincided with the area where the greatest mosquito development occurred.  
 GDD is a measure of the suitability of meteorological conditions for mosquito 
growth. Increased GDD is associated with an increase in the number of generations of 
mosquitoes within a given time period and a resultant increase in the potential risk of 
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WNV infection. In the present study, as GDD increased the odds of infection increased. 
GDD was highly correlated with ecoregion and also decreased from south to north 
following a similar pattern as the ecoregions map. Because accounting for ecoregion 
explained much of the variability in meteorological conditions, the variables representing 
the meteorological data were eliminated from the final model. 
Only use of herd-mosquito control and ecoregion were significantly associated 
with infection status when combined in the final model. Ecoregion was modeled as a 
fixed effect to estimate differences in infection status across geographic regions. The 
odds ratios show decreasing risk of infection from southwest to northeast. Housing in a 
barn with fans or a barn sealed at night to prevent mosquitoes from entering provided 
some protection against infection with WNV. Due to the small number of farms that used 
mosquito control methods, the absence of a significant protective effect associated with 
the use of smudges (2 herds, 20 horses total) does not necessarily exclude this as a useful 
prevention measure. There was also no evidence that insecticide use provided protection 
against infection. The effectiveness of smudges and insecticides are likely influenced by 
the timing and consistency of application. 
This study used ELISAs for both IgM and IgG to evaluate serologic status and 
classify horses as infected or not and then to assess potential prevention tools.  Few 
horses would have been classified as infected on the basis of IgM alone. As well, all IgM 
positive samples occurred during August. This antibody persists for a short time period 
and thus would not be helpful in serologic surveillance after the infection season (Ostlund 
et al. 2001). The use of a single IgM test at any point in time during the mosquito season 
will, therefore, underestimate the number of infected horses.  The IgG ELISA was useful 
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in this study as this was the first season of vaccination for the majority of horses. 
Unknown vaccination status, multiple years of vaccination with the same or different 
vaccines, and natural infection with WNV from previous years will potentially 
complicate the use of IgG antibody tests in future serologic studies. Thus, future 
serologic surveillance will likely need to focus on the use of serial IgM testing during the 
period of risk of infection.  
Because of Saskatchewan’s large size and varying climate, regional differences 
were expected in the distribution of infection. The known distribution of C. tarsalis, the 
mosquito species capable of transmitting the virus to horses, is limited to the southern 
half of the province. Within this area, a gradient of infection risk was present and 
followed ecoregions, or temperature, precipitation and GDD gradients from the south to 
north end of the risk zone. The use of mosquito control measures at the farm level 
reduced the odds of infection within each ecoregion. Effective use of all the various 
mosquito control measures and knowledge of areas of risk should aid in the protection of 
horses against WNV infection.     
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6.  A case-control study of factors associated with development of clinical disease 
due to West Nile virus, Saskatchewan, 2003. 
 
 
 
 
6.1  Introduction 
West Nile Virus (WNV) was first diagnosed in horses in North America in the 
late summer of 1999 (Ostlund et al. 2001). Clinical signs in horses ranged from mild to 
severe with case fatality rates of 25-40% (Ostlund et al. 2001, Trock et al. 2001). Not all 
infected horses develop clinical signs. One review article suggested that approximately 
10% of horses infected with WNV exhibit neurological symptoms, which have been 
corroborated by experimental equine infections (Castillo-Olivares et al. 2004, Bunning et 
al. 2002).  
    Researchers in the United States have examined the extent of sub-clinical 
WNV infection in horses. In a 1999 study conducted in New York state, serum samples 
were collected from 69 clinically normal horses kept on farms where at least one 
clinically diseased horse had been confirmed (Trock et al. 2001). Twenty of the 69 horses 
(29%) were antibody positive for the virus. In a 2000 study on Staten Island, 8% (7/91) of 
clinically normal horses from seven stables were seropositive; in one of the stables, 5/6 
horses were seropositive (Trock et al. 2001).  New York serosurveys conducted in 1999 
and 2000 revealed higher seroconversion of clinically normal stable mates (23% and 5% 
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respectively) compared with seroconversion on farms without clinical disease (8% and 
1% respectively) (Kramer et al. 2001).  
Controlled challenge trials have demonstrated protection against viremia in horses 
vaccinated with West Nile Innovator (Wyeth Animal Health, Guelph, Ontario, Canada) 
(Ng et al. 2003). In other studies, all of the horses, which were vaccinated with sufficient 
time to develop immunity prior to showing clinical signs, survived (Salazar et al. 2003) 
and vaccination reduced the odds of death from clinical signs (Schuler et al. 2003). 
Another study reported that even if the vaccine was not administered in sufficient time 
prior to the infection season, it could reduce the risk of death by up to 44% (Ward et al. 
2006). None of these studies was designed to assess whether vaccination would prevent 
development of clinical signs. In a cohort study that followed vaccinated and 
unvaccinated horses, vaccination seemed effective in preventing clinical disease (Gardner 
et al. 2007).  
Previous studies have not yet identified other individual risk factors that were 
significantly associated with development of clinical disease. For example, the ages of 
case horses and clinically normal seropositive herd-mates were not significantly different 
in a study from New York in 1999 (Ostlund et al. 2001).  
Based on the spread of WNV across the continent during the previous year, horses 
in Saskatchewan were expected to be at high risk of exposure to the virus in the summer 
of 2003. Most horses in the province of Saskatchewan are housed outside with little 
protection against exposure to mosquitoes. As a result, vaccination, in addition to other 
mosquito abatement methods was recommended for preventing clinical disease. A case-
control study was undertaken in the summer of 2003 in anticipation of the outbreak to 
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identify risk factors for development of clinical disease in horses, which could potentially 
be used to make recommendations for control.  
  
6.2 Material and methods 
6.2.1 Study protocol 
All laboratory-confirmed clinical cases of WNV in Saskatchewan (SK) were 
recorded in 2003. A confirmed ‘clinical case’ was any equid with clinical signs consistent 
with WNV and a positive Immunoglobulin (Ig)M enzyme-linked immunosorbent assay 
(ELISA) test from Prairie Diagnostic Services (PDS) in Saskatoon, SK. From the affected 
properties identified, a subset of case farms was randomly selected along with an equal 
number of control farms. Case farms were those having at least one clinical case of WNV 
on the premises in 2003, a minimum of five horses on the property and an owner willing 
to participate in our investigation. A control farm was the nearest property to a case farm 
with at least five horses and an owner willing to participate in the study, and where there 
were no confirmed or suspected clinical cases of WNV disease.  
Study participants completed a form in the presence of the investigator that 
provided the legal land location, individual characteristics of all sampled horses, herd and 
individual management methods, and information about mosquito control measures used 
on farm. Approximately 10 ml of blood was collected from five to ten horses from each 
farm. All samples from both case and control farms were collected within a three-month 
period of the onset of disease on the case farm. The disease status of each farm was 
monitored until the end of the mosquito season to ensure control farms did not become 
case farms.  
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6.2.2 Sample to positive ratio and IgM and IgG ELISA 
All samples were classified as positive, suspicious or negative for both IgG and 
IgM based on the optical density (OD) results of the appropriate ELISA. A sample-to-
positive (S/P) ratio was then calculated for the IgG test results as follows: S/P 
ratio=(sample OD-negative control OD)/(positive control OD –  negative control OD). 
The OD was determined as the difference in values between the duplicate wells 
on the plate for each test and control sera. Sera were tested on tissue culture derived 
WNV antigens in one of the wells. In the other well, sham infected tissue culture antigen 
preparations (control antigen) were used to ensure the specificity of the response was to 
WNV. The positive control from the top left corner was used in the calculation of the 
above formula for the first four rows of the plate and the positive control at the bottom 
right corner of the plate for the bottom four rows.  
Both the IgM and IgG assays used in this study were antibody capture ELISAs 
using reagents supplied by BioReliance Corporation (Rockville, Maryland). No 
sensitivity or specificity estimates were available for the reagents used in this test.  
For the IgM ELISA, 100 microlitres of a 1:250 dilution of monoclonal antibody 
specific for Equine IgM in Phosphate buffered saline (PBS) was coated onto wells of a 
polyvinyl chloride (PVC) ELISA plate and incubated overnight at 4°C. The plates were 
washed five times between each step of the process. Control and test sera were then 
diluted in PBS-T, added to duplicate wells of the ELISA plate and incubated for 2 hours 
at 37 °C. Then 100 microlitres of WNV antigen or control antigen preparations were 
diluted 1:5 in PBS-T, added to one of the duplicate wells and incubated for 2 hours at 37 
°C. One hundred microlitres of a 1:100 dilution of WNV specific monoclonal antibody 
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were added to the test wells. The monoclonal antibody was diluted in PBS-T + 5% skim 
milk. The plates were incubated for 2 hours at 37 °C. Then 100 microlitres of a 1:100 
dilution of anti-mouse IgG –Horse Radish Peroxidase (HRPO) conjugate in PBS-T + 5% 
skim milk were added to each well and incubated for one hour at 37 °C. Finally 100 
microlitres of ABTS (2,2’-azino-di(3-ethyl-benzthiazoline-6-sulfonate, KPL cat# 50-66-
00) were added to each well and incubated for 30 minutes at 37 °C. The test was read 
using a spectrophotometer at 410 nm. A positive test was one that had a net O.D. of 0.2 
or greater after subtraction of the control (duplicate) well O.D. and had at least 2 times 
the control well value. A suspicious test met one of these criteria and a negative test met 
none of the criteria. 
For the IgG ELISA assay used in this study, 100 microlitres of a 1:50 dilution of a 
WNV specific monoclonal antibody was added onto wells of a polyvinyl chloride (PVC) 
ELISA plate and incubated overnight at 4°C. The plates were washed five times between 
each step in the process. The WNV antigen and control antigen were diluted 1:50 in IgG 
lysis buffer (PBS+0.3% Igepal CA-630 Sigma #I3021) and incubated at room 
temperature for 15 minutes. Then 100 microlitres of the diluted antigen and control 
antigen were added to one of the duplicate wells on the ELISA plate and incubated at 37 
°C for 2 hours. The dilutions of the control and test sera were prepared in PBS-T + 4% 
normal goat serum (all test sera are diluted 1:200). A total of 100 microlitres of the 
diluted samples and controls were added to the duplicate wells and incubated at 37 °C for 
2 hours. Then 100 microlitres of anti-Equine IgG HRPO conjugate diluted in PBS-T + 
5% skim milk + 4% normal goat serum were added. One hundred microlitres of ABTS 
(KPL cat# 50-66-00) were added to each well and incubated for 30 minutes at 37 °C. The 
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test was read using a spectrophotometer at 410 nm. Positive, suspicious and negative test 
results are as defined above. 
 
6.2.3 Determination of infection status 
A positive IgM sample was indicative of recent WNV infection. Infection status 
for vaccinated horses was based on a positive IgM result or an IgG result above the 
appropriate cutoff value. An IgG cutoff value for infection status (yes or no) was 
determined to be equal to or greater than 0.305 S/P if vaccinated twice and equal to or 
greater than 0.760 S/P if vaccinated three times (Epp et al. 2007). Infection status for 
non-vaccinated horses was based on any positive (or suspicious) IgM or IgG ELISA 
result.  
 
6.2.4 Horse data   
Horses were classified by sex, color, age and breed type but not by specific breed. 
Breed type was divided into three groups: light horses, draft horses, and crosses and 
ponies which included miniatures and mules. Sex was reported in three categories: mare, 
gelding and stallion. Color was divided into three categories: darks (chestnut, sorrel, 
brown, black or bay), light (gray, white, palamino, buckskin or dun), and multi-colored 
(roan, paint, pinto and appaloosa). Size was recorded as the circumference of the girth 
and was divided into two categories: small girth (≤ 69 inches) and larger girth (> 69 
inches). Age was divided into three categories: young (5 years or younger), middle-aged 
adults (6-18 years) and older adults (older than 18 years). Housing was also classified 
 126
into three groups: housed in an enclosed barn, access to a simple three sided shelter with 
corral or pasture, or no access to a shelter in open pasture with or without trees. 
 
6.2.5 Farm level data 
Herd locations were mapped using ArcView GIS (version 3.2) and ArcGIS 
(version 8.0, Environmental Systems Research Institute Inc, Redlands, California). The 
location was displayed as a point using the centroid-of-the-polygon for the legal land 
location.  
 Primary shelter of the majority of horses on the premise was recorded using the 
above categories. On-farm mosquito control was classified as whether or not any method 
of mosquito control was used. When mosquito control was reported, the method was 
recorded as use of fans in a barn and/or sealed at night, smudges (smoky fire used to ward 
off mosquitoes), general insecticides, or no mosquito control attempted. The proportion 
of sampled horses vaccinated on each farm was also recorded as: none (0%), part (1-
99%) and all (100%). 
 
6.2.6 Statistical analysis 
Each potential risk factor was assessed to determine whether it was associated 
with clinical disease status of individual horses using data from all horses in case and 
control farms in a logistic regression model (SPSS ver 14.0, Chicago, IL, USA). In the 
second step, this process was repeated using only data from the horses classified as 
infected on both case and control farms.  
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To assess whether the infection pressure was similar on both case and control 
farms the proportion of serologically positive horses was analyzed with a logistic 
regression model (MlwiN ver 2.02, Centre for Multilevel Modelling, Institute of 
Education, London, UK). The average proportion across all farms was calculated from 
the estimate and standard error in a null model and the comparison of the case and control 
farm proportions was assessed in a model with farm status (case versus control) for a) all 
horses on each farm including clinical horses and b) only asymptomatic horses on each 
farm.  
Vaccine efficacy or the attributable fraction exposed was calculated using 
EpiTable (EpiInfo version 6, CDC, Division of Surveillance and Epidemiology, Atlanta, 
Georgia, USA).  
In the final step, each potential risk factor was assessed to determine whether it 
was associated with the farm disease status in a logistic regression model (SPSS ver 14.0, 
Chicago, IL, USA).  
All independent variables with P > 0.25 in the univariate assessments were 
considered in developing the final multivariate models. Manual backwards elimination of 
variables was used to achieve a final model containing only the statistically significant 
exposure variables and any nonexposure risk factors that were either significant or acted 
as important confounders. Nonexposure risk factors were defined as confounders if 
removing or adding the factor changed the effect estimate for the exposure by more than 
10% and the factor was retained in the final model. Biologically reasonable interactions 
were assessed between significant risk factors (P <0.05) in the final model.  
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 6.3 Results 
Of 123 farms with a clinical case(s) in 2003, 63 (51%) farms had 5 or more horses 
on the property. However, only 44 case farms were willing to participate in the study. Of 
these,  23 (53%) were randomly selected and matched by location to 23 control farms. A 
total of 300 horses, including 25 clinical cases were sampled from these 46 farms. The 
median number of samples collected on each farm was 6 (range, 5 to 10). Two farms had 
two clinical cases each at the time of sample collection; one additional farm had a second 
clinical case after sampling was completed which was not included in analysis. Sampling 
was initiated on August 23 and concluded on November 1, 2003. The median proportion 
of each herd that was tested was 50% (range, 2% to 100%). 
All samples from both case and control herds were collected within three months 
of the onset of clinical signs on the case farm. There were 7 positive and 3 suspicious 
non-clinical horses by IgM ELISA (n=275). All 25 clinical case horses were IgM positve. 
All positive IgM samples were collected before September 30th, 2003. Samples from non-
clinical horses were also analyzed with IgG ELISA resulting in 172/275 (63%) positive, 
12/275 (4%) suspicious and 91/275 (33%) negative results as assessed by the test 
protocol. For non-clinical horses, 7 were positive on IgM only, 171 were positive on IgG 
only, and no horses were positive on both IgG and IgM. Based on the appropriate cutoff 
value for the IgG ELISA, 78/133 (59%) vaccinated non-clinical horses were above the 
cutoff value and were considered exposed to WNV infection during the 2003 season.  
Of the 300 horses sampled, 193 (64%) were classified as WNV infected;  70% 
(108/154) on case farms and 58% (85/146) on control farms (Table 1). Sixty-one percent  
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(168/275) of horses without clinical signs were infected with WNV; 64% (83/129) on 
case farms and 58% (85/146) on control farms. There was no significant difference in the 
proportion of asymptomatic infection between case and control farms (P = 0.22).  
The first clinical disease case was reported in August 2003 in 65% (15/23) of case 
farms. Twenty-five of the 193 infected horses (13%) exhibited neurologic symptoms. 
Most individual horse characteristics were similar on case and control farms. The age 
distribution of both types of farms were skewed toward the younger age categories (Table 
1). There were three foals (2 -3 ½ months old) with clinical disease in this study. Two of 
the foals were from mares that were vaccinated for WNV, of which one survived. The 
vaccination status of the horses differed between case and control farms as well as 
between individual clinical diseased and non-diseased horses (Table 1 and 2).   
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Table 1: Description of animal and management characteristics in both case and control 
farm horses; individual data. 
WNV Infection status Case farm horses  Control farm horses 
Clinical 
infected 
Asymp. a 
infected  
 
Not 
infected 
Total Asymp. a 
infected 
Not 
infected 
Total  
Variables 
25 83 46 154 85 61 146 
Class of equid Light  
Pony /other 
Draft/draft cross 
 
18 
3 
4 
68 
8 
7 
34 
8 
4 
120 
19 
15 
69 
4 
12 
44 
8 
9 
113 
12 
21 
Coat color Lights 
Darks 
Multis 
 
6 
15 
4 
14 
52 
17 
5 
36 
5 
25 
103 
26 
10 
63 
13 
10 
40 
10 
20 
103 
23 
Sex Mare 
Gelding 
Stallion 
 
9 
13 
3 
39 
41 
3 
19 
24 
3 
67 
78 
9 
43 
41 
1 
33 
26 
2 
76 
67 
3 
Primary 
individual 
housingb 
Barn 
Simple shelter 
No shelter 
 
0 
4 
21 
0 
23 
59 
0 
13 
33 
0 
40 
113 
0 
31 
53 
8 
23 
30 
8 
54 
83 
Age category 0-5 years 
6-18 
19+ years 
 
9 
13 
3 
39 
41 
3 
22 
22 
2 
70 
76 
8 
31 
46 
8 
28 
27 
6 
59 
73 
14 
Girth size 
categoryb 
Small girth 
Medium girth 
Large girth 
 
0 
1 
1 
1 
13 
3 
9 
6 
1 
10 
20 
5 
0 
17 
3 
6 
12 
0 
6 
29 
3 
Vaccination No  
Yesc 
 
24 
1 
63 
20 
31 
15 
118 
36 
27 
58 
21 
40 
48 
98 
Travel No  
Yes 
 
25 
0 
75 
8 
46 
0 
146 
8 
77 
8 
55 
6 
132 
14 
Use Pleasure 
Breeding 
Competition 
Farm/ranch work 
 
19 
3 
1 
2 
57 
17 
3 
6 
35 
8 
1 
2 
111 
28 
5 
10 
57 
21 
7 
11 
34 
16 
11 
0 
91 
37 
18 
0 
Mosquito control 
(Individual) b  
 
No 
Yes 
22 
3 
75 
7 
43 
3 
140 
13 
76 
8 
42 
19 
118 
27 
Herd Sizeb 5-10 horses 
11-25 horses 
26-50 horses 
50+ horses 
12 
9 
2 
2 
43 
30 
3 
6 
20 
18 
6 
2 
75 
57 
11 
10 
24 
39 
6 
15 
20 
22 
6 
13 
44 
61 
12 
28 
aAsymp. = asymptomatic,    
bcategory has missing values  
cvaccination status means fully vaccinated with two or more doses of vaccine by company protocol. 
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Table 2: Description of disease onset and herd management factors in both case and 
control farms; farm level data. 
Variables Case farms 
(N=23) 
Control farms 
(N=23) 
Number of clinical WNV equids At least one 
Two or more 
 
21 
2 
0 
0 
Date of onset of first equid with 
clinical signs 
July 
August 
September 
 
1 
15 
7 
0 
0 
0 
Farm mosquito control measures At least one method 
Nothing 
 
4 
19 
5 
18 
Primary herd shelter  None 
Simple 
Barn 
 
18 
5 
0 
14 
8 
1 
Herd size 5-10 horses 
11-25 horses 
26-50 horses 
50+ horses 
 
12 
8 
2 
1 
7 
10 
2 
4 
Farm vaccination category No vacc 
Partly vacc 
All vacc 
15 
7 
1 
4 
6 
13 
 
Based on the results of the initial unconditional analysis of individual horse 
disease status, vaccination and primary individual shelter were considered for inclusion in 
the final model (Table 3). In the final multivariable analysis, vaccination status was the 
only factor associated with disease status (diseased versus not diseased) (Table 4). The 
estimate of vaccine efficacy for the prevention of the development of clinical disease was 
96% (95% CI 67% to 99%, P<0.0001).  
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Table 3: Unconditional analysis: for a) individual disease status (all horses showing 
clinical disease or not showing clinical disease), b) individual (infected horses only) 
disease status and c) farm status (case farm or control farm).  
 Disease Status Model Variable Category N 
OR 95% CI P 
Vaccination No  
Yes 
 
300 22.5 
ref 
3.0, 168.5 0.002 Individual  
Individual 
sheltera 
None 
Some shelter 
298 2.9 
ref 
1.0, 8.8 0.05 
Vaccination No  
Yes 
 
193 20.8 
ref 
2.8, 157.3 0.003 Individual  
(infected 
Horses only) 
Individual 
sheltera 
None 
Some shelter 
193 2.5 
ref 
0.8, 7.7 0.10 
Model Variable Category N Farm Status 
    OR 95% CI P 
Farm Herd 
Sheltera 
None 
Some shelter 
46 2.3 
ref 
0.6, 8.5 0.2 
 Farm 
Vaccination 
 
No vacc 
Part vacc 
All vacc 
46 48.8 
15.2 
ref 
4.8, 493.0 
1.5, 152.5 
0.004 
a Categories barn and simple shelter were combined to continue analysis (too few entries for 
barn, would not converge). 
 
 
 
 
 
 
 
 
 
 
For the subset analysis based on the initial unconditional analysis of individual 
disease status for only the infected horses, vaccination and primary individual shelter 
were again considered for inclusion in the final model (Table 3). In the final 
multivariable analysis considering only the infected horses, vaccination was the only 
factor associated with disease status (diseased versus not diseased) (Table 4).  
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Table 4: Multivariable analysis: for a) individual disease status (all horses showing 
clinical disease or not showing clinical disease), b) individual (infected horses only) 
disease status and c) farm status (case farm or control farm).  
Disease status Model N Variable Category 
OR 95% CI P 
Individual 300 Vaccination No vaccine 
Yes vaccine 
 
22.5 
Ref 
3.0, 168.5 0.002 
Individual 
(infected 
horses only) 
193 Vaccination No vaccine 
Yes vaccine 
20.8 
Ref 
2.8, 157.3 0.003 
Farm status Model N Variable Category 
OR 95% CI P 
Farm 46 Farm Vaccination  No vacc 
Part vacc 
All vacc 
 
48.8 
15.2 
Ref 
4.8, 493.0 
1.5, 152.5 
0.004 
 
 
At the farm level, there were some potential differences in the use of shelter, 
vaccination, and herd size between case and control herds (Table 2). Based on the initial 
unconditional analysis of farm status, farm vaccination status and primary herd shelter 
were considered for inclusion in the final model (Table 3). In the final multivariable 
analysis, farm vaccination status was associated with the farm status (case versus control 
farm) (Table 4). All three models were also assessed with random effects models 
(accounting for herd and location by ecological region), however, the variance of the 
random effects were zero in the null models, suggesting herd location was not an 
important confounder in this analysis, and thus was not pursued further.  
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6.4 Discussion  
Although vaccination has been reported to have a protective effect with respect to 
disease outcome (recovery or death) when horses show neurological symptoms (Salazar 
et al. 2004, Schuler et al. 2004, Ward et al. 2006), this study provided some of the first 
field evidence that vaccination can protect against the development of clinical disease. A 
96% vaccine efficacy from a field study in the face of a natural outbreak is remarkable. 
Using data from other concurrent studies during this outbreak, the vaccine efficacy 
remained at 97% (95% CI 93.5%, 98.4%) (Epp et al. 2005).  
 Vaccination had a substantial effect upon disease at the level of both the farm and 
the individual horse. Non-vaccinated horses were 23 times more likely to exhibit clinical 
signs of disease than vaccinated horses. This relationship was consistent even when only 
those horses exposed to and infected with WNV were used in the analysis. Farms were 
more likely to have had a clinical case when none of or only a portion of the horses in the 
herd were vaccinated. This study demonstrates that vaccination is highly efficacious and 
an important preventive measure against the development of clinical illness.  
The proportion of asymptomatic infection in non-clinical  stable mates on case 
farms was higher than studies in the eastern USA, but similar to the Californian cohort 
study (Trock et al. 2001, Kramer et al. 2001, Gardner et al. 2007). A key difference was 
that horses in the cohort study were housed on dry lots or irrigated pastures while the 
horses in the eastern states were housed in stables. In this study, the proportion of 
asymptomatic infection was similar in both the case and control farms, while the 
proportion of vaccinates was considerably higher on control farms. With similar 
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asymptomatic infection proportions, the difference in vaccination is a key risk factor that 
determines the occurence of clinical disease.  
Other vaccines have entered the market since this study was conducted; 
Recombitek (Merial Canada Inc., Baie d’Urfe, Quebec, Canada), a DNA vaccine (Fort 
Dodge Animal Health, Fort Dodge, Iowa, USA) and a chimera vaccine, (PreveNile, 
Intervet, Inc. Millsboro, Deleware, USA). Of these, only the recombinant vaccine has 
been shown efficacious in a field study (Gardner et al. 2007). All vaccines claim to 
prevent viremia, a precursor for clinical disease development (Long et al. 2005, Chiang  
et al. 2005, Siger et al.2006). Due to the efficacy and availability of the first vaccine on 
the market, the subsequent introduction of the other vaccines into the market will increase 
consumer options and cost competitiveness.   
Cost effectiveness of vaccination in the prevention of clinical disease could not be 
assessed in either the cohort study or our study (Gardner et al. 2007). However, it was 
inferred in the cohort study to be financially prudent based on a crude comparison of the 
average cost of each clinical case and the cost of vaccination. In this study, only one of 
the clinical horses was vaccinated for WNV, supporting the idea that even when 
administered correctly, some horses may respond poorly to vaccination. Further research 
into the vaccines may elicit reasons for these different responses. 
WNV prevention strategies are presently based on vaccination, housing 
recommendations, and mosquito control measures. Methods such as on-farm mosquito 
control or housing in barns have been shown to be effective at reducing the risk of 
infection (USDA 2001). Failure of our study to show an effect of mosquito control upon 
the odds of development of clinical disease may have been due to limited adoption of 
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these strategies in the study population. However, there were no clinical horses housed in 
barns within this study. The mechanisms involved in which horses develop disease once 
infection occurs were also not evaluated in this study.  This study has shown that 
vaccination provides remarkable protection against the development of disease, even in 
the absence of concerted efforts to reduce the risk of exposure to the virus.  
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 7.  Equine West Nile Virus surveillance as a component of an integrated surveillance 
program over a four year period in Saskatchewan: 2002 - 2005 
 
 
 
 
 
7.1 Introduction 
When West Nile Virus (WNV) first emerged in North America in 1999, its 
clinical presentation in humans was mistaken for a different arbovirus in the same family, 
St. Louis Encephalitis virus (Drexler 2002). Public health officials later realized that 
earlier integration of information from birds and mammals could have unlocked the 
mystery sooner (Drexler 2002). With the subsequent spread of the virus, WNV 
surveillance became a central focus of both local and national governing bodies. 
This paper documents equine surveillance in the province of Saskatchewan in 
four years (2002-2005) beginning with the introduction of the virus. It also explores the 
usefulness of equine surveillance as a component of the overall program for monitoring 
West Nile Virus in the province of Saskatchewan (SK).  
 
7.2 Surveillance in Saskatchewan: 2002-2005 
In 2002, serologically WNV positive horses were reported to Saskatchewan 
Agriculture Food and Rural Revitalization (SAFRR) by three different sources: Prairie 
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Diagnostic Services (PDS) in Saskatoon, Manitoba Provincial Laboratory in Winnipeg, 
and Canadian Food Inspection Agency (CFIA). No definition of a “clinical case” was 
provided by SAFRR and no information on the clinical signs of the tested horses was 
recorded. Reporting of cases was voluntary on the part of the horse owners, veterinarians, 
and laboratories.  
In 2003, information was collected systematically by Western College of 
Veterinary Medicine (WCVM) researchers on all horses with neurological symptoms for 
which samples were submitted to the regional laboratory. All large and mixed animal 
practices in Saskatchewan were asked: 1) to send all samples for WNV detection into 
PDS in Saskatoon, SK for Immunoglobulin (Ig)M enzyme-linked immunosorbant assay 
(ELISA) and 2) to allow PDS to notify the WCVM research team of any positive result 
from samples submitted by the clinic. A “confirmed clinical case” was defined as a horse 
with one or more of the classic signs of WNV; such as ataxia, recumbency, paralysis or 
paresis of limb(s), or death and a positive IgM ELISA test. A “probable clinical case” did 
not have any confirmatory testing but had clinical signs consistent with WNV. Post-
season surveillance of a random sample of clinics in the fall of 2003 was used to estimate 
the number of probable WNV cases per region. Information was shared with 
Saskatchewan Health’s integrated surveillance initiative.  
In 2004, twenty-two private veterinary clinics located within each of the ten 
Regional Health Authorities (RHA) in the southern portion of the province reported 
weekly on the number of laboratory-confirmed clinical WNV cases and probable clinical 
WNV cases each had seen or heard of in their area. Information collected included date 
of onset of clinical signs and location. 
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In 2005, nineteen veterinary clinics from nine RHAs reported weekly on the 
number of confirmed clinical cases and probable clinical cases each had seen or heard of 
in the respective area. Information collected included date of onset of clinical signs and 
location. To increase the number of confirmed cases, Saskatchewan Health sponsored the 
testing of probable clinical cases. In addition, all clinics within the province of 
Saskatchewan were asked for permission to allow the researchers to be notified of all 
positive IgM test results obtained by PDS (similar to 2003).  
The full integrated surveillance initiative was coordinated by Saskatchewan 
Health and, in addition to horse statistics, included the following: dead bird surveillance 
information from Canadian Cooperative Wildlife Health Center (CCWHC website), 
mosquito speciation information, virus isolation from mosquito pools and human case 
statistics from Saskatchewan Health (Saskatchewan Health website), and daily 
temperature and precipitation information from Environment Canada (Environment 
Canada website). All components of the surveillance program were combined to confirm 
WNV activity in various geographic areas which drove the decision making process.  
 
7.3 Surveillance results  
In 2002, there were 29 documented positive diagnostic samples (Table 1). Only 
the location of the submitting clinic was recorded. No information was available on the 
presenting clinical signs for the tested horses nor was the health outcome of each horse 
reported, however six of the positives were from tests done on brain tissue. Although the 
date of onset of clinical signs was not recorded, no samples were tested prior to August 1. 
The primary focus of the reported cases was the southeast corner of the province. 
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 In 2003, 82% (65/79) of clinics gave permission to access positive test results. A 
total of 133 positive IgM samples were documented by PDS (Table 1). Exact location 
was known for 130 cases, while the submitting clinic’s location was known for the other 
3 cases. The first onset date for clinical signs was July 30th, 2003 and the last date of 
onset was on September 19th, 2003. Clinical signs reported by owners were consistent 
with WNV. Of the 130 horses with known health outcome, 57 died or were euthanized 
(44%). Post season surveillance suggested that the number of confirmed clinical cases 
was approximately 1/5 of the potential number of cases in the province (Epp et al. 2007). 
The number of days from clinical onset to when a veterinarian visited the farm ranged 
from 0 to 49 with an average of three days. The number of days from clinical onset to a 
laboratory diagnosis ranged from 1 to 56 with an average of seven days.  
In 2004, ten probable clinical horse cases were reported with confirmatory testing 
initiated in three cases, all three with negative results (Table 1). The first of these three 
cases was reported on July 24th. Clinical outcome was not reported. Locations were 
reported by RHA only. 
In 2005, 49% of clinics (38/77) gave permission to access positive results. There 
were ten confirmed clinical cases and four probable clinical cases reported (Table 1). 
Outcome and vaccination status of the horses was not reported. The first date of onset of 
clinical signs was reported as July 26th and the last date was reported as September 24th. 
Table 2 lists data for 2002 to 2005 for the following: bird data derived from the 
CCWHC website, human and mosquito derived from the Saskatchewan Health website, 
and temperature and precipitation data derived from the Environment Canada website. 
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Table 1:  Results of surveillance: 2002 to 2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year RHA a Clinics 
Reporting b 
Potential 
Cases c 
Laboratory 
confirmed 
Sun Country -- -- 19 
Five Hills -- -- 1 
Cypress -- -- 1 
Regina Qu’Appelle -- -- 5 
Sunrise -- -- 1 
Saskatoon -- -- 1 
Heartland -- -- 1 
Kelsey Trail -- -- 0 
P.A. Parkland -- -- 0 
 
 
 
 
 
2002 
Prairie North -- -- 0 
Sun Country 7 20 10 
Five Hills 4 28 12 
Cypress 5 48 18 
Regina Qu’Appelle 9 58 18 
Sunrise 7 21 13 
Saskatoon 9 7 22 
Heartland 6 8 10 
Kelsey Trail 5 2 5 
P.A. Parkland 3 12 8 
 
 
 
 
 
2003 
Prairie North 8 21 17 
Sun Country 3 1 0 
Five Hills 2 3 0 
Cypress 2 1 0 
Regina Qu’Appelle 3 0 1 negative 
Sunrise 2 0 0 
Saskatoon 3 0 0 
Heartland 3 0 1 negative 
Kelsey Trail 2 1 0 
P.A. Parkland 1 0 0 
 
 
 
 
 
2004 
Prairie North 2 1 1 negative 
Sun Country 3 0 2 
Five Hills 2 0 2 
Cypress 2 0 1 
Regina Qu’Appelle 3 0 1 
Sunrise 2 2 0 
Saskatoon 2 2 2 
Heartland 2 0 0 
Kelsey Trail 1 0 2 
P.A. Parkland 0 0 0 
 
 
 
 
 
2005 
Prairie North 2 0 0 
a For RHA locations see map available online at http://www.health.gov.sk.ca/ph_rha_map.html 
b”Clinics reporting was all participating clinics in each of the surveillance programs in each of 
the years. 
c’Probable cases’ in 2003 was recorded from a random 1/3 of all clinics within the RHA, but 
from only the reporting clinics in 2004 and 2005. 
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Table 2: Results of other components of the integrated surveillance; 2002 to 2005. 
Year RHA a Humansa Birds Positive mosq. 
Poolsb 
Environment 
conditionsc 
Sun Country  4  
Five Hills  8  
Cypress  2  
Regina Qu’Appelle  7  
Sunrise  11  
Saskatoon  5  
Heartland  7  
Kelsey Trail  0  
P.A. Parkland  0  
 
 
 
 
 
2002 
Prairie North  0  
 
Temp: 
18°C 
 
Prec: 
196.9 mm 
 
 
Sun Country 100 3 2 
Five Hills 225 9 4 
Cypress 152 25 2 
Regina Qu’Appelle 256 32 0 
Sunrise 38 5 2 
Saskatoon 62 37 6 
Heartland 93 24 3 
Kelsey Trail 2 5 0 
P.A. Parkland 8 10 3 
 
 
 
 
 
2003 
Prairie North 11 7 0 
 
Temp: 
18.6°C 
 
Prec: 
97.5 mm 
Sun Country 1 0 18 
Five Hills 2 2 1 
Cypress 1 0 4 
Regina Qu’Appelle 1 9 0 
Sunrise 0 1 2 
Saskatoon 0 9 0 
Heartland 0 0 2 
Kelsey Trail 0 1 1 
P.A. Parkland 0 7 1 
 
 
 
 
 
2004 
Prairie North 0 0 1 
 
Temp: 
15°C 
 
Prec: 
228.2 mm 
Sun Country 17 1 63 
Five Hills 6 0 3 
Cypress 3 2 8 
Regina Qu’Appelle 20 8 10 
Sunrise 6 0 8 
Saskatoon 5 2 12 
Heartland 3 0 2 
Kelsey Trail 0 0 3 
P.A. Parkland 0 1 0 
 
 
 
 
2005 
Prairie North 0 0 1 
 
Temp: 
16.2°C 
 
Prec: 
267.5 mm 
a Human cases include WNV fever, asymptomatic and neurological cases. No cases in 2002. 
b A positive mosquito pool  is a collection of a species of mosquitoes that is positive for WN virus. No 
sampling in 2002. 
c Environmental conditions are for Saskatoon Health region; overall average temperature (Temp.) and 
total rainfall (Prec.) for the months of June, July and August combined. 
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7.4 Discussion 
7.4.1 Horse surveillance 
One purpose of surveillance is to provide evidence of whether or not a disease 
exists in a geographic area (Salman 2003). Saskatchewan Health’s integrated surveillance 
program included information on WNV activity from multiple different sources; wild and 
domestic animals, human cases, and vectors. All of these components have potential 
limitations. For example, wild bird submissions are highly influenced by human-related 
factors and can be limited geographically or temporally (Ward et al. 2006). Vector data, 
such as presence of WNV positive pools of mosquitoes, require an adequate number of 
monitoring locations to obtain a complete geographic picture, which can be difficult with 
a large study area. Access to human data is limited by confidentiality concerns. All of 
these surveillance components would be representative of urban locations but could be 
under-represented in more rural locations.  
Equine surveillance has both advantages and limitations relative to other sources 
of data on the geographic spread of this virus. Advantages include: a) predominantly rural 
locations, b) few travel any distance away from the farm, c) most are housed outdoors 24 
hours a day with little or no protection against mosquitoes, d) most are observed on a 
regular basis by their owners, and e) testing has a quick turnaround time with limited 
confidentiality concerns. Limitations include: a) reporting of WNV probable horses to 
veterinarians, especially mild cases decreases as public awareness and interest decreases 
and b) the cost of testing is the responsibility of the owner and may not be considered 
cost effective. Finally because vaccination of horses has been shown to decrease the 
chances of a horse developing clinical signs (Epp et al. 2005), widespread adoption of 
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vaccination could also potentially affect the interest and cooperation of veterinarians and 
owners in the surveillance program. In addition, surveillance solely based on 
identification of clinical horses would be under-representative of actual WNV activity in 
an area.  
The use of an existing network of rural practitioners was a key component of the 
equine surveillance program in the summers of 2003 through 2005. While this was an 
effective way to gather information on an emerging disease, the case tracing system was 
time consuming. Permission to access information on samples submitted to the laboratory 
was required for confidentiality reasons. Laboratory submission forms did not provide 
complete information for tracking the disease and thus telephone interviews often were 
necessary. Although veterinarians were asked to report necessary information, such as 
location, date of clinical signs and vaccination status, compliance was highly variable. In 
2004 and 2005, weekly faxed reminders and telephone follow-up were required for up to 
50% of participating clinics. Even with additional monetary incentives for participating 
veterinary clinics, compliance in weekly reporting was highly variable. All of these 
factors could potentially be barriers to future use of horses in surveillance for WNV 
activity. 
 
7.4.2 Interpretation of horse data 
The Saskatchewan equine surveillance systems changed from 2002 through 2005. 
Data from 2002 was collected retrospectively from laboratories that received submissions 
and as such could have been an underestimate. Equine surveillance for 2003 through 
2005 used a consistent case definition, accurate dates on onset and locations, involvement 
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of a network of veterinarians and one local laboratory. However, the number of clinics 
involved in surveillance was limited in 2004 and 2005 to include only those that were the 
most compliant in 2003 and were likely to see horses in their practice. Despite these 
differences, general inter-year trends in WNV activity from 2002 to 2005 can be 
explained by the ecology of the virus as reported in other areas of North America such as 
North Dakota (Bell et al. 2005).  
In 2002, WNV activity in horses was low with the geographic extent primarily in 
the southeastern corner adjacent to the province of Manitoba. We presume this represents 
a late introduction of the virus into the province with insufficient time to promote 
extensive amplification of the virus. WNV was epidemic in 2003, evidenced by the high 
number of horse cases in addition to high dead bird numbers, positive mosquito pools, 
human cases, and suitable climate conditions. In 2004, unusually cool and wet conditions 
produced very little evidence of WNV activity in all surveillance components. We 
presume this represented prolonged mosquito development, prolonged extrinsic 
incubation of the virus, alteration of human behavior, and decreased congregation of 
birds and mosquitoes due to increased wetland habitat. In 2005, WNV activity in horses 
was decreased substantially from 2003 despite having favorable environmental 
conditions and evidence of high WNV activity in mosquitoes. A key difference between 
these years was improved wetland and surface water conditions across many areas of the 
province (personal communication, Phil Curry, Saskatchewan Health). 
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7.4.3 Use of horse data in the integrated system 
Previous analysis associated within this equine surveillance program has showed 
that horses could serve as surrogates for humans but were not effective early predictors of 
human risk (Corrigan et al. 2006). Inclusion of information from all components of the 
integrated surveillance initiative gave the most complete picture of risk to humans. The 
combined information was used to determine levels of human risk geographically and 
facilitate decision making regarding interventions. For example, as the evidence of WNV 
activity in a locale increased, more intensive larviciding (or even adulticiding) might be 
suggested as well as initiation of targeted public awareness campaigns (personal 
communication, Phil Curry, Saskatchewan Health, WNV Coordinator). 
In 2002, horse and bird surveillance provided the first indication that the virus 
was circulating in the province. In 2003, all health regions in the province reported WNV 
cases in humans and horses at roughly the same time. The horse cases did provide 
additional information on the geographic distribution of the virus, particularly in the rural 
portions of the RHAs where little information was available from mosquito, bird, or even 
human data. A cluster analysis of the 2003 data confirmed that horse case clusters 
continued to occur as the season progressed, indicating continued activity of WNV 
(Corrigan et al. 2006). A post-season evaluation of the 2003 Saskatchewan Health 
Integrated Initiative recommended the continuation of surveillance including horses for 
the coming year.  
In 2004, horse surveillance did not detect any WNV activity. However, the 
number of probable horse cases by region was similar to WNV activity reported by at 
least one of the other surveillance groups: human cases, dead birds or positive mosquito 
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pools. Evidence of WNV activity was not identified by all components in all regions of 
surveillance in 2005. Only one region, Kelsey Trail, reported 2 confirmed horse cases but 
no confirmed human cases. In conclusion, since the integrated program based its response 
decisions (from communication to adulticiding) on a gradient scale of risk, equine 
surveillance was a useful component in providing evidence of WNV activity by region. 
In 2006, the integrated surveillance program was reduced by excluding both dead 
bird and targeted equine surveillance. Instead, Saskatchewan Health relied on mandatory 
passive reporting of laboratory confirmed horse cases via federal and provincial 
government agencies. Reasons for the decision to exclude targeted horse surveillance 
included budget, the issue of vaccination and its effects on the identification of clinical 
cases, and the targeting of all surveillance towards urban versus rural areas. Mosquito 
surveillance is thought to provide the most measurable assessment of risk to humans and 
is to remain the cornerstone of the WNV surveillance in Saskatchewan (personal 
communication, Phil Curry). 
Ultimately, the amount of public interest and the resulting resources available will 
determine the intensity of future WNV surveillance. This initiative has proven that lines 
of communication can be established between members of wildlife, veterinary and public 
health organizations. Many surveillance initiatives could be instituted for other important 
zoonotic diseases such as Hantavirus, Lyme disease, Q-fever, rabies and tularemia. This 
integrated initiative has proven that a collaborative approach to the surveillance of 
emerging and endemic zoonotic diseases is possible and will provide a template for 
future events. 
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8.  Predicting geographical risk of infection with West Nile virus for horses; 
Saskatchewan, 2003. 
 
 
 
 
 
8.1 Introduction 
The introduction of West Nile virus (WNV) into North America sparked an 
interest in predicting where and when the virus would appear (USDA 2000, Rogers et al. 
2002a). Geographic tracking of individual cases showed they appeared to occur 
randomly, making prediction of when and where individual cases would occur impossible 
(USDA 2000). However, using geographical information systems (GIS), remotely sensed 
data (satellite imagery), ecological variables, and other spatial analysis techniques, 
production of maps identifying areas of higher risk of infection were possible (Kitron 
2000, Rogers et al. 2002a). This approach has been used for other vector-borne diseases, 
such as Lyme disease and malaria (Dister et al. 1997, Rogers et al. 2002a).  
Vector-borne diseases are particularly amenable to spatial and temporal analysis 
as they are highly influenced by regular, seasonal climate, and environmental changes 
(Kitron 2000). The classic epidemiologic triad adapted for West Nile Virus simplistically 
depicts the relationship between the pathogen (virus), vector, the hosts (birds and 
mammals), and environmental conditions (Gordis 2000) (Figure 1). Mosquitoes become 
infected with the virus and transmit it to multiple bird species, a cycle which amplifies 
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the virus. Governed by environmental conditions and host behaviors, mosquitoes can 
spread WNV to other incidental hosts, such as humans and horses. In the Canadian 
province of Saskatchewan (SK), the primary mosquito species involved is Culex (C.) 
tarsalis which begins to transmit the virus to incidental hosts around mid-July (Curry 
2004).  
 
 
Figure 1: Classic Epidemiological Triad for West Nile Virus. 
 
Environmental conditions determine the timing and intensity of the WNV cycle. 
Mosquitoes are cold-blooded and are therefore especially sensitive to regular seasonal 
changes in climate and environment, such as vegetation cover, rainfall, humidity, and 
temperature (Hay et al. 1996, Mellor et al. 2000). In addition, as the climate or habitat 
changes in an area due to human influence, mosquito species can establish in areas where 
they would otherwise not have flourished (Jonsson et al. 2000, Orme-Zavaleta et al. 
2006). This is most notably demonstrated by the introduction of WNV to North America. 
The hot and humid conditions in New York City in August 1999 were the original 
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explanation for the numerous reported sightings of dead birds, mainly crows (Zellicoff at 
al. 2005). While the source of the introduction of WNV is not known, it is widely 
accepted that the favorable conditions which existed in 1999 allowed the establishment of 
WNV in the local mosquito and bird population (Epstein 2001, Rogers et al. 2002a).  
Many components of the complex ecosystem-based transmission cycle are 
governed by fluctuations in climate (Rainham 2005). The extrinsic incubation period 
(time required from an infectious bloodmeal until transmission of the virus) is governed 
by temperature (Reisen et al. 2006). Congregation of mosquitoes and birds is essential to 
the amplification cycle and influenced by the availability of water sources (Kramer et al. 
2001). Environmental conditions affect the behaviors of humans, specifically when time 
spent outdoors occurs at peak periods of infectivity, dusk or dawn (Loeb et al. 2005).   
Defining the risk of acquiring infection with WNV is a key component to public 
health intervention strategies (Rainham 2005). Public Health officials use methods of 
mosquito control and public education to decrease the risk for human exposure. The 
programs are undertaken and prioritized largely based on environmental conditions 
conducive to mosquito development and surveillance for clinical disease in host species. 
Prioritization of vector-borne disease programs in the overall public health budget is a 
juggling act, affected by limited funding availability but a perceived risk by the public in 
the face of limited mortality or morbidity. Knowledge of the risk of infection would assist 
health officials by determining particular areas in which to concentrate control and 
surveillance programs thereby producing the maximum predictive advantage with 
minimum expense. If knowledge of risk was available earlier on a yearly basis, programs 
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could be adapted to match the predictions and possibly mitigate the potential for human 
infection in high risk areas. 
Predictive risk mapping is a process by which components of the disease cycle 
(epidemiological, environmental and/or entomological) are used to create models and 
subsequent probability of risk category/group membership maps (Kitron 2000, Brooker et 
al. 2002). The methods have become more practical for a broader range of diseases and 
study locations because remote sensing can now provide environmental information at 
required spatial and temporal resolution (Beck et al. 2000, Rogers et al. 2002b) However, 
caution must be exercised to ensure that the appropriate resolution, variables of interest 
and methodologies are used to accurately address the questions being asked (Beck et al. 
2000, Kitron 2000).  
WNV was identified in both birds and horses Saskatchewan in 2002. A series of 
prospective cohort studies were undertaken in 2003 to monitor the progress of this 
emerging public health issue. This chapter details the creation of a model to define areas 
of low, medium, and high risk of WNV infection in the province of Saskatchewan in 
2003 and assess its predictive ability using 2005 data.  
 
8.2 Materials and methods 
8.2.1 Proportion of WNV infected horses  
Information on serological status of horses in the province was compiled and 
summarized at the rural municipality (RM) level. Blood samples had been collected from 
923 horses during the summer of 2003 as part of a series of studies to determine factors 
affecting the risk of infection, clinical disease, and case fatality. For the first study, data 
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were summarized from 133 clinical cases with laboratory confirmation of WNV infection 
that were reported to the research team by the local laboratory (Epp et al. 2007a). A 
second study randomly sampled horses from 20 herds across SK at two separate time 
periods to determine serological status (Epp et al. 2007b). Results were also obtained 
from over 300 horses in a case-control study where the 23 case farms selected included a 
subset of the clinical case horses identified by the first study (Chapter 6). Finally, 
serological results were summarized from a rapid assessment study which sampled horses 
around seven cities based on positive mosquito trap locations (Corrigan 2005).  
The samples were tested by both an in house Immunoglobulin (Ig)G and IgM 
enzyme-linked immunosorbant assay (ELISA) at Prairie Diagnostic Services (Epp et al. 
2007b). The horses were defined as infected or not infected based on the ELISA results 
(Epp et al. 2007b). If a horse was IgM positive, it was considered recently infected 
whether showing clinical signs of WNV or not. If a horse was IgG positive but not 
vaccinated, it was considered infected, whether showing clinical signs of WNV or not. If 
a horse was vaccinated and IgG positive, the result was further characterized by 
calculating a sample-to-positive (S/P) ratio. If the horse was vaccinated twice and the S/P 
ratio was >0.30, the horse was considered infected. If the horse was vaccinated three 
times and the S/P ratio was > 0.78, the horse was considered infected with WNV. If the 
S/P ratio was less than either cutoff value, the horse was considered not infected.  
The proportion of tested horses that were infected was calculated for each RM 
where 5 or more horses were sampled. Each RM with sufficient data to determine a 
proportion infected (known RM) was classified by category of risk of infection (group) 
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with WNV based on the 25th and 75th percentiles: low (0 – 29.9%), medium (30 – 
77.7%), and high risk (77.8 – 100%).  
In 2005, 196 horses were sampled and tested for WNV antibodies with an IgM 
ELISA only. Ten horses showed clinical signs of disease while the rest were sampled 
through cooperation with veterinarians already visiting the farms for other reasons, 
primarily Coggins testing (test for Equine Infectious Anemia). Infection status in horses 
was based on the blood sample results as previously described. The proportion infected 
was calculated by RM where 5 or more horses had been sampled. The same categories of 
risk of infection (groups) were used to label these sampled RMs (known RM-2005).  
 
8.2.2 Environmental variables 
8.2.2.1 Temperature 
Land Surface Temperature (LST) was obtained through National Aeronautics and 
Space Administration (NASA) Earth Observing System (EOS) Gateway for the Moderate 
Resolution Imaging Spectrometer (MODIS) satellite. These data are distributed by the 
Land Process Distributed Active Archive Center (LPDAAC) located at the United States 
Geological Survey (USGS) center for Earth Resources Observation and Science (EROS): 
http://lpdaac.usgs.gov. The images were joined together (mosaicked) and clipped to show 
only the province of Saskatchewan using PCI Geomatica 9 (PCI Geomatics, Richmond, 
Ontario, Canada). Seventeen images were obtained as 8 day composites beginning May 1 
and ending September 13 for 2003 and 2005. The images included daytime (maximum) 
and nighttime (minimum) temperatures and were manipulated to give a mean LST 
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(average of the day and nighttime images). For each time period, the average value per 
RM was calculated for all three variables for both 2003 and 2005 for each time period.   
Minimum (min), maximum (max), and mean temperature (ºC) were also obtained 
from climate stations on a daily basis for both 2003 and 2005 through Environment 
Canada. Eight day composites (average min, mean, or max temperature per time period) 
were created to match the time periods of the remotely sensed data. For each time period, 
stations which were missing data from 50% or more of the days were assigned as 
missing. Interpolation between stations was accomplished with Inverse Distance 
Weighting (IDW) using ArcGIS 9.0 (ESRI Inc., Redlands, CA, USA). IDW is a quick 
deterministic interpolation of the data with minimal input of parameters. For each time 
period, the average value per RM was calculated for all three variables for 2003 and 
2005.  
Cumulative growing degree days (GDD) are the sum of the positive daily 
differences between 14.3ºC (the threshold for activity of C. tarsalis and virus 
transmission) and the mean temperature for that day (Woody Ornamentals 2003).   The 
nine time periods used in analysis were defined as the cumulative GDD from May 1 until 
the beginning or middle of each month, ie. time period 1 was from May 1 until May 15 
while time period 9 was from May 1 until September 15. GDD values were recorded as 
unknown at and after a time period in which there was missing data from that station. 
GDD were calculated for each climate station for 2003 and 2005 and interpolation 
between stations with complete data each time point was accomplished using the IDW 
method in ArcGIS 9.0. For each time period, the average value per RM was calculated 
for both 2003 and 2005.  
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8.2.2.2 Precipitation 
Precipitation values (mm) were obtained for 2003 and 2005 on a daily basis from 
Environment Canada. Eight day composites (total precipitation per time period) were 
created to match the remotely sensed time periods. Interpolation between stations was 
accomplished using IDW method in ArcGIS 9.0. For each time period, the total value per 
RM was calculated for 2003 and 2005.  
 
8.2.2.3 Vegetation 
Normalized Digital Vegetation Index (NDVI) and Enhanced Vegetation Index 
(EVI) were obtained from EOS Gateway for the MODIS satellite (distributed by 
LPDAAC: USGS: EROS). NDVI is a simple index of vegetation cover based on near 
infra-red and red reflectance bands of satellite imagery which allows monitoring of 
seasonal and inter-annual changes in vegetation growth (Jensen 2005). EVI is a modified 
NDVI which incorporates a soil adjustment factor and correction for atmospheric 
scattering. The EVI has improved sensitivity for dense vegetation areas (Jensen 2005). 
Nine images were obtained as 16 day composites starting April 23 and ending September 
13th for both 2003 and 2005. For each time period, the average value per RM was 
calculated using PCI Geomatica 9.0 for both variables.  
 
8.2.2.4 Land cover 
South Digital Land Cover dataset (North Digital and South Digital Land Cover) 
based on satellite imagery from 2000 for the province of Saskatchewan was obtained 
from Information Services Corporation of Saskatchewan (ISC). Classifications were 
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aggregated to make the number of categories used in the analysis more manageable. The 
aggregated categories included: water, wetland (bog, marsh, fen, etc), treed (pine, spruce, 
hardwood, softwood, etc), ground (rock, recent burn, cutovers, barren land), agriculture 
(cropland, pasture) and urban (settlements, roads). The percentage of RM covered by 
each of the categories was calculated using PCI Geomatica 9.0.  
 
8.2.2.5 Elevation 
Digital Elevation Model (DEM) was obtained from NASA: Jet Propulsion 
Laboratory: Shuttle Radar Topography Mission (SRTM) based on satellite images from 
2000. The mean, majority, minimum, maximum and range of elevation were calculated 
for each RM.  
 
8.2.2.6 Wetlands 
The percentage of permanent and temporary wetlands by RM was obtained from 
Ducks Unlimited Canada’s Habitat Inventory of wetlands and water bodies based on 
Landsat imagery from 1984 to 1993.  
 
8.2.2.7 Census data 
The number of horses per RM was obtained from Statistics Canada using 2001 
Consolidated Census Subdivisions (CCS).  
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8.2.2.8 Latitude and Longitude  
The latitude and longitude of the centroid of each RM was extracted from RM 
shape files using ArcGIS 9.0.  
 
8.2.2.9 Ecoregion 
Geographical differences exist across the province and can also be indicated by 
ecoregions. Ecoregions are a subdivision of ecological zones characterized by regional 
ecological factors such as vegetation, soil, climate, water, and fauna (Marshall et al. 
1999). Within the geographic area covered by the RMs (does not include the northern 
half of the province), there are six ecoregions: Cypress Upland, Mixed Grasslands, Moist 
Mixed Grasslands, Aspen Parkland, Boreal Transition and Mid-Boreal Uplands. Using 
ArcGIS 9.0, each RM was assigned the ecoregion which comprised the largest 
proportion. 
 
8.2.3 Statistical analysis 
The whole dataset from 2003 was divided into a (a) training dataset (consisting of 
a random selection of 53 out of 67 known RMs) and (b) testing dataset (consisting of the 
remaining 14 known RMs and 231 unknown RMs). Two groupings of models were 
created: early season (May 1 to July 11) and whole season (May 1 to September 13).  
Discriminant analysis was used to predict membership in the three mutually 
exclusive groups (low, medium and high risk) (SPSS 14.0, SPSS Inc. Chicago, IL, USA) 
(Klecka 1980). All variables and all time periods were introduced individually into the 
model for univariable analysis. Variables and time periods for which P >0.10 were 
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excluded from any further analysis. An important assumption of discriminant analysis is 
that variables are not highly correlated with each other. Therefore, each variable with 
multiple statistically significant time periods by the univariate analysis was reduced using 
principle component analysis (SPSS 14.0, SPSS Inc. Chicago, IL, USA). This condenses 
the multiple statistically significant time points into one or two principal components 
which were then entered into multivariable models (Dohoo et al. 2003). The temperature 
related variables (GDD, temperature and LST) were also highly correlated with each 
other and were, therefore, used individually as the basis for separate models for both 
early and whole season.  
Models used unequal weightings to adjust the posterior probabilities to account 
for prior knowledge of probable group membership. For example, since more than 50% 
of the known RM observations were in the medium risk category, this was given more 
weighting in the analysis than the other two categories. Separate matrices (to account for 
unequal group covariance matrices) were used when Box’s M test was significant and the 
prediction accuracy percentage changed substantially from a model that used a common 
matrix for all groups.  
RMs were classified into one of the risk categories by predicting the group (low, 
medium or high risk) to which the individual RM most likely belonged. The selection of 
the best model was determined using the overall classification or prediction accuracy 
percentage for the known RMs in both the training and testing datasets. This was defined 
as the proportion of known RMs correctly classified based on the pre-model classification 
(based on the proportion data) compared to post-model re-classification (based on the 
model classification) (Klecka 1980).  
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Individual RMs were assigned to a group (low, medium or high risk) based on 
which group the RM had the highest probability of belonging to (Klecka 1980). For 
example, an RM could have a probability of group membership in low risk of 90% , 
medium risk of  9% and high risk of 1%. Therefore, that RM would be classified in the 
low risk group with a probability of group membership of 90%. Caution must be 
exercised when RMs have probabilities that are less than 75%, as membership may be 
only slightly more probable in one risk group over another. Therefore, attempts were 
made to maximize the probability of group membership for all RMs in each group (low, 
medium, or high risk). Production of prediction maps from the best final models for both 
early and whole season was completed using ArcGIS 9.0.   
The training dataset for 2003 (53 known RMs) was used to train the 2005 dataset 
(comprised of 10 known RMs and 288 unknown RMs). Then, the same variables as for 
the 2003 dataset were used for both the 2005 early and whole season models. Production 
of prediction maps from the early and whole season models was completed using ArcGIS 
9.0.   
 
8.3 Results 
8.3.1 Distribution of infection in horses 
The locations of clinically affected horses and serologically positive horses were 
compared between 2003 and 2005 (Figure 2, 3 and 4). There were 7 RMs with WNV 
infected horses in both years, 5 RMs with infected horses in 2005 that were adjacent to 
RMs with infected horses in 2003 and 1 RM with an infected horse in 2005 that was not 
sampled in 2003.  
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Figure 2: Distribution of the number of clinical cases (WNV clinically affected horses) 
for 2003 by RM.  
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Figure 3: Distribution of the total number of WNV serologically positive and clinically 
affected horses for 2003 by RM. 
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Figure 4: Distribution of the total number of WNV IgM serologically positive and 
clinically affected horses for 2005 by RM. 
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8.3.2 Creation of the Models - 2003   
Of the 923 horses, 133 were clinical cases. The other 790 were asymptomatic, of 
which 395 (50%) were exposed to WNV. There were 67 RMs out of 298 included in the 
study area for which 5 or more horses were sampled. Based on calculating the proportion 
of infected horses by RM and the defined proportion per category, each RM was 
classified into a risk category: 16 low risk, 33 medium risk and 18 high risk.  
The variables significant (P<0.10) in univariable models and used in further 
multivariable analysis included: GDD, mean temperature, mean LST, land cover (treed, 
water and wetland only), NDVI, mean DEM and precipitation (Table 1).  
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Table 1: Variables (with statistically significant time periods) tested in multivariable 
temperature based models for both early and whole season predictions. Bolded entries 
comprised the final prediction models for both early and whole season 
Time-
line 
Model Mean 
LST a 
Mean 
Temp-
erature a 
GDD c Precipitation a NDVI d Other time constant 
variables  
1 June 26-
July 11 
NA NA  June 2-25 April 23-
May 8 
DEM (mean), Latitude, 
Ecoregion, Land Cover e 
2 NA b July 4- 11 NA June 2-25  April 23-
May 8 
DEM (mean), Latitude, 
Ecoregion, Land Cover  
Early 
Season 
3 NA NA May 1-
June 15 
June 2-25  April 23-
May 8 
DEM (mean), Latitude, 
Ecoregion, Land Cover  
1 June 26-
Sept.13  
NA NA June 2-25, 
July 4-19  
Aug 13-
Sept 13 
DEM (mean), Latitude, 
Ecoregion, Land Cover  
2 NA July 4-
Sept. 5  
NA June 2-25, 
July 4-19 
Aug 13-
Sept 13 
DEM (mean), Latitude, 
Ecoregion, Land Cover  
Whole 
Season 
3 NA NA May 1-
Sept 15  
June 2-25, 
July 4-19 
Aug 13-
Sept 13 
DEM (mean), Latitude, 
Ecoregion, Land Cover  
a Remotely sensed time period (8 day composite), these underwent principle component analysis to be included in the model when 
more than one time period was significant.  
b NA=not applicable, refers to variable not used in that models analysis. 
c Bimonthly time period, cumulative GDD from May 1 until the end of the time period listed. 
d Remotely sensed time period (16 day composites), these underwent principle component analysis to be included in the model when 
more than one time period was significant. 
e Land cover included treed, water and wetland percentages. 
 
 
The best early season model included variables: mean LST, precipitation, land 
cover, mean DEM and NDVI. The overall classification accuracy was 74% for training 
dataset and 64% for testing dataset. The group predictions and the probability of grouping 
by RM were mapped (Figure 5 and 6). 
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Figure 5: Early season (time periods from April 23 to July 11) model (LST, precipitation, 
NDVI, land cover, mean DEM). Predicted group membership (low, medium or high risk 
of infection) for 2003 by RM. 
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 Figure 6: Early season (time periods from April 23 to July 11) model 1 (LST, 
precipitation, NDVI, land cover, mean DEM). Probability of group membership (low, 
medium or high risk of infection) for 2003 by RM.  
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Comparison of variables by group indicate that decreasing rainfall throughout 
June was the most important indicator for high risk group membership, followed by 
higher mean LST in July, and higher mean DEM. Lower percentage of treed, water and 
wetland area in the RM and slightly lower NDVI were secondary indicators of high risk 
group membership. The number of RMs in the three risk categories based on the results 
of the early season model was: 42 in the low risk group, 184 in the medium group, and 72 
in the high risk group. The average probability of group membership for each category 
was 88% in the low risk group, 69% in the medium group, and 74% in the high risk 
group.  
The best whole season model included variables: mean LST, precipitation, land 
cover and NDVI. The overall classification accuracy was 70% for training dataset and 
71% for testing dataset. The group predictions and the probability of grouping by RM 
were mapped (Figure 7 and 8). 
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 Figure 7: Whole season (time periods from May 1 to September 13) model (LST, 
precipitation, NDVI, land cover). Predicted group membership (low, medium, or high 
risk of infection) for 2005 by RM. 
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Figure 8: Whole season ( time periods from May 1 to September 13) model (LST, 
precipitation, NDVI, land cover). Probability of group membership (low, medium, or 
high risk of infection) in 2003 by RM. 
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Comparison of variables by group showed that higher rainfall in June with lower 
rainfall in July was the most important indicator of high risk group membership followed 
by higher mean LST in July-September, lower NDVI at the end of August/beginning of 
September and lower percentage of water area per RM. Lower percentage of treed and 
wetland area per RM were secondary indicators of high risk group membership. The 
number of RMs in the three risk categories using the whole season model was: 44 in the 
low risk group, 178 in the medium group, and 76 in the high risk group. The average 
probability of group membership for each category was 85% in the low risk group, 67% 
in the medium group and 71% in the high risk group. 
 
8.3.2 Predictive ability - 2005 
The training dataset used for both the early season and whole season models was 
53 known RMs from 2003. The testing dataset for 2005 only included 10 known RMs, all 
with the estimated category of membership as low risk. As such, the training and testing 
dataset overall classification accuracy percentages were not considered indicative of 
overall model accuracy.  
For the early season model, the testing classification accuracy was 10% and the 
average probability of group membership was 89% in the low risk group, 69% in the 
medium group and 79% in the high risk group. The number of RMs in the three risk 
categories by the early season model was: 24 in the low risk group, 172 in the medium 
group, and 102 in the high risk group. Comparison of variables by group showed a 
similar pattern to 2003. The group predictions and the probability of correct grouping by 
RM were mapped (Figure 9 and 10). 
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 Figure 9: Early season (time periods from April 23 to July 11) model (LST, precipitation, 
NDVI, land cover, mean DEM). Predicted group membership (low, medium or high risk 
of infection) for 2005 by RM. 
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 Figure 10: Early season (time periods from April 23 to July 11) model (LST, 
precipitation, NDVI, land cover, mean DEM). Probability of group membership (low, 
medium or high risk of infection) 2005 by RM. 
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For the whole season model, the testing classification accuracy was 30% and the 
average probability of group membership in 2005 was 78% in the low risk group, 68% in 
the medium group and 74% in the high risk group. The number of RMs in the three risk 
categories for the whole season model was: 57 in the low risk group, 148 in the medium 
group, and 93 in the high risk group. Comparison of variables by group showed a similar 
pattern to 2003. The group predictions and the probability of grouping by RM were 
mapped (Figure 11 and 12). 
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 Figure 11: Whole season (time periods from May 1 to September 13) model (LST, 
Precipitation, NDVI, Land cover). Predicted group membership (low, medium or high 
risk of infection) for 2005 by RM. 
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Figure 12: Whole season (time periods from May 1 to September 13) model (LST, 
Precipitation, NDVI, Land cover). Probability of group membership (low, medium or 
high risk of infection) for 2005 by RM. 
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8.4 Discussion 
The models and predictive risk maps of WNV infection developed here are based 
on environmental conditions and not an estimate of risk based on clinical disease case 
load. The models in this study try to predict geographically which areas are at risk of 
infection (high, medium or low risk) using the proportion of horses infected, whether 
showing clinical signs or not, by region. Therefore, they were not affected by the rate of 
vaccination in these areas, as this would affect the number of clinical horses reported 
(Chapter 6).   
To truly understand, model and ultimately control aspects of WNV infection, a 
picture of the complexity of the transmission cycle must be established. Expansion of the 
classic epidemiological triad provides a picture of how the environmental conditions 
affect each other as well as potential vector and host components (Figure 13). The 
important environmental variables included in this analysis were precipitation, 
temperature, elevation, vegetation and land cover, specifically wetlands, water and treed 
areas.  
Using these environmental variables, a predictive model provided approximately 
70-74% overall model accuracy in 2003 depending on whether the data were limited to 
early season or whole season time periods. Prediction of high and low risk RMs was 
better than for medium risk RMs. Obviously, the complexity of the cycle is not 
completely explained by these variables and their interactions. In addition, factors such as 
biodiversity, predators, parasites, food availability and spatial resources will affect 
interactions between the vector and hosts, while immune status of the hosts will become 
more important the longer the virus remains endemic in an area (Rainham 2005).  
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 Figure 13: Detailed pathway of environmental influence on the cycle of West Nile Virus. 
Circles indicate environmental variables that influence all aspects of the amplification 
and spillover cycles (boxes), in addition to interactions between environmental variables.  
 
The variable of primary importance in the prediction of risk of infection was 
precipitation, with precipitation from June important in the early season model and 
precipitation from June and July important in the whole season model. Mosquito life 
cycles (abundance and composition) and breeding site habitat (presence, size and 
persistence) are influenced by rainfall (Mellor et al. 2000, Shaman et al. 2005a). In 
Florida, drought-like conditions in spring followed by increased rainfall patterns in 
summer and fall facilitate WNV transmission (Shaman et al. 2005b). Different mosquito 
species will react differently to patterns of rainfall (Shaman et al. 2005a). C. tarsalis 
prefers rainfall followed by hot and dry conditions because it uses standing water with 
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increased organic content for oviposition which would be washed away by rainfall (Curry 
2004, Shaman et al. 2005a). Both prediction models emphasize that higher rainfall at the 
beginning of June, decreasing towards the end of June, with minimal rainfall in July is 
associated with high risk areas whereas lower rainfall in June compared to July is 
indicative of low risk areas.   
Another variable of importance was mean LST from July in the early season 
model and July and August in the whole season model. Increasing temperatures are 
linked to both increased survival of mosquitoes, increased biting habits and decreased 
extrinsic incubation period (Mellor et al. 2000, Reisen et al. 2006). Evidence of the effect 
of temperature on the transmission of WNV can be seen in 2004. In Central Red River 
Valley of North Dakota and Minnesota, temperatures and, therefore, the amount of 
thermal accumulations or degree-days was almost half of previous years with 
substantially lower number of human cases of WNV (Bell et al. 2005, Bell et al. 2006). A 
similar pattern of no confirmed horse cases and colder, wetter climate was observed in 
Saskatchewan during 2004 (Chapter 7). In the prediction models, higher rainfall in spring 
(June) followed by higher temperatures in July and August were indicative of high risk 
areas in both the early and whole season models.  
Different temperature related variables were used in the models. LST was 
determined to be a slightly better predictor than either mean climate station temperature 
or GDD which was derived from the climate station data. This is likely because the 
climate station data required interpolation to provide a continuous map from which 
average data for each RM could be calculated, whereas the satellite data was provided on 
a continuous 500 meter scale. Studies have shown that LST (obtained on an 8 x 8 km or 
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even 1 x 1 km basis) and ambient temperatures (derived from climate stations) are quite 
similar, especially if other variables such as NDVI or latitude were included in the 
analysis (Hay et al. 1999, Green et al. 2002).  Therefore, for large areas, LST has several 
advantages over climate station derived temperature data and will become a cornerstone 
of epidemiological studies in the future (Hay et al. 1999).  
The amount and type of vegetation in an area is influenced by both temperature 
and precipitation (Hay et al. 1996). It has been proposed that WNV foci could be 
identified based on the presence of conducive mosquito habitat, specifically determined 
by water and vegetation (White 2001). A northern Indiana study looked at whether NDVI 
was associated with the occurrence of equine WNV cases (Ward et al. 2005). It 
determined that NDVI could be useful for predicting hotspots for implementation of 
mosquito control measures, but that a limiting factor for the use of NDVI would be the 
amount of agriculture in the area. In the present study, NDVI from the first week in May 
(early season) or the end of August and beginning of September (whole season) were 
important predictors. The NDVI from the beginning of the season could be an indication 
of the amount of previous fall and winter precipitation, especially in a year when warmer 
spring conditions facilitated earlier growth. The NDVI from the end of August and 
beginning of September would be indicative of vegetation amounts without a lot of 
agricultural influences, as in an average year, harvest would be well underway by these 
dates. Ward et al. hypothesized that once harvest is underway NDVI has a better 
discriminatory power to identify small areas where conditions are still suitable for vector 
habitat.  
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Land cover was another important variable in the model. The percentage of the 
RMs covered in trees, water or wetland areas differed between high risk (low 
percentages) and low risk (high percentages). C. tarsalis prefers shallow, often stagnant 
water of high organic content with little tree cover surrounding the sites, such as water-
filled hoof prints near livestock watering sites (Curry 2004). A generalization would be 
that the RMs with high wetland and treed areas would not be considered ideal locations 
for WNV infection to occur. The predictive models identified these RMs as low risk 
areas. Elevation was a useful variable in the early season model. RMs with higher 
average elevation were more likely to be classified as high risk RMs. In the south central 
area of Saskatchewan in 2003, the human cases did follow the higher elevation of the 
Missouri Couteau, where the wetlands are concentrated in the low lying valleys and low 
depression areas (personal communication, Phil Curry, Saskatchewan Health).  
The predictive ability of the model for 2005 data was compromised as all of the 
surveyed RMs were initially classified as low risk RMs. This was both due to a low 
number of sampled horses as well assessment of infection status based solely on IgM 
ELISA. This led to an inability to use the known 2005 RMs as a means to test the overall 
model’s accuracy (training or testing datasets) or assessing predictor variable importance. 
Visually however, the risk predicted by environmental variables seems to indicate a shift 
in the high risk areas from 2003. The predicted area of high risk in the western portion of 
the study area (both early and whole season models) matches the area with the highest 
number of C. tarsalis mosquitoes trapped in 2006 (personal communication, P. Curry, 
Saskatchewan Health). On the other hand, the actual location of the RMs with positive 
cases in 2005 mirrors that of 2003. This indicates that although environmental risk of 
 186
WNV infection changes in a yearly basis, WNV activity and the spatial distribution of 
cases may not. This has been seen with other spatial analysis of bird and human cases in 
Ontario (Beroll et al. 2007). In addition, the area with the most positive pools of 
mosquitoes was in the southeastern corner and did not correspond to the model 
predictions. The complex relationship that exists between environmental risk, mosquito 
abundance and infectivity and actual disease transmission to various host species cannot 
be adequately summarized by a single predictive model from two years of limited horse 
data. The model is missing key information on the amplification cycle which would 
likely make it more predictive of risk of infection.  
Finally, the models were created with a training set of data, comprised of a 
randomly selected portion of the RMs where sampling of horses occurred in 2003. A 
different randomly selected training dataset could have produced slightly different 
results. In addition, these models relied on summarized and interpolated environmental 
data for each RM, which can produce a loss of inherent heterogeneity in the data and 
introduce errors. As such, caution should be exercised when referring to any of the 
individual RM predictions made on the maps. Instead, the maps will be useful to indicate 
general but larger areas of high risk of infection. 
 
8.5 Conclusions  
The usefulness of the model as a predictor of high risk areas must be coupled with 
the knowledge of vector abundance and host population dynamics. If the environmental 
model predicts an area of high risk where there is not a large population of incidental 
hosts, the high risk pattern will not be mirrored in the distribution of cases in these 
populations. In addition, access to services for diagnosis of clinical cases in both equine 
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and humans is more limited in sparsely populated areas. Historically,  maps of mosquito 
vectors indicate high risk areas to consistently be in the southeastern portion of the 
province. In 2005, these factors likely influenced the distribution of cases, although this 
theory could not be confirmed as only one location at the edge of the high risk RMs was 
sampled. As well, early season predictions can be negated by altered environmental 
conditions later in the season not highly conducive for mosquito development. More 
information on the connection between high environmental risk and WNV infection 
could be obtained from using the models in conjunction with other surveillance methods, 
particularly mosquito data.  
The usefulness of the models as components of a surveillance initiative is the 
most promising. Indication of environmental conditions conducive to WNV would be 
useful in determining sites for intensified mosquito surveillance or control. By 
incorporating multiple years of data into the model, the accuracy and stability of the 
predictions will increase (personal communication, Martin Hugh-Jones). These prediction 
models were based solely on the epidemic year as the training set of data. Subsequent 
years did not produce the number of cases seen in 2003 in either the clinical cases or the 
asymptomatic horses, particularly because of the interference of vaccination despite 
environmental conditions of risk. Multiple years of data would reduce the dependency of 
the model on 2003 data. The distribution of cases in subsequent years indicates that 
WNV infection follows a more spatially conservative and consistent distribution rather 
than one that solely follows environmental risk (Chapter 7).  
These models have identified time periods and variables to use in consideration of 
environmental contribution to WNV activity. They have also identified caution in 
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interpreting emerging disease models based on single epidemic year data. With further 
research, greater accuracy in predicting WNV risk of infection will occur. In addition, 
future incursions of mosquito-borne diseases will benefit from the knowledge gained 
from targeted surveillance accomplished now in the inter-epidemic period.  
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9.  Summary and Conclusions 
 
 
 
 
 
 
 
 
 
9.1 Concluding remarks 
 
In the spring of 2003, WNV was an emerging problem for both horses and 
humans in Saskatchewan and much of North America. The primary objective of this 
thesis was to describe the epidemic in horses by exploring individual, herd, and 
geographic risk factors for infection, for development of clinical disease, and for clinical 
disease outcomes. The second objective was to use the information collected from horses 
and predict risk of infection.  
 
9.1.1  Clinical cases of WNV in horses in 2003 and factors associated with case 
fatality 
The epidemic of WNV clinical disease in affected horses was documented by 
collecting data about management, vaccination status, horse characteristics, and location 
(Chapter 3). Horses in this study had mild to severe clinical signs of disease. The final 
outcomes of the disease documented in this study were death, euthanasia, or recovery. 
The data were analyzed to identify risk factors for fatality from clinical disease. 
The highest number of clinically affected horses occurred in the grasslands 
ecoregion. This ecoregion consists of habitat and climatic conditions primarily favored by 
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the mosquito, C. tarsalis,  which makes it a “hotspot” of infection and clinical disease. In 
2003, West Nile virus made an appearance in horses beyond where infection was 
geographically predicted to occur based on historical mosquito distribution maps 
(personnal communication, Phil Curry, Saskatchewan Health). One explanation for the 
appearance of WNV as far north as Meadow Lake, SK, was that the climate and 
environmental condition were sufficient for establishment of the mosquito C. tarsalis in 
areas this species had not previously been reported.  
 The clinical epidemic began at the end of July and continued to the middle of 
September, while asymptomatically infected horses were found as early as June. The 
onset of clinical signs for the majority of cases was from middle of August until the 
begining of September. This pattern was consistent across all years of targetted 
surveillance, 2003-2005. This pattern was also consistent with studies from other regions 
of North America, with the season being progressively longer in the southern latititudes. 
For example, Texas had its’ first reported case near the end of June with the majority of 
cases reported from September to October (Ward 2006).  
In the analysis of the data from horses with clinical signs, the date of onset was an 
important predictor of fatality. This could be related to ecology of the virus or 
promptness of recognition of clinical signs by the owner and timing of supportive 
treatment. In addition, stallions and horses with a light coat color were also more likely to 
die from clinical disease. The reasons for these findings require further study.  
Because the study was limited to inclusion of horses with serological testing 
results, there was potential for reporting bias. A post-season survey of veterinarians 
identified geographical differences in the reporting and testing of clinically affected 
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horses for WNV. Reasons for the lack of testing ranged from monetary to personnal 
recommendations to the owners.   
 
9.1.2  Using serology to describe the infection status of horses 
Serology was used to describe the infection status of horses across the province in 
2003. Due to the introduction of a killed vaccine in the fall/winter of 2002, information 
was needed on how to interpret the immunoglobulin (Ig)G and IgM enzyme-linked 
immunosrobant assay (ELISA) in the face of vaccination. Two studies were completed, 
one describing the kinetics of naturally induced antibody titres over time and the other 
describing antibody titres in response to vaccination (Chapter 4). Using these data, cutoff 
values for identification of horses which were both naturally infected and vaccinated 
were established for use in the serologic prevalence study (Chapter 5) and the case-
control study (Chapter 6).  
Because of the introduction of other vaccines onto the commercial market after 
2003, the reported cutoff values cannot be applied to future studies. Multiple years of 
different vaccination protocols and varying degrees of natural exposures would also 
interfere with interpretation of serological data after 2003. Therefore, the use of non-
vaccinated horses would be recommended in any new serologic studies.  
 
9.1.3  Serological study to investigate the risk of non-clinical infection 
In addition to describing reports of clinical WNV infection (Chapter 3), a second 
study was completed to describe the distribution of non-clinical infections (Chapter 5). In 
this study, horses from across the province were sampled at two different times with the 
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intent to monitor the occurrence of seroconversion to WNV. For each horse sampled, 
investigators collected management data, vaccination status, horse characteristics, and 
location. The data were analyzed to identify risk factors for infection with WNV. 
Serologically positive horses were found across the entire study area, but a south 
to north gradient of decreasing infection corresponding to ecological regions was 
observed. The grasslands ecoregions (Mixed and Moist Mixed) had the highest 
prevalence of asymptomatically infected horses while the northern most area of the study 
region (the start of the Boreal Forest) had the lowest prevalence. As well, the 
implementation of some form of mosquito control on the farm was associated with a 
lower risk of infection.  
A serological study of this type would be hard to conduct in the future, due to the 
multiple vaccines and vaccine protocols being used. While there is no evidence that 
vaccination reduces the risk of infection, vaccination will limit the utility of the ELISA in 
determining infection status. The use of non-vaccinated horses would be the only feasible 
option. Because of the limited numbers of horses sampled in each ecoregion, it was not 
possible to determine if there was also a difference in prevalence from east to west with 
the available data. 
 
9.1.4 Case-control study of factors associated with clinical disease 
The objective of the next study was to identify risk factors for development of 
clinical disease (Chapter 6). A case-control study was designed to compare horses 
sampled on farms with clinical disease and horses from farms that did not have clinical 
disease. Data were collected for each sampled horse about management, vaccination 
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status, and horse characteristics. Because control farms were the nearest location to a case 
farm fitting the study criteria, location and geography variables were not considered as 
potential risk factors. 
Both case and control farms had similar prevalences of infection in horses without 
any signs of clinical disease. Risk factors for the development of clinical disease in 
horses were compared across horses and herds enrolled in this study. One of the most 
important findings from this thesis was that vaccination with the killed vaccine was 
highly efficacious at preventing development of clinical disease.   
As a side note, this study also emphasized that surveillance based solely on 
identification of clinically affected horses could have underestimated WNV activity. 
Specifically this could have occured in areas with higher vaccination rates, typically areas 
deemed to be at higher risk of infection.  
 
9.1.5  Multi-year surveillance for WNV in Saskatchewan 
The objectives of the next chapter of this thesis (Chapter 7) were to describe all 
data available on WNV activity in horses from 2002 to 2005  and to determine the role of 
equine studies in an integrated surveillance intiative by Saskatchewan Health over this 
four year period. Although the methods evolved over the four year period, the results 
were comparable to other components of the surveillance system as well as other similar 
geographic locations.  
The inclusion of horse data (clinical cases and infection) were considered useful 
by Saskatchewan Health (internal evaluation of the surveillance initiative, Phil Curry, 
Saskatchewan Health). The inclusion  of the horse data confirmed activity patterns seen 
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in other components of surveillance in 2003/2005 and identified regions of high activity 
where no human cases were found in 2005. However, the collection of horse data were 
time consuming, particularly because veterinarians did not completely fill out or 
complete laboratory submission or weekly reporting forms without repeated reminders.  
Reliance on reporting of horses with clinical signs in the absence of active 
screening was also recognized to dramatically underestimate the epidemic as indicated by 
the previously mentioned post-season survey and the extensive use of vaccination. 
Therefore, with limited financial resources, the surveillance of horses as well as dead 
birds were discontinued in 2006. Likely, surveillance activities specifically for WNV will 
continue to decline; particularly if cases of WNV in humans remain low. This exercise 
did, however, suggest that the integrated component of the surveillance initative could be 
modified and employed again in the event of another emerging infectious zoonotic 
disease.  
 
9.1.6  Predictive risk mapping of WNV infection 
The culminating objective of this thesis was to see if a model could be created to 
predict areas of high risk without the need for costly surveillance (Chapter 8). Horse data 
collected in the previously mentioned studies were combined with other sources of 
environmental data to create predictive risk maps. 
The modeling process demonstrated that using only one or two years of data was 
not ideal for model building and that predictive models should be based on mulitple years 
of data for better accuracy. More surveillance data from 2005 or data from more than one 
follow up year would have increased the utility of the resulting prediction model. The 
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number of horses sampled was too few to adequately train the model with 2005 data. As 
well, the RMs with adequate data to determine infection prevalence in 2005 all initially 
fell in the low risk group. This made assessment of the overall prediction accuracy of the 
2005 models potentially unreliable.  
However, the model did identify variables of interest in predicting risk. The 
variables included in the final model were land surface temperature, precipitation, 
vegetation cover, land cover  (specifically trees, water and wetland), and possibly 
elevation. All of these variables affect the vector population which is the primary mode 
of transmission of the virus to susceptible hosts. In addition, the models did suggest 
specific time periods for meteorological and environmental data that were important 
predictors, such as precipitation in June and temperature during July and August. Use of 
these variables in future surveillance projects may aid in the detection of virus hotspots 
geographically and temporally.  
 
9.2 Conclusion 
The 2003 epidemic provided a novel opportunity to study an important zoonotic 
disease emerging in a new environment. The epidemic was described in detail, focusing 
on risk factors for infection with WNV, development of clinical disease, and finally, 
factors affecting the risk of fatality from clinical disease. The thesis demonstrated that 
horse data can be useful in an intergrated surveillance system for the benefit of human 
health. Finally, this thesis featured a modelling and mapping technique which could 
identify areas of high risk of infection for horses using readily accessible environmental 
data for minimal cost.   
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Appendix A 
  
 
Dear Colleagues                                                                                                                                  June 23, 2003 
 
    We are writing to seek permission to be 
informed of West Nile Virus positive horses in 
your practice and permission to contact the 
owners of affected animals.  This initial contact is 
to inform you of the study and to prepare for the 
season ahead. 
 
   The research team is associated with the Western 
College of Veterinary Medicine, Saskatoon, 
Saskatchewan. This summer, we intend to conduct a 
case-control study in order to learn more about risk 
factors (including vaccination) related to the 
occurrence of clinical West Nile Virus infection 
(WNV) of horses in Saskatchewan.  A critical aspect 
of this study is the identification of affected (clinical 
cases) and non-affected herds (no clinical cases) of 
horses in Saskatchewan.  
 
  We hope to locate clinically affected animals by 
having the Prairie Diagnostics Services (PDS) in 
Saskatoon inform us when they confirm the 
diagnosis of WNV (blood or postmortem) in Sask. 
horses. However, this will only be possible if 
veterinary practices in Saskatchewan sign a release  
 
                                                         
allowing the laboratory to inform us regarding the 
identity of practices submitting one or more 
positive samples. The submission of any suspected 
WNV samples to PDS would help to facilitate this 
study.  
 
    In the event that a positive result does originate 
in your practice, we will first contact your clinic. 
We will not contact the horse owner without first 
contacting you and obtaining specific permission 
for follow-up. We will request your help in 
obtaining permission of the owner for us to conduct 
a detailed herd investigation and the collection of 
blood samples from other horses resident in the 
herd.  Further, we will ask your assistance in 
identifying and obtaining the co-operation of the 
owner of a control herd (a herd with no clinical 
disease nearest to the affected herd) where a similar 
investigation will be conducted.  
 
   All data collected during our study, including the 
identity of all practices, practitioners, owners and 
horses will be held in confidence.  Reports will 
identify the location of case and control premises 
by provincial region or health district only. 
 
Thank you for your assistance, 
 
Hugh G.G. Townsend DVM, MS, Cheryl Waldner DVM, PhD, Tasha Epp DVM 
 
I/We hereby grant permission to Prairie Diagnostic Services Limited to inform Drs. Hugh Townsend, Cheryl 
Waldner or Tasha Epp whenever my/our practice submits a diagnostic specimen for the purpose of 
making/confirming the diagnosis of WNV infection in horses. We understand the data collected will be treated with 
confidentiality and only a summary of the data will be published. Complete & fax this form to (306) 966-7159 by 
June 27th. 
 
 
Clinic Name______________________________________________________________________ 
 
 
_______________________   ____________________________   ___________________ 
Name    Signature    Date   
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Equine West Nile Virus Case Investigation Reporting Form  
 
 
 
Owner’s Name ________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province____________________________  Postal code___________     __________ 
 
Legal Land Description (where horse(s) is located most of the summer) 
__________________________________________________ 
 
Tel. H (_____) ______-__________            W (_____) _____-_______ 
 
Email ____________________________________________________ 
 
 
Veterinarian __________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province___________________________    Postal code_________  _________    
  
Tel. W (_____) _____-_______                      Fax (_____) ______-_________ 
 
Email ____________________________________________________ 
 
 
Clinical Case Definition: 
An equine with clinical signs plus one or more of the following: detection of IgM and or IgG antibody to the virus by 
ELISA or by PCR on tissues. Clinical signs must include one or more of the following: ataxia (wobbly), inability to 
stand (recumbent), multiple or single limb paralysis or death.  
Date of symptom onset of case horse: ____/____/_____ 
 
For office use: 
Date of case sample sent to lab  _____/_____          
Type of sample sent____________________ 
 
Date of on farm samples sent to lab _____/____ 
Number of samples sent   ______ 
Results ?    ______ 
 
Outcome of illness:   
    __ Recovered         
    __still ill 
    ___unknown          
    __Died (dd/mm) ___/___/___ 
   ___ Euthanized  (dd/mm)  ___/___/___                   
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Herd level factors 
 
How many total equids (horses, ponies, donkeys, mules) are on the premises? _______     
          
In three weeks prior to Case horse’s onset of symptoms, overall, what have the horses primarily had access to? 
   ____ simple shelter *       ____no shelter**      ____enclosed barn    
* simple shelter is one of three sides, lean-to, etc          **pasture/corrals with or without bush cover 
 
What preventative measures have been taken to avoid/control mosquitoes (overall in the herd)? More than one 
answer can be marked but identify main control with a #1. 
      ____  ____nothing     
      ____  ____fans in barn    
      ____  ____altered lighting around barn   
      ____  ____insecticide on premises (brand name__________________________________) 
      ____  ____sealed barn (kept indoors at night)  
      ____  ____smudges     
      ____  ____habitat/water removal    
 
 Horse Information 
*Non case horses are horses that did not show any symptoms of WNV during the mosquito 
season 
 Case horse Non-case* 1 Non-case 2 Non-case 3 Non-case 4 
Name of horse      
Lab number      
Brand/identifier      
Breed  Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Age (Year of birth)      
Sex  St      F       G St      F       G St      F       G St      F       G St      F       G 
Body size 
(by girth tape) 
     
Primary use: Pl       Br     C   
F/R        R 
Pl       Br     C   
F/R        R 
Pl      Br     C   
F/R        R 
Pl       Br     C   
F/R        R 
Pl       Br     C         
F/R        R 
  Pl – Pleasure       Br- Breeding       C- Competition      F/R – Farm/Ranch         R - Racing       
  Mosquito control?       
         
Insecticide (spray, 
etc) 
 
Y         N           
 
Y         N 
 
Y         N 
 
Y        N 
 
Y        N 
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 Shelter No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
   Blanketing  None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
Vaccination? 
Date of first 
Vaccination 
(dd/mm/yy) 
     
# of vaccinations 1       2        3 1       2        3 1       2        3 1       2        3 1       2        3 
Who vaccinated? Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
 
 
 
Did any of the horses travel off farm in the three weeks before onset of symptoms (a distance of greater 
than 10 miles)? 
 Case Horse Non-case 1 Non-case 2 Non-case 3 Non-case 4 
Location       
Date 
(dd/mm to dd/mm) 
     
Location      
Date 
(dd/mm – dd/mm) 
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Re: West Nile Virus Study 2003 
Dear Veterinarian: 
 
 
    Thank you for participating in our studies this past mosquito season. We are in the 
process now of having the lab data organized and will then proceed to put the picture of 
WNV in Saskatchewan together.  
    Total cases reported this year by PDS for the province of SK was 133. What we would 
like to be able to estimate is the number of undiagnosed cases across the province as well 
as the potential vaccination rate across the province. We are hoping again for your 
cooperation in this matter. 
 Please take the time to read and answer the question below. This form can be faxed back 
to (306) 966-7159 Attention: Tasha Epp. If we have not heard back from you in 3 
business days, we will be contacting you by phone.  
 
 
 
1. Estimate the number of possible clinical cases of West Nile virus your clinic saw or 
conversed about over the phone about but never sent blood work for testing. A 
clinical case would be a horse that had mild to severe neurological symptoms.  
 
________________________________ 
 
 
2. How much vaccine (doses) was sold by your clinic during these two time periods? 
 
(A)    prior to July 1st, 2003 ________________________ 
   
 
(B)    after July 1st, 2003 __________________________ 
 
 
CLINIC __________________________________________ 
 
  Thanks you for taking the time to answer these questions.  
 
WCVM WNV team, Dr. Townsend, Dr. Waldner, Dr. Tasha Epp, Dr. Rebecca Corrigan 
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Appendix B 
Dear Horse Owner
Since 1999, West Nile Virus (WNV) has spread 
across the continent with great speed, affecting 
birds, horses and humans. Last summer was the 
first time the province of Saskatchewan 
experienced WNV. This virus can manifest itself 
in severe clinical disease that debilitates horses 
or even results in death. 
A team of investigators from the Western 
College of Veterinary Medicine in Saskatoon is 
working to get answer about WNV this summer. 
With the assistance of horse owners and 
veterinarians in the province, our team is 
attempting to determine what factors may 
influence the chances of horses becoming 
infected or show disease. Factors such as 
location, individual horse factors, management 
practices or vaccination. 
What we are asking of you is to allow a visit to 
your premises by a research team member. 
During this visit we would ask to take blood 
samples from resident horses on the premises to 
test for antibodies to WNV. As well, we ask you 
to assist in filling out a simple questionnaire that 
addresses the areas of interest mentioned 
previously. The results of the blood testing will 
be reported back to you through your 
veterinarian to facilitate any questions that might 
arise. 
 
This data (including the identity of all owners and horses) will be kept strictly confidential 
and only a summary of the data (location by provincial region or health district) will be 
published. 
If at any time you wish to withdraw from this study, you are free to do so. 
 
Thank you very much for your assistance, 
Hugh G.G. Townsend DVM, MS, Cheryl Waldner DVM, PhD,   Tasha Epp DVM 
I hereby grant permission to the research team of Drs. Hugh Townsend, Cheryl Waldner or 
Tasha Epp for a herd visit, blood sampling for testing of WNV antibodies and the 
completion of an investigation form. I understand that the information will be kept 
confidential and I can withdraw from the study at any time. When the results of the testing 
are completed, the info will be reported to me through my veterinarian. 
 
_______________________   ____________________________   ________________ 
              Name                                  Signature                                    Date 
Address_____________________________________________________ 
 
Phone number (where can be reached during the daytime)_____________________ 
 
Please indicate your veterinarian  _____________________________________   
 
Clinic__________________________________ 
 
 
 
         
 
Equine West Nile Virus Seroprevalence Investigation Reporting Form  
 
Sampling Date 1: ____/____/____ (dd/mm/yy)     
 
Sampling Date 2: _____/_____/______ 
 
 
 
Owner’s Name ________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province____________________________  Postal code___________     __________ 
 
Legal Land Description (where horses are located most of the summer) 
_______________________________________________________ 
 
Tel. H (_____) ______-__________            W (_____) _____-_______ 
 
Email ____________________________________________________ 
 
 
 
Veterinarian __________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province____________________________  Postal code___________     __________ 
 
Tel. W (_____) _____-_______                      Fax (_____) ______-_________ 
 
Email ____________________________________________________ 
 
 
Additional Comments: 
______________________________________________________________________________________
______________________________________________________________________________________
____________________________________________ 
 
FOR OFFICE USE: 
 
Lab Information:  Date of samples sent to lab__________________________ 
                              Number of samples sent____________________________ 
                              Results received? _________________________________ 
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Herd level questions: 
How many equids (horses, ponies, donkeys, mules) are on the premises?________ 
 
In the last three weeks, overall, what have the horses primarily had access to? 
          ____simple shelter*                 _____ no shelter**                        _____enclosed barn 
*simple shelter is three sided, lean-to, etc       ** pasture/corrals with or without bush cover 
 
Have you used any of these overall herd preventative measures to avoid mosquitoes in the last 
three weeks? More than one answer can be marked but identify main control with a #1. 
      ________   _____nothing        
      ________   _____altered lighting around barn         
      ________   _____fans in barn 
      ________   _____insecticide on premise (brand name____________________________) 
      ________   _____smudges      
      ________   _____habitat/water removal   
      ________   _____sealed barn (kept indoors at night) 
 
 
 
HORSE INFORMATION 
 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 
Horse’s name      
Lab number      
Brand/ Identifier      
Breed  Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Age (year of birth)      
Sex  St     F     G St      F      G St       F       G St       F      G   St     F     G 
Body size (by girth 
tape) 
     
Primary use Pl     Br     C          
 
F/ R     R  
Pl      Br      C     
   
F/R     R 
Pl     Br      C 
   
F/R      R 
Pl     Br     C   
   
F/R      R 
Pl      Br      C 
    
F/R       R 
Pl – pleasure         Br – Breeding         C – Competition         F/R – Farm/Ranch        R - Racing 
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Mosquito control?      
Insecticide use 
(sprays, etc) 
 
Y           N 
 
Y             N 
 
Y             N 
 
Y             N 
 
Y             N 
Shelter No  
Simple 
barn 
No  
Simple 
barn 
No  
Simple 
barn 
No  
Simple 
barn 
No  
Simple 
barn 
Blanketing 
 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
Vaccination?      
Date of 1st Vaccination 
 (dd/mm/yy)   
     
# of vaccinations 1      2       3 1      2        3 1      2       3 1      2       3 1      2       3 
 Who Vaccinated? Vet       
  Owner 
Vet        
Owner 
Vet    
Owner 
Vet        
Owner 
Vet        
Owner 
 
 
 Horse 6 Horse 7 Horse 8 Horse 9 Horse 10 
Horse’s name      
 Lab number      
Brand/ Identifier      
Breed  Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Pony 
Light 
Draft 
Cross(L*D) 
Other 
Age  (year of birth)      
Sex  St     F    G St       F        G St        F       G  St       F       G St       F       G 
Body size (by girth 
tape) 
     
Primary use: 
 
Pl    Br   C         
 
F/ R     R 
Pl    Br   C         
 
F/ R     R 
Pl    Br   C         
 
F/ R     R 
Pl    Br   C         
 
F/ R     R 
Pl    Br   C         
 
F/ R     R 
Pl – pleasure         Br – Breeding         C – Competition         F/R – Farm/Ranch        R – Racing 
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Mosquito control?      
Insecticide use 
(sprays, etc) 
 
  Y        N 
 
   Y         N 
 
   Y          N 
 
  Y         N 
 
  Y          N 
Shelter 
No  
Simple 
No  
Simple 
barn 
 No  
Simple 
 barn 
No  
Simple 
 barn 
No  
Simple 
barn 
No  
Simple 
barn 
Blanketing 
 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
None 
Dusk to Dawn 
Continuous 
Vaccination?      
Date of First Vaccination 
  (dd/mm/yy)   
     
# of vaccinations 1      2       3 1      2       3 1      2       3 1      2       3 1      2       3 
Vaccinated by whom? Vet        
Owner 
Vet        
Owner 
Vet        
Owner 
Vet        
Owner 
Vet        
Owner 
 
 
Have any of the horses traveled off farm in the last three weeks (a distance greater than 10 miles)? 
 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 
Location      
Date 
(dd/mm - dd/mm) 
     
Location      
Date 
(dd/mm –dd/mm) 
     
 
 Horse 6 Horse 7 Horse 8 Horse 9 Horse 10 
Location      
Date 
(dd/mm – dd/mm) 
     
Location      
Date 
(dd/mm – dd/mm) 
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Appendix C 
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Dear _____________________________ 
 
 
      As part of a West Nile Virus study at the Western College of Veterinary Medicine, 
University of Saskatchewan, we are asking your assistance in identifying control herds 
for our case control study. The following is a herd from your clinic that had a clinical 
case of West Nile Virus this season: 
 
                                     
_______________________________________  
 
The criteria for a control herd is that it has had no clinical (neurological, confirmed by lab 
work) case of West Nile Virus this season, it is as close as possible to the case herd and 
has as least 5 horses on the premises. If you can help us in this matter, please indicate the 
name and phone number of a potential herd. 
 
 
_________________________________     ph # ____________________________ 
 
Also, due to time constraints we are looking to contract your clinic to take the blood work 
from these farms once they have agreed to the study (our research team will call and talk 
to them about what is involved). If you are willing to do this, please indicate whom to 
contact was the owners have been reached. 
 
 
 
 
There is no time frame specific to do the blood taking within, but we hope to have this 
completed by the end of October. We would request that the blood work from the two 
farms be done within a few days of each other to ensure the best comparable results. 
 
Thank you for your time,  
 
Tasha Epp, DVM, grad student WCVM 
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To: __________________________ 
 
 
Here are the instructions in regards to the blood sampling for the West Nile Virus study. 
 
1. Please label the tubes with the horse’s name and the owners last name. 
 
2. On the PDS form, put  “for the West Nile Virus study, RS-Townsend 7-01457” so 
that it gets charged to our study and not the owners.  Also, if you could put the date 
the samples were taken that would help a lot. Please indicate it is for “WNV IgM 
Elisa”.  
 
3. Please have the bleeding done by the end of October, and both case and control farm 
within a few days of each other at the most. 
 
4. Please take up to 8 blood samples (minimum of 5) from each place (both case and 
control farm). It does not matter if they are vaccinated or not. Whatever is available to 
bleed works for us (any age, breed, etc). 
 
5. I will contact the owners for all the information about the horses and management 
once the blood work is complete. I will also contact the owners with the results of the 
testing at that time. 
 
6. For the charges your clinic has for taking the blood samples (mileage fee and blood 
taking fee), please direct those to the study as well. The invoice can be sent to Tasha 
Epp, LACS, WCVM, U of S, 52 Campus Drive, Saskatoon, SK, S7N 5B4. 
 
 
Thanks you for all of your help. 
 
 
Tasha Epp 
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Equine West Nile Virus Control Investigation Reporting Form  
 
 
Owner’s Name ________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province____________________________  Postal code___________     __________ 
 
Legal Land Description (where horse(s) is located most of the  
summer)__________________________________________________ 
 
Tel. H (_____) ______-__________            W (_____) _____-_______ 
 
Email ____________________________________________________ 
 
 
Veterinarian __________________________________________________________ 
 
Address ______________________________________City/Town_______________ 
 
Province___________________________    Postal code_________  _________  
    
Tel. W (_____) _____-_______                      Fax (_____) ______-_________ 
 
Email ____________________________________________________ 
 
 
Control herd and Clinical Case Definition: 
   To qualify as a control herd, there must be and have been no case animals present on the farm during study period. 
   An case is an equine with clinical signs plus one or more of the following: detection of IgM and or IgG antibody to the virus by 
ELISA or by PCR on tissues. Clinical signs must include one or more of the following: ataxia (wobbly), inability to stand 
(recumbent), multiple or single limb paralysis or death.  
 
 
For Office Use:  
 
Lab information:  Date samples sent to lab _____/_____/_____ (dd/mm/yy) 
                             Number of samples sent ___________ 
                             Results?  _______________ 
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          Herd level Factors 
 
How many total equids (horses, ponies, donkeys, mules) are on the premises? _______    
 
In the last three weeks, overall, what have the horses primarily had access to?  
     ______ simple shelter*   _____ no shelter**      _______enclosed barn 
*simple shelter is three sided, lean-to, etc          ** pasture/corrals with or without bush cover 
 
Have you used any of these overall herd preventative measures to avoid mosquitoes in the last three 
weeks? More than one answer can be marked but identify main control with a #1. 
      ____   _____nothing     
      ____   _____fans in barn    
      ____   _____altered lighting around barn   
      ____   _____insecticide on premises (brand name__________________________________) 
      ____   _____ sealed barn (kept indoors at night) 
      ____   _____smudges      
      ____   _____habitat/water removal  
       
Individual Factors 
       
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 
Name of horse      
Lab Number      
Brand/identifier      
Breed  Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Pony 
Light 
Draft 
Cross (L*D) 
Other 
Age (year of birth)      
Sex  St       F       G St       F       G St       F       G St       F       G St       F       G 
Body size 
(by girth tape) 
     
Primary use: Pl      Br     C 
  F/R        R 
Pl      Br     C 
  F/R        R 
Pl      Br     C 
  F/R        R 
Pl      Br     C 
  F/R        R 
Pl      Br    C 
  F/R        R 
Mosquito Control? 
Insecticide (spray, 
etc) 
 
Y        N 
 
Y       N 
 
Y       N 
 
Y        N 
 
Y        N 
 Shelter No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
No 
Simple 
Barn 
  Blanketing  None 
Dusk to Dawn 
None 
Dusk to Dawn 
None 
Dusk to Dawn 
None 
Dusk to Dawn 
None 
Dusk to Dawn 
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Continuous Continuous Continuous Continuous Continuous 
Vaccination? 
Date of first 
vaccination 
(dd/mm/yy) 
     
# of vaccinations 1       2        3 1       2        3 1       2        3 1       2        3 1       2        3 
Who vaccinated? Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
Vet 
Owner 
 
Have any of the horses travel off farm in the last three weeks (a distance of greater than 10 
miles)? 
 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 
Location      
Date (dd/mm to 
dd/mm) 
     
Location      
Date (dd/mm to 
dd/mm) 
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Appendix D 
 
West Nile Reporting Form (2004): 
 
Clinic name: _______________________________________ 
 
Week #: ____________________________________________ 
 
To be completed weekly and sent in for surveillance 
compilation. ** starred entries are required, others only if known. 
 
**Probable 
(P) or 
confirmed 
positive (L) 
Date of 
onset  
(if known) 
Outcome of 
illness 
(if known) 
**RM 
/nearest  
town 
WNV 
Vaccine 
history 
(if known) 
     
     
     
     
     
 
Probable (P) : A horse showing classic symptoms of WNV but not 
tested by the lab 
Confirmed Positive (L): A horse with classic symptoms that was 
tested positive for IgM antibodies by the lab. 
 
Please fax to___(306) 966-7159___ Attention: Tasha Epp or 
Rebecca Corrigan. 
 
Thank you 
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2004 Summary Report of Clinical WNV Horse Case Surveillance Evaluation 
 
Purpose:  The purpose of the clinical WNV horse case surveillance was to provide an estimation of which 
RHAs had WNV cases in the horse population in order to evaluate potential risk of WNV in the human 
population, in conjunction with other surveillance being done by Saskatchewan Health 
 
Key Accomplishments: 
? Surveillance was initiated in the Sun Country, Five Hills, Cypress, Regina/Qu’Appelle, Sunrise, 
Saskatoon, Heartland, Kelsey Trail, Prince Albert Parkland and Prairie North health regions 
? 22 private veterinary clinics and the Western College of Veterinary Medicine participated in 
surveillance 
? A total of 10 suspicious clinical horse cases were recorded 
? Confirmatory testing was initiated in 4 cases; no confirmed clinical horse cases occurred during 
2004 
 
RHA Sun 
Country 
Five 
Hills 
Cypress Regina 
Qu’Appelle
Sunrise Saskatoon Heartland Kelsey 
Trail 
Prince 
Albert 
Parkland
Prairie 
North 
Number of 
Clinics 
Reporting 
3 2 2 3 2 3 3 2 1 2 
Number of 
Suspicious 
Horse 
Cases 
1 3 1* 1** 0 0 1** 1 0 2  
(1**) 
Number of 
Confirmed 
Horse 
Cases 
0 0 0 0 0 0 0 0 0 0 
Week(s) of 
Occurrence 
34 29, 
31, 
33 
34 -- -- -- Unknown Unknown -- 32, 
33 
 
*Was to undergo IgM ELISA testing for confirmation but was lost 
**Underwent confirmatory testing with IgM ELISA and came back negative 
 
Highlights of 2004 Surveillance: 
? A good response came from private clinics throughout Saskatchewan.  They were very interested 
in participating in the surveillance and were extremely helpful 
? Weekly follow-up via fax or telephone for all clinics was easy to do 
? A large number of clinics participated from each RHA which resulted in an extensive coverage of 
the province  
 
Recommendations for 2005: 
? Confirmatory testing with IgM ELISA in suspicious cases was low—setting aside money to 
confirm “x” number of tests of the first reported suspicious cases in each RHA may help to 
increase the number of confirmed cases of WNV 
o Veterinary clinics would need to be made aware of this potential funding early in the 
season in order to advise clients with horses displaying potential clinical signs of WNV 
o A timeline of testing, based on the rainfall, mosquito activity and other predictors of 
WNV ecology, would need to be established to avoid testing horses before potential 
WNV cases could likely occur 
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Dear Colleagues                                                                                                                 June 2005                                  
 
We are writing to seek permission to be informed of West Nile Virus positive horses in your 
practice.  This initial contact is to inform you of the study and to prepare for the season ahead. 
 
The research team is associated with the Western College of Veterinary Medicine, Saskatoon, 
Saskatchewan. This summer, we intend to conduct surveillance of the occurrence of clinical West 
Nile Virus infection (WNV) of horses in Saskatchewan and test blood samples submitted for 
Coggins tests from July 10th to September 15th for antibodies to WNV. 
 
We hope to locate clinically affected animals by having the Prairie Diagnostics Services (PDS) in 
Saskatoon inform us when they confirm the diagnosis of WNV (blood or postmortem) in Sask. 
horses. However, this will only be possible if veterinary practices in Saskatchewan sign a release 
allowing the laboratory to inform us regarding the identity of practices submitting one or more 
positive samples. The submission of any suspected WNV samples to PDS would help to facilitate 
this study. 
 
We hope to obtain permission to test blood samples sent in for Coggins tests during the specified 
time period by having you the veterinarian submit a release form, signed by the owner at the time 
of sample collection. The release form must be included with the Coggins submission and the 
sample sent to PDS. The sample will be tested for IgM antibodies and the result will be sent back 
to you, the submitting veterinarian to be forwarded to the owner. 
 
We will not require any contact with the horse owners for either portion of surveillance. 
However, we will request your help in obtaining the location of where the horse was residing in 
the three weeks prior to symptoms developing.  This can be an exact legal land description or 
merely the Rural Municipality name/number. Please include this information on the submission 
form to the lab for clinical cases and on the release form for the Coggins test submissions. 
 
All data collected during our study, including the identity of all practices, practitioners, owners 
and horses will be held in confidence.  Reports will identify the locations by rural municipality or 
health district only. 
 
 
Thank you for your assistance, Hugh G.G. Townsend DVM, MS, Cheryl Waldner DVM, PhD, Tasha Epp DVM 
 
I/We hereby grant permission to Prairie Diagnostic Services Limited to inform Drs. Hugh Townsend, 
Cheryl Waldner or Tasha Epp whenever my/our practice submits a diagnostic specimen for the purpose of 
making/confirming the diagnosis of WNV infection in horses. We understand the data collected 
(specifically horse location) will be treated with confidentiality and only a summary of the data will be 
published. Complete & fax this form to (306) 966-7159 by June 27th. For any questions, phone Tasha Epp 
at (306) 966-7166. 
 
Clinic Name______________________________________________________________________ 
 
_______________________   ____________________________   ___________________ 
Name    Signature    Date     
 223
WNV Release Form:  
This form is to accompany the submission of a blood sample for Coggins testing. Please photocopy as needed. 
 
Time period allow for submission of samples: samples taken between July 10th and September 15th, 2005 
 
The samples will be tested for IgM antibodies to West Nile Virus. This test indicates whether the horse has been 
exposed to WNV recently. If the horse is showing no symptoms of WNV and the test is positive, the horse will 
likely not show any symptoms but instead will clear or may have already cleared the infection with the virus 
uneventfully. Only the location and test result information will be used for research purposes.   
 
This form must be completed for testing to ensue, so please ensure all areas are completed as indicated. 
 
 
I/We (owner of the horse) hereby give permission to the West Nile Virus (WNV) research team at the 
Western College of Veterinary Medicine (WCVM) to use the submitted sample and the following 
information for research purposes. The sample is to be tested at Prairie Diagnostic Services Limited (PDS) 
in Saskatoon, SK for IgM antibodies to West Nile Virus (WNV). The test result is to be sent to my 
veterinary listed below. We understand the data collected (specifically horse location) will be treated with 
confidentiality and only a summary of the data will be published.  
 
 
 
_______________________   ____________________________   ___________________ 
Name of owner      Signature    Date     
 
_______________________________________________________ 
Legal land location (of the horse in the two weeks prior to sampling) 
 
 
 
 
Veterinarian: ____________________________________________ 
Vet clinic: ______________________________________________ 
Clinic fax number: _______________________________________ 
Clinic phone number: _____________________________________ 
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West Nile Reporting Form (2005): 
 
Clinic name: _______________________________________ 
 
Week #: ____________________________________________ 
 
To be completed weekly and sent in for surveillance 
compilation.  
 
Probable (P) 
or confirmed 
positive (C) 
Test result 
(indicate if 
awaiting result) 
Week (or date)  
of onset of  
symptoms 
RM/nearest  
town 
    
    
    
    
    
 
Probable (P): A horse showing classic symptoms of WNV but not tested 
by the lab 
Confirmed Positive (C): A horse with classic symptoms that tested 
positive for IgM antibodies by the lab. (Please indicate horses that are 
being tested but the result is not confirmed yet in this category as well.) 
 
 
Please fax to___(306) 966-7159___ Attention: Tasha Epp 
 
Thank you 
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2005 Summary Report of Clinical WNV Horse Case Surveillance Evaluation 
 
Purpose:  The purpose of the clinical WNV horse case surveillance was to provide an estimation 
of which RHAs had WNV cases in the horse population in order to evaluate potential risk of 
WNV in the human population, in conjunction with other surveillance being done by 
Saskatchewan Health 
 
Key Accomplishments: 
? Surveillance was initiated in the Sun Country, Five Hills, Cypress, Regina/Qu’Appelle, 
Sunrise, Saskatoon, Heartland, Kelsey Trail and Prairie North health regions (only Prince 
Albert Parkland did not have representation) 
? 19 private veterinary clinics and the Western College of Veterinary Medicine participated 
in surveillance 
? A total of 10 confirmed and 4 probable clinical horse cases were recorded 
? Confirmatory testing was charged to Saskatchewan Health in 7 cases 
 
RHA Sun 
Countr
y 
Five 
 Hills 
Cypress Regina 
Qu’Appelle 
Sunrise Saskatoon Heart
-land 
Kelsey 
 Trail 
Prince 
 Albert  
Parkland 
Prairie 
North 
Number of  
Clinics 
 Reporting 
3 2 2 3 2 2 2 1 0 2 
Number of 
Probable  
Horse Cases 
0 0 0 0 2 2 0 0 0 0 
Number of 
Confirmed  
Horse Cases 
2 2 1 1 0 2 0 2 0 0 
Total number  
of cases 
2 2 1 1 2 4 0 2 0 0 
Week(s) of 
Occurrence 
30, 35 35, 36 35 33 32 33, 38 -- 30, 37 -- -- 
 
Week 30 corresponds to July 24 – 30th and week 37 corresponds to September 11 -17th, 
2005. 
 
 
Highlights of 2005 Surveillance: 
? A good response came from private clinics throughout Saskatchewan.  They were very 
interested in participating in the surveillance and were extremely helpful 
? Weekly follow-up via fax or telephone for all clinics was easy to do but did become time 
consuming as the weekly response rate did drop off significantly in September  
? Clinics response rate to the weekly faxing ranged from 20 – 100% 
? A large number of clinics participated from each RHA (except from Prince Albert 
Parkland) which resulted in an extensive coverage of the province; reporting clinics also 
informed researcher of other clinics to contact in regards to other potential clinical cases  
? Coverage of a small number of confirmatory tests with IgM ELISA was a success  
o Veterinary clinics were aware of this potential funding early in the season and 
were able to use this to test horses displaying potential clinical signs of WNV 
where the owner didn’t want to test 
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o The timeline of testing confined to between mid-July and mid-September was 
effective in confirming a few negative horses in mid-July despite these horses 
showing symptoms seemingly consistent with WNV, defining the first confirmed 
positive case in late July and the last recorded positive case in mid-September. 
 
 
Recommendations for future surveillance: 
? Continue the free testing portion of the program to ensure confirmation of at least the first 
positive per RHA 
? Continue the use of sentinel veterinary clinics only if there will be a person solely in 
charge of reminders (phone calls as vets do not read faxes) for clinics to report weekly 
? Weed out the clinics with poor response rates and potentially replace with other clinics in 
those regions; keep at least 2 clinics per RHA for the most comprehensive coverage of 
the area (RHAs 8 and 9 could get away with only one clinic per region) 
? Continue the recording of both probable and confirmed cases of WNV clinical disease in 
horses as a part of an integrated surveillance initiative 
  
 
 
 
 
 
 
